Characterization of miR-574-5p decoy to CUGBP1 in human lung cancer cells using a mass spectrometry proteomics approach by Emmerich, Anne Caterina
  
 
 
Characterization of miR-574-5p decoy to 
CUGBP1 in human lung cancer cells using a 
mass spectrometry proteomics approach 
 
Vom Fachbereich Biologie der Technischen Universität Darmstadt  
Zur Erlangung des akademischen Grades  
Doctor rerum naturalium  
(Dr. rer. nat.) 
 
 
 
 
Dissertation von 
M. Sc. Anne Caterina Emmerich 
Erstgutachterin: Dr. Meike Julia Saul 
Zweitgutachterin: Prof. Dr. Beatrix Süß 
Darmstadt 2020 
 
 
 
 
__________________________________________________________________________ 
 
2 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Emmerich, Anne Caterina:  Characterization of miR-574-5p decoy to CUGBP1 in human lung 
cancer cells using a mass spectrometry proteomics approach 
Darmstadt, Technische Universität Darmstadt  
Jahr der Veröffentlichung der Dissertation auf TUprints: 2020  
URN:   urn:nbn:de:tuda-tuprints-91406 
Tag der mündlichen Prüfung: 28.02.2020 
 
Veröffentlicht unter CC BY-SA 4.0 International 
https://creativecommons.org/licenses/  
 
__________________________________________________________________________ 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In der Wissenschaft gleichen wir alle nur den Kindern, die am Rande des Wissens hie und da einen Kiesel 
aufheben, während sich der weite Ozean des Unbekannten vor unseren Augen erstreckt. 
Sir Isaac Newton (1643 – 1727) 
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Summary 
The bioactive lipid mediator prostaglandin (PG) E2 is generated by the enzyme microsomal 
prostaglandin E2 synthase-1 (mPGES-1). Especially in lung tumors, mPGES-1 was shown to 
be significantly overexpressed which contributes to a pro-tumorigenic microenvironment. 
Current medication interfering with the negative effects of PGE2 comprise only non-steroidal 
anti-inflammatory drugs (NSAIDs). While these have effective analgesic properties and are 
commonly used as pain killers, treatment of tumor growth is still inconclusive. Probably, only 
subgroups of cancer patients exhibit an abnormal prostanoid profile. Therefore, a reliable 
biomarker is necessary to identify patients who could benefit from said treatment. In a recent 
study, it was discovered that a specific microRNA (miR) can induce mPGES-1 gene 
expression. The miR-574-5p prevents binding of the inhibitory CUG-RNA binding protein 1 
(CUGBP1) to the 3´ untranslated region (UTR) of mPGES-1. This non-canonical decoy 
function of miR-574-5p leads to an increased mPGES-1 protein level. Following, an induction 
of PGE2 formation triggers the progression of lung tumor growth in vivo. Interestingly, the entire 
influence on tumor progression could be blocked with the addition of a specific mPGES-1 
inhibitor, confirming the huge influence of miR-574-5p on (patho-) physiological mPGES-1 
functions. In this study, a proteomics approach was conducted in order to further characterize 
this decoy mechanism in human lung cancer cells. The aim was to gather global insights into 
the proteome changes related to miR-574-5p and CUGBP1, especially in a compartment 
specific manner. Further, it was aimed to identify new CUGBP1 targets and find out if they are 
also affected by the decoy function of miR-574-5p. Two new CUGBP1 targets were validated 
herein: NADH-Ubiquinone Oxidoreductase Core Subunit S2 (NDUFS2) and Mothers against 
decapentaplegic homolog 2 (SMAD2). However, both NDUFS2 and SMAD2 are independent 
from miR-574-5p levels. In a bioinformatical 3’UTR analysis of potential CUGBP1 targets, it 
was shown that the specific splicing pattern of mPGES-1 is unique, comprising two long 
CUGBP1 binding motifs with a 3’UTR intron in between. Only 11 other transcripts harbor a 
similar but not identical pattern in their sequence. Hence, it is assumable that this novel decoy 
mechanism is specifically regulating mPGES-1 in A549 lung cancer cells. This might be caused 
by the unique splice pattern of mPGES-1. However, further experiments are needed to confirm 
this hypothesis. Nevertheless, specificity of the decoy mechanism would open up new 
opportunities for lung cancer patients. By using miR-574-5p as a biomarker, one could stratify 
those patients with high mPGES-1 levels who have a higher chance to benefit from the anti-
tumorigenic potential of NSAID therapy.  
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Zusammenfassung 
Der biologisch aktive Lipidmediator Prostaglandin (PG) E2 wird enzymatisch von der 
mikrosomalen Prostaglandin E2 Synthase (mPGES-1) generiert. Es konnte gezeigt werden, 
dass mPGES-1 speziell in Tumoren der Lunge stark angereichert ist. Durch die damit 
verbundene vermehrte Bildung von PGE2 kommt es zu einer kanzerogenen Tumorumgebung. 
Hier setzen sogenannte non-steroidal anti-inflammatory drugs (NSAIDs) an. Während diese 
effektive analgetische Eigenschaften aufweisen und häufig als Schmerzmittel genutzt werden, 
ist die Behandlung von Tumoren dennoch umstritten. Es wird vermutet, dass nur eine 
Subpopulation von Krebspatienten ein entartetes Prostanoidprofil aufweist. Daher wäre ein 
verlässlicher Biomarker vonnöten, mit dem man diese Patienten identifizieren kann, die dann 
von einer NSAID-Therapie profitieren könnten. Kürzlich wurde eine spezielle mikroRNA (miR) 
identifiziert, die die mPGES-1 Genexpression induzieren kann. Die miR-574-5p verhindert die 
Bindung des inhibitorischen CUG RNA Bindeprotein 1 (CUGBP1) an den 3‘ untranslatierten 
Bereich (UTR) von mPGES-1. Diese nicht-kanonische Decoy Funktion von miR-574-p führt zu 
einem erhöhten mPGES-1 Proteinlevel. Dadurch kommt es zur vermehrten PGE2 Synthese, 
welche daraufhin das Tumorwachstum in vivo begünstigt. Durch die zeitgleiche Gabe eines 
spezifischen mPGES-1 Inhibitors konnte jedoch der gesamte Einfluss auf das Voranschreiten 
des Tumors verhindert werden. Dadurch konnte der immense Einfluss der miR-574-5p auf die 
(patho-) physiologischen Funktionen von mPGES-1 gezeigt werden. In dieser Studie wurde 
nun der Decoy Mechanismus mit Hilfe einer Proteomik-Studie in humanen 
Lungenkarzinomzellen weiter charakterisiert. Das Ziel war es globale Kompartment-
spezifische Einsichten in die miR-574-5p- und CUGBP1-vermittelten Änderungen des 
Proteoms zu erhalten. Des Weiteren sollten neue CUGBP1-regulierte Transkripte identifiziert 
werden, um herauszufinden, ob diese ebenfalls durch den Decoy Mechanismus der 
miR-574-5p beeinflusst werden. Zwei neue CUGBP1-regulierte Transkripte konnten dabei 
validiert werden: die NADH-Ubiquinone Oxidoreductase Core Subunit S2 (NDUFS2) sowie 
das Signalmolekül Mothers against decapentaplegic homolog 2 (SMAD2). Die Regulation 
beider Zielgene war jedoch unabhängig von miR-574-5p. In einer bioinformatischen Analyse 
aller 3’UTRs von möglichen CUGBP1-regulierten Transkripten stellte sich heraus, dass das 
spezifische mPGES-1 Spleißmuster einzigartig ist. Es umfasst zwei lange CUGBP1 
Bindesequenzen, getrennt durch ein 3’UTR Intron. Ein ähnliches, wenn auch nicht identisches 
Muster, konnte in nur 11 weiteren Transkripten gefunden werden. Daher ist es annehmbar, 
dass der Decoy Mechanismus spezifisch nur die mPGES-1 Expression in A549 
Lungenkarzinomzellen reguliert. Dies könnte potenziell auf das spezifische Spleißmuster 
zurückzuführen sein, obwohl weitere Experimente nötig sind, um diese Hypothese zu 
bestätigen. Nichtsdestotrotz könnte die Spezifität des Decoy Mechanismus neue 
Zusammenfassung 
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Möglichkeiten für Lungenkrebspatienten darstellen. MiR-574-5p könnte als Biomarker genutzt 
werden, um jene Patienten mit hohen mPGES-1 Leveln zu identifizieren. Diese könnten dann 
von den inhibitorischen Effekten einer NSAID-Behandlung auf das Tumorwachstum 
profitieren. 
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1. Introduction 
Transcription is one of the most fundamental processes in biological systems. It reliably 
produces the required amounts of RNA which are necessary for the maintenance of general 
cellular functions but also for the reaction to rapid changes of environmental circumstances. In 
multicellular organisms, every individual cell shares the same genome, however expressing a 
characteristic cell type specific protein profile. To orchestrate this kind of specificity, a 
tremendous amount of regulatory action is required. In fact, various post-transcriptional 
regulation mechanisms are responsible for fine-tuning of the intracellular protein repertoire [1].  
 
1.1 Post-transcriptional mechanisms of gene regulation  
Post-transcriptional regulation can occur at any step of mRNA processing, from transcription 
to translation, both within the nucleus as well as in the cytoplasm [2]. Shortly, mRNA 
processing starts as soon as transcription is initiated by Polymerase II [3]. Afterwards, pre-
mRNAs are capped, spliced, edited and polyadenylated. Then, mature mRNAs are exported 
into the cytoplasm through the nuclear pore complex [4]. In the cytoplasm, mRNAs can be 
translated into proteins, stored in stress granules, processing bodies (P-bodies) or they can be 
marked for degradation (see Figure 1).  
All these steps are mediated by a myriad of factors, most of them RNA-binding proteins (RBPs) 
with some of them binding the pre-mRNA even during transcription [5]. Regulatory 
mechanisms include among others interference with splicing, editing or polyadenylation as well 
as mRNA (de-) stabilization, localization and finally translational inhibition [2]. For instance, 
polyadenylation is a critical step as it stabilizes the mRNA molecule and prevents rapid 
degradation in the cytoplasm [6]. The longer the 3’ poly(A)-tail, the longer the mRNA can 
survive in the cytoplasm, where it gradually gets shorter by deadenylation [7]. Initiation of 
translation however, stops further deadenylation which indicates that poly(A)-shortening is a 
mechanism of regulation. The deadenylation is mediated by the poly(A) ribonuclease (PARN) 
[8]. Recruitment of PARN is thereby mediated by binding of RBPs or miRs [9] [10] [11] [12].  
Another example for a regulatory mechanism is mRNA storage in intracellular particles called 
P-bodies. mRNAs get recruited there by interaction with RBPs or miRs [13]. P-bodies were 
described to play a role in all kinds of mRNA decay mechanisms, however it was also 
demonstrated that mRNAs were temporary stored there for later translation [13]  [14] [15].  
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Figure 1: mRNA processing. 
Genes consists of a promoter region directly upstream of the transcription start site (TSS), 
numerous exons and introns as well as untranslated regions at the 5’ and 3’ end. The DNA is 
transcribed by Polymerase II, generating the precursor mRNA (pre-mRNA). Processing 
includes addition of a 5’ 7-methylguanylate (5’ m7G) cap, polyadenylation of the 3’ end (An 3’) 
as well as splicing to remove intronic sequences. All these processing steps can concurrently 
occur during transcription although a consecutive order is indicated in the figure for facilitation 
purpose. Mature mRNA is exported into the cytoplasm where its fate is influenced by 
localization, degradation or successful translation. Modified from [14] [15]. 
 
Post-transcriptional regulation is mainly based on cis-regulatory elements (CRE) [18]. In this 
context, CREs are defined as regions of non-coding DNA or RNA that provide binding sites for 
trans-acting factors such as RBPs or transcription factors. CREs can be upstream or 
downstream of coding sequences (CDS) or even within introns and are mostly termed 
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enhancers or silencers, depending on their regulatory function [19]. Of note, one CRE can be 
bound by numerous trans-acting factors and vice versa, which is called pleiotropy. Moreover, 
interactions, synergisms or competition of various trans-acting factors as well as the 
combination of activating or inhibitory CREs further elevates the complexity of gene expression 
regulation [18]. In the following chapters, three types of post-transcriptional regulation 
mechanisms are described in more detail as they stand in the focus of this thesis (see chapters 
1.1.1 Alternative Splicing, 1.1.2 RNA-binding proteins (RBPs) and 1.1.3 microRNAs (miRs)). 
 
1.1.1 Alternative splicing 
Alternative splicing (AS) is a fine tuning process of higher eukaryotes which enables a variation 
in the in- or exclusion of sequence parts of a pre-mRNA and thus provides greater biodiversity 
of proteins from an established number of genes [20]. There are several estimations towards 
how many of all transcripts are alternatively spliced which range up to 25% in Caenorhabditis 
elegans (C. elegans), 60% in Drosophila melanogaster [21] and even 90% in humans [22] [23]. 
Investigations concerning different human tissues revealed that roughly 50% of alternatively 
spliced isoforms are differentially expressed among tissues indicating that AS also provides 
cell type specific isoforms [24]. However, there are recent publications questioning the impact 
of AS on protein diversity, as apparently many RNA isoforms could not be found on protein 
level in large scale proteomics studies [19] [20]. Nevertheless, this does not render the fact 
that AS is a pivotal process in regard of post-transcriptional regulation and physiological 
homeostasis. Defects in AS can even cause different diseases most of all cancer development 
and progression [27].  
During the splicing process it is decided which parts of the sequence are included in the mature 
mRNA and which ones are removed [28]. Consequentially, several mature mRNAs can result 
from one pre-mRNA. There are distinct types of AS (see Figure 2). Constitutive splicing 
describes the canonical form including one exon after the other and removing all the intronic 
parts. One variant is exon skipping, which describes the case when one exon is cut out 
together with the adjacent introns. Vice versa, an intron can also be included in the mature 
mRNA. Further, there can be mutually exclusive exons, also called cassette exons. Finally, the 
5’ and 3’ splice sites can vary. All these variations lead to different mRNAs and thereby also 
to different amino acid sequences during translation [29]. 
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Figure 2: Different types of AS. 
Colored boxes indicate exons; thin lines in between resemble introns. The different forms of 
AS can lead to distinct mature mRNAs which also influences the amino acid sequence of the 
proteins. Modified from [30]. 
 
 
The large complex which mediates the splicing process is called spliceosome. It comprises 
over 300 proteins and nucleic acids [31] [32], while the core is composed of five small nuclear 
ribonucleoproteins (snRNPs) U1-2, 4-6 [33]. Furthermore, additional trans-acting factors of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) [34] or Serine/arginine (SR) protein family 
[35] act as repressors or activators by binding to silencer or enhancer regions to regulate 
splicing activity depending on the cell type, the developmental stage or the gene [36]. 
Generally, the spliceosome binds to splice sites and cuts out the intronic sequences. Thereby, 
assembly and dissociation of the spliceosome subunits appear periodically and recur for every 
intron [37]. Thus, the splicing process can be divided in three parts: assembly of the 
spliceosome, catalytic splicing (actual removal of the intron) and recycling of the snRNPs [29]. 
The decision which part of the pre-mRNA is an exon and which is intron depends on a number 
of cis-elements. Conserved cis-elements adjacent to splicing sites are called splicing acceptor 
sites. They are found on exon-intron-boundaries of pre-mRNAs and are often UG-rich such as 
UUCUG and UGUU [38] [39].  
Generally, introns consist of a 5’ donor site, a branch point and a 3‘ acceptor site. Apart from 
the few self-splicing introns [40], most introns need a spliceosome to be cut out. There are two 
types of introns: the most common type of intron is processed by the so-called major 
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spliceosome and has a 5’ GU and a 3’ AG, whereupon the GU is strictly conserved and 
surrounded by a less conserved sequence (see Figure 3). The much more uncommon AU-AC 
type intron is processed by the minor spliceosome [41]. 
 
 
Figure 3: General structure of a GU-AG intron. 
Framed by two exons, the intron starts with a 5’ splice site that contains a conserved GU within 
a less conserved sequence. The branch point containing a highly conserved A is followed by 
a pyrimidine rich region and finally the AG comprising 3’ splice site. Modified from [41] [42]. 
Py: Pyrimidine nucleobase (cytosine or uracil) 
 
Interestingly, splicing not only occurs in the CDS of pre-mRNAs but also in UTRs. Removal of 
introns obviously has a tremendous impact on the length. Shorter 3'UTR isoforms have fewer 
binding sites for trans-acting factors such as miRs and are consequently more stable, resulting 
in higher protein level [43]. Higher expression rates in turn are linked to proliferating cells. 
Therefore, it is no surprise that shorter 3’UTRs can often be found in oncogenes and are 
associated with carcinogenic cells [44]. Nevertheless, it is often thought that 3’UTR splicing 
inevitable leads to nonfunctional transcripts due to nonsense-mediated decay (NMD). 
However, this is only the case when the intron is less than 55 nucleotides (nt) from a 
termination codon resulting in a pre-mature stop codon [45] [46]. Splicing within UTRs still does 
not gain much attention, although estimations on how many human UTRs contain introns range 
from 35% in 5’UTRs [47] to 6-16% in 3’UTRs [48] [49].  
In general, AS has a crucial impact on all kinds of cellular functions. Dysregulation can even 
lead to variances in cell cycle control, proliferation or apoptosis [50]. Therefore, it is discussed 
in literature to announce AS an additional hallmark of cancer [51]. Especially genomic splice 
site point mutations seem to be affected. For instance, there are at least 29 different splice site 
mutations in the Tumor Protein P53 (TP53/p53) gene that are found in all kinds of tumor types 
including lung cancer, breast cancer and leukemia [52]. It is well described that during normal 
differentiation oncogenes are inactivated via AS, whereas in tumor cells AS is manipulated to 
inactivate tumor suppressors [53] [54] [55] [56]. This underlines the importance of AS and post-
transcriptional regulation in general for physiological and cellular homeostasis. 
 
1.1.2 RNA-binding proteins (RBPs) 
RBPs fulfill a crucial role in post-transcriptional gene expression. Generally, it is proposed that 
unbalanced expression and function of RBPs occurs in the context of uncontrolled cell 
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proliferation and promotes tumor growth [57]. This reflects the relevance of protein-RNA 
interactions in cellular homeostasis. However, a definite causal connection has not yet been 
described [58] [59].  
In fact, RBPs control stability, decay, translation as well as localization of mRNAs (see Figure 
4A). They are able to shuttle mRNAs between the nucleus and the cytoplasm to actively 
translating ribosomes, stress granules or P-bodies [4] [60] [61] [62] [63] [64]. Vice versa, RBPs 
can also be the target of regulation by RNAs rather than being a regulating factor. The 
discovery of long non-coding RNAs (lncRNAs) and their association with the organization, 
scaffolding or inhibition of protein arrangement made it clear that RNA can also act on its bound 
protein, which contradicts the general view that it is normally the other way round. Thereby, 
RNAs can have an impact on localization, stability, interactions or functions of a protein (see 
Figure 4B) [65]. 
 
 
Figure 4: Interaction of RBPs with RNAs. 
Functional crosstalk of RBP/RNA interaction can occur in both directions. (A) RBPs can bind 
to RNAs via RNA-binding domains, influencing various aspects of the RNAs functions and fate. 
(B) By displaying protein-binding activity, certain RNAs (e.g. lncRNA) can affect various protein 
functions. Modified from [65]. 
 
 
The formation of a RNA-Protein-complex, also called ribonucleoprotein (RNP) complex is 
mediated by specific RNA-binding domains (RBDs) [66] [67]. Thereby, different specificities 
and affinities are based on sequence and structure of the RNA target. RBDs can be classified 
as followed: RNA-recognition motifs (RRMs), double stranded RBDs or Zinc finger domains 
[4]. Those RBDs can then bind to CREs mostly in 3’UTRs of mRNAs.  
One of the best described CREs are probably AU-rich elements (AREs). They are ubiquitously 
found in 3’UTRs of mRNAs [68] and interact with a variety of RBPs which can tag the RNA for 
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rapid degradation [69] but also stabilization [70]. In recent years, a similar sequence element 
called GU-rich element (GRE) was discovered. GREs are highly conserved throughout 
evolution and were primarily found in 3’UTRs of mRNAs with short half-lives [71]. Generally, 
GU-rich sequences appear in ca. 5% of RNAs in the human transcriptome [72]. They can 
regulate splicing, translation, deadenylation or mRNA decay, depending on the RBP they 
interact with during different intracellular settings [73] [74]. It was elucidated that GREs are 
specifically targeted by the CELF (CUG-Binding protein and embryonically lethal abnormal 
vision-type RNA binding protein like factors) family of RBPs [71].  
 
1.1.2.1 CUGBP1 and the CELF family of RBPs 
The CELF family influences a wide range of post-transcriptional processes, such as AS [75] 
[76] [77], deadenylation [9], C-U editing [78] [79], transport [80] [81] [82], translation [83] and 
most of all mRNA decay [84] .  
The RBP family is evolutionary conserved and comprises 6 members: CELF1-6 [85] [86] [87]. 
All of them harbor three RRMs, two N-terminal RBDs and one in the C-terminal region [88] [89] 
(see Figure 5). The divergent domain is potentially important for functional regulation but this 
is still discussed throughout literature. While CELF1 (CUG-RNA binding protein 1; CUGBP1) 
and CELF2 (CUGBP2) are ubiquitously expressed among cell types and tissues and fulfill a 
role in embryonic development [90] [91] [92] [93], CELFs 3-6 are only expressed in fully 
developed cells and are exclusively found in nervous tissue [94] [95] [88]. Although, it was 
proposed several years ago that the family members have redundant functions in mRNA 
regulation [96], it was later demonstrated that all have specific RNA binding affinities and 
distinct functions [97]. Physiologically, CELFs are crucial regulators for all kinds of 
developmental processes. This is especially well described for xenopus [98]. Besides, there 
are also several mouse models describing CELF-mediated shifting from fetal to adult 
alternative splice variants of several skeletal muscle transcripts [75] [99] [100]. Whereas it is 
experimentally confirmed that CELFs bind to C/UG-rich splicing acceptor sites, a prediction if 
this inhibits or activates AS is impossible, as it strongly depends on the cellular context [101].  
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Figure 5: General structure of the CELF family members. 
All CELF members consist of three RRMs: two N-terminal ones and one C-terminal RRM, with 
a divergent domain in-between that distinguishes them. Numbers indicate amino acids. 
Modified from [102].  
 
CELFs preferentially bind to 15-22 nt long GU-rich sequences [103] [104] [105] whereas, most 
RBDs bind shorter (GU-rich) motifs like TAR DNA Binding Protein (TARDBP) [106]. GREs 
have defined consensus sequences based on the pentameric GUUUG (see Table 1) which 
was originally identified in human T-cells [71]. Today, it is known that GRE-containing 
transcripts appear in a variety of cells, including other immune cells, mouse brain cells or 
human cancer cells [84]. While the exact outcome mostly depends on cellular and 
environmental context, GREs also transfer instability when cloned in otherwise stable 
transcripts [71]. 
 
Table 1. Comparison of different GRE clusters.  
 
GRE mRNAs were clustered (one mismatch allowed) into five subclasses based on the number of 
pentameric (GUUUG) repeats and surrounding sequences. K stands for G or U. Clusters I and II contain 
four or more overlapping GUUUG pentamers and are found in only a few hundred transcripts such as 
transcription factors, cell cycle regulators and intercellular communication genes. Clusters III, IV and V 
represent shorter sequences with less repetition and are found in several thousand transcripts. CELF: 
CUGBP Elav-Like Family Member; ELAVL4: Embryonic Lethal Abnormal Vision Like Neuron-Specific 
RNA Binding Protein 4; RBM38: RNA Binding Motif Protein 38; TARDBP: TAR DNA Binding Protein. 
Based on [107] and [72]. 
 
Cluster GRE sequences Functional categories Trans-acting factors 
I GUUUGUUUGUUUGUUUGUUUG 
transcription factors, cell 
cycle, cell metabolism, 
cell–cell communication 
regulators 
CELF1, CELF2, 
ELAVL4, RBM38, 
TARDBP, FUS 
II GUUUGUUUGUUUGUUUG 
III GUKUGUUUGUKUG 
IV KKGUUUGUUUGKK 
V KKKU/GUKUG/UKKK 
Introduction 
__________________________________________________________________________ 
 
20 
 
In the focus of this thesis is the CELF family member CUGBP1. It was first discovered in 1996 
and described to regulate myotonic dystrophy type 1 (DM1) [108].  Initial SELEX experiments 
(systematic evolution of ligands by exponential enrichment) demonstrated that CUGBP1 
preferably binds GU-repeat sequences (UGU) [104]. To date, it is also described to bind to 
GC-rich or even A-containing sequences [109]. CUGBP1 in general is known as an inhibitory 
post-transcriptional regulator. It is responsible for mRNA deadenylation [9], subsequent 
degradation  [110] or AS [111] [112] and is conserved in a variety of species including humans, 
mice, drosophila and xenopus [113] [114]. It was found that knockdown of CUGBP1 led to a 
severe stabilization of GRE containing transcripts [115] [116] [117] which underlines its 
function as gene expression repressor. In contrast to its paralogue, CUGBP2 which rather 
stabilizes targets [118].  
The activity of CUGBP1 is regulated via its phosphorylation status [119]. In total it has 9 
described phosphorylation sites mostly on serines or threonines [120]. Through 
hyperphosphorylation by Protein Kinase C, CUGBP1 is stabilized and reveals elevated splicing 
activity in DM1 [121]. In mouse myoblasts, CUGBP1 is described to be phosphorylated at 
serine 28 by AKT Serine/Threonine Kinase 1, which influences its function as translational 
regulator during myocyte differentiation and murine heart development [122]. Finally, it was 
shown that phosphorylation by cyclin D3-CDK4/6 additionally interferes with CUGBP1’s RNA 
binding capacity [123]. So overall, phosphorylation seems to be one key factor for CUGBP1 
regulation on many levels. 
As regulator of AS, CUGBP1-mediated exon skipping or inclusion depends on the 
developmental stage of the cell [112]. This function is best investigated in the context of DM1 
[111]. The autosomal dominant neuromuscular disease is characterized by a trinucleotide 
repeat extension in the gene for myotonic dystrophy protein kinase (DMPK) resulting in an 
impaired gene expression [124]. In that regard, a balance between CUGBP1 and the splicing 
factor muscle blind like protein 1 (MBNL1) is essential. Gain of CUGBP1 function goes along 
with loss of function of MBNL1 which leads to AS of a variety of crucial transcripts [124]. The 
outcome can include heart conduction problems, impaired muscle strength, cataract 
development or insulin resistance [125]. Moreover, CUGBP1 influences ca. 50% of heart 
development-related transcripts by changing the splicing events between fetal and adult 
developmental stages [126].  
Several promising studies with mouse models are investigating CUGBP1’s effects on cardiac 
dysfunction and cardiomyopathy [126] [127]. However, CUGBP1 functions are too diverse to 
distinguish between effects based on AS, mRNA degradation or deadenylation. Interestingly, 
up to now it is not known how exactly CUGBP1 mediates deadenylation of human transcripts. 
Concerning mammalians, it is only known that CUGBP1 recruits PARN in the human hepatoma 
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cell line Huh7 [128] and cell-free assays [9]. Interaction with PARN surely does indicate 
involvement of deadenylation [84] but this is still under investigation. As deadenylation is a 
crucial step in degradation of mammalian transcripts [129] [130], it was consequential to 
investigate if CUGBP1 is involved in other mechanisms of mRNA decay. It is postulated that 
there exists some kind of CUGBP1-mediated decay process [71], but to date there are no 
studies elucidating the exact mechanism. It is well studied that CUGBP1 regulates whole 
networks of transcripts (regulons) involved in murine myoblast growth and differentiation, 
including crucial targets associated with cell cycle and survival [110]. In addition, CUGBP1 
plays an important role in the rapid alteration of expression profiles during the activation of 
human T-cells through alternative polyadenylation [131]. In activated primary T-cells, 
hyperphosphorylation of CUGBP1 impairs its binding to target mRNAs. The results are 
increased protein levels of the targets which include a variety of proteins associated with an 
activated proliferative cell type [132].  
Additionally, CUGBP1 also plays a role in the regulation of translation. It has activating 
properties, observed at many stages of cellular development [133] [134]. However, under 
stressful conditions CUGBP1 can also act as silencer and suppress translation in conjunction 
with several other proteins [135]. Additionally, the mode of action apparently depends on the 
context and cell type. It was recently described that in mesenchymal cells as well as MCF-10A 
breast cancer cells, CUGBP1 has a positive effect on translation of a variety of mRNAs 
involved in epithelial to mesenchymal transition (EMT) [136] [137]. Whereas in intestinal 
epithelial cells it represses translations of the insulin like growth factor 2 receptor mRNA. 
Overall, the mechanisms of how CUGBP1 is involved in translation, deadenylation and mRNA 
decay are not fully elucidated to date. 
 
1.1.3 MicroRNAs (miRs) 
MiRs are highly conserved non-coding RNAs and complete the complex network of post-
transcriptional regulators covered within this thesis. MiRs are described as short single 
stranded RNAs of approximately 21 nt length. The first miR was discovered in 1993, when Lee 
et al. found lin-4 in the first larval stage of the nematode C. elegans. They discovered that this 
small RNA was able to repress the lin-14 gene expression by complementary binding to its 
3’UTR [138]. The name “microRNA” was defined not before the year 2001, though [139].  
There are several ways of miR biogenesis (see Figure 6). On the one hand, a subset of miRs 
is derived from introns (mirtrons) or even exons of protein-coding genes, meaning their 
expression is depending on the host gene [140] [141] [142]. On the other hand, miRs can also 
by transcribed from specific miR-genes by RNA polymerase II [143] [144]. Transcription of 
miR-genes creates so-called primary miRs (pri-miRs) which are further processed via splicing, 
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editing and polyadenylation [144] [145]. The double stranded pri-miRs are usually several 
hundred nucleotides long and form a hairpin structure [146] [147]. A large microprocessor 
complex comprising the RNA binding protein DiGeorge Syndrome Critical Region 8 (DGCR8) 
and the ribonuclease III Drosha further processes the pri-miR to generate the much shorter 
precursor-miR (pre-miR) [146] [148] [149]. In contrast, mirtron-derived pre-miRs are generated 
by the spliceosome and an additional processing step mediated by the debranching enzyme, 
to form a hairpin from a single stranded intron [150].  
Nuclear export of all pre-miRs is then conducted by the shuttle protein exportin-5 which 
recognizes a two nt overhang at the 3’ end of the hairpin [149]. During this energy consuming 
step, the Ras-related nuclear protein (RAN) provides the necessary guanosine triphosphate 
(GTP) [151]. Cytosolic pre-miRs need to be further processed. Therefore, the RNA 
Polymerase III Dicer is recruited [149] [152]. Enzymatically, the loop structure is removed from 
the hairpin by Dicer, resulting in an 18-22 nt long miR duplex [153]. Although either strand of 
the miR duplex is potentially functional, usually only one strand does fulfill physiological 
functions, while the other one is degraded [147] [154]. 
 
 
Figure 6: miR biogenesis. 
miRs can either be transcribed from specific miR genes or spliced from intronic sequences of 
host genes. In the ladder case, the spliceosome and a debranching enzyme are necessary to 
generate the pre-miR. Specific miR genes produce an intermediate molecule called pri-miR 
which is capped and polyadenylated and further processed by Drosha to create the pre-miR. 
With the help of RAN-GTP and Exportin-5, the pre-miR is shuttled to the cytoplasm where it is 
processed by Dicer to generate a miR duplex, which finally leads to the mature miR of 18-22 
nt length. Modified from [155]. 
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MiRs fulfill an essential role in physiological homeostasis by regulating all kinds of cellular 
functions. Thus, it is no surprise that dysregulation of miRs can cause severe impairment of 
normal body functions and can lead to diseases including autoimmune conditions [156], heart 
[157] [158] [159] and kidney diseases [160], hereditary diseases such as non-symptomatic 
progressive hearing loss [161] and many different types of cancer [162].  
Indeed, many miRs are associated with cancer development and progression and are 
intensively studied in that regard. In general, miRs that are associated with cancer are called 
oncomiRs [163]. This term applies to all miRs that show a differential expression level in tumor 
cells, if they act as oncogenes or tumor suppressors [164]. A prominent example is miR-21, 
which has been shown to be increased in most types of cancers including tumors of the colon, 
lung, breast, pancreas, as well as leukemia and lymphoma [165] [166] [167]. In contrast, in 
many tumors types, a global decrease in overall miR levels has been described [168] [169]. 
Additionally, a severe shortening of 3’UTRs was observed. Shorter 3’UTRs are beneficial 
because they provide a smaller number of miR binding sites, allowing for upregulation of 
oncogenes [170]. This is based on the canonical miR function as inhibitor of gene expression, 
which will be explained in the following chapter. 
 
1.1.3.1 Canonical miR functions 
Conventionally, miRs are known as global gene expression repressors. They bind to 3’UTRs 
of target mRNAs and impair proper translation or even lead to degradation of the mRNA. Either 
mechanism leads to a decreased protein level. This mode of action is called RNA interference 
(RNAi). Originally, it was described for small interfering RNAs (siRNAs) which act against viral 
infections [171].  
Mainly in plants, miRs show a near perfect pairing, while target recognition in animals is 
mediated by a specific seed region within the miR sequence. It is located at position 2-8 on the 
5’ end of the miR [172]. In most cases, the seed region base pairs with responsive elements 
in the 3’UTR of the mRNA targets. Although, computational analysis reported that miR binding 
sites are also found all over 5’UTRs and coding-sequences [173] [174].  
The key to canonical miR functionality is the formation of the RNA-induced silencing complex 
(RISC) [175]. This protein complex is formed minimally by Argonaute 2 (AGO2) [176] [177] and 
the respective miR, but usually it also comprises other proteins from the AGO family [178] as 
well as further RISC-associated proteins such as DEAD-box helicase 20 [179]. However, to 
date the exact composition of the RISC is not yet fully understood and seems to vary between 
studies.  
The miR duplex is recruited to the RISC by Dicer. Within the complex, it is decided which strand 
of the duplex functions as guide strand and which one is degraded by RISC [180]. Usually, the 
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strand with higher 5’ end stability is the functional one [181]. The bound miR is then used to 
target specific mRNAs via Watson-crick base pairing while the AGO proteins are responsible 
for the mode of action of gene regulation [180]. MiRISC can influence the gene expression of 
mRNA transcripts via two different mechanisms [182] [183]. Dependent on the level of 
complementarity, miR binding either leads to translational repression or RISC-mediated 
degradation of the mRNAs. These are the commonly known functions of miRs, however in the 
last few years diverse studies described a variety of further functions and modes of action that 
miRs are involved with. 
 
1.1.3.2 Non-canonical miR functions 
For a long time, miRs were only considered to bind to mRNAs and act as post-transcriptional 
repressors. Only a few years ago, it was discovered that miRs can also have a variety of totally 
different functions. For example, miRs which are secreted in exosomes are incorporated by 
donor cells and can interact with toll-like receptor 7/8 (TLR7/8) [184]. Fabbri et al. found that 
human miR-21 and miR-29a can both be secreted by tumor cells to act on human TLR8 or 
murine TLR7 in adjacent immune cells and induce a pro-inflammatory immune response [184]. 
In the following, several studies confirmed the interaction e.g. in the context of neuroblastoma 
[185], neuropathic pain [186] or murine myoblasts [187] or even in the context of Alzheimer’s 
disease [188].  
The discovery of this unusual miR function was accompanied by a variety of studies also 
describing novel modes of actions. For instance, miRs were found to act as activator or silencer 
of transcription. The first one was miR-327, which was described to induce Cadherin-1 (CDH1) 
and Cold Shock Domain Containing C2 (CSDC2) in human prostate cancer cells via a 
complementary promoter sequence [189]. Later, there was similar evidence for various other 
miRs, however the exact mechanism is still unclear. 
Furthermore, miRs can also control miR maturation. For example, Let-7 forms a positive 
feedback loop by binding to its own pri-miR. In turn, further processing of the pri-miR is 
enhanced which elevates the mature let-7 levels in C. elegans [190]. On the other hand, 
miR-709 is able to block maturation of other miRs. It binds to a specific motif in the 
miR-15a/16-1 pri-miR structure in murine cells and inhibits further processing [191]. Moreover, 
miRs can also interact with other non-coding RNAs. It was found that 4% of all AGO-mRNA 
tags were associated with lncRNAs, indicating that miRs could recruit AGOs to lncRNAs to 
influence their stability or function [192].  
This thesis focuses on the new non-canonical decoy function of miRs. Eiring et al. initially 
demonstrated that miR-328 can interact with the RBP hnRNP E2 [193]. In this context, miR-328 
positively influences the gene expression of CCAAT/enhancer-binding protein alpha (CEBPA) 
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by acting as competitive inhibitor to hnRNP E2 in leukemic blasts. This new decoy function is 
independent of the miR’s seed region and solely functions through interference with the RBP. 
In 2016, it was revealed that this novel mode of action does not only influence gene expression 
of CEBPA alone, but also S100A9 was validated as miR-328/hnRNP E2 decoy target in 
monocytes [194]. The list was recently extended to HMGB1 as well as 141 further proteins 
which were also predicted as decoy targets [195]. Hence, the miR-328 and hnRNP E2 decoy 
seems to have a global impact on a variety of targets and was even observed in different cell 
types. 
Recently, this decoy mechanism was also described for miR-574-5p and CUGBP1 in A549 
lung cancer cells [196] which will be discussed more closely in the following chapters. 
 
1.1.3.3 MiR-574-5p  
MiR-574-5p is a mirtron encoded in the first intron of the gene FAM114A1. This gene is coding 
for the nervous system overexpressed protein 20 (NOXP20), which is overexpressed in the 
brain [197] although NCBI GEO data [198] indicate that it might be expressed all over the body, 
especially in mesenchymal cells [199]. Nevertheless, there is still very little known about the 
function of NOXP20. Only the fact that it contains a caspase recruiting domain gives a hint that 
it might be involved in apoptosis [197]. It is implied that miR-574-5p expression is connected 
to NOXP20 expression. However, since there are no publications on the regulation of NOXP20 
expression, no further conclusions can be drawn from that.  
So far, only two publications describe how miR-574-5p expression is regulated. There is 
evidence that NFκB transcription factor p65 could regulate its transcription in mice in a context 
of neurological disorders [200]. Furthermore, it has been observed that the amyloid precursor 
protein APP influences the miR-574-5p level in the development of the cerebral cortex, 
although by an unknown mechanism [201]. 
Regulation of not the expression but rather the functionality of miR-574-5p is described more 
closely in literature. There are reports of three different lncRNAs to regulate miR-574-5p. While 
lncRNA-MFI2-AS1 (melanotransferrin) influences miR-574-5p in colon cancer cells [202], in 
breast cancer it is lnc-Zinc Finger Protein 469 (ZNF469)-3 which binds to miR-574-5p [203]. In 
papillary thyroid carcinoma cells, lnc-PTCSC3 (Papillary Thyroid Carcinoma Susceptibility 
Candidate 3) is described to have an impact by binding to miR-574-5p [204]. In this case, the 
interaction is further associated with Wingless-Type MMTV Integration Site Family Member 1 
(Wnt) signaling. MiR-574-5p regulates β-catenin/Wnt-signaling via suppressor of cancer cell 
invasion (SCAI) and thereby influenced invasion and migration of the tumor cells [204].  
Indeed, the relationship between miR-574-5p and Wnt signaling is described in several other 
studies. In colon and thyroid cancer, Wnt signaling was found to be activated by inhibition of 
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the RBP quaking (Qki) [205] [206]. In fact, miR-574-5p targets Qki-6/7 which results in a 
reduced protein level [205]. In turn, Qki no longer acts as suppressor of β-catenin and the Wnt 
signaling pathway is activated [207]. Both leads to further progression of tumor growth by 
facilitating proliferation and inhibiting apoptosis of the colon cancer cells. In contrast, 
miR-574-5p is also described to act anti-tumorigenic in two other colorectal cancer studies by 
targeting metastasis-associated in colon cancer protein 1 (MACC1) [208] or MYC Binding 
Protein (MYCBP) [202].  
On the other hand, the influence of miR-574-5p on lung cancer development seems to be 
unambiguous. Several publications showed that miR-574-5p acts pro-metastatic and 
enhances tumor progression of (non-) small cell lung cancer ((N)SCLC) by targeting among 
others checkpoint suppressor 1 (CHES1) and protein tyrosine phosphatase receptor type U 
(PTPRU) [209] [210] [211]. Additionally, miR-574-5p also seems to promote cell growth in the 
context of coronary artery disease by binding to the mRNA of zinc finger DHHC-type containing 
14 (ZDHHC14) [212]. Finally, miR-574-5p is described to repress the expression of ceramide 
synthase 1 (CerS1) together with HDAC1 [213], while it can also act in concert with miR-361-5p 
in white adipose tissue to regulate early B cell factor 1 (EBF1) [214]. 
 
 
Figure 7: Canonical targets regulated by miR-574-5p. 
miR-574-5p has been described to directly target a variety of mRNAs. Thereby, it influences 
various types of cancers, as well as cardiovascular and neurological conditions. miR-574-5p 
binds the mRNAs of the respective proteins, and downregulates the expression. Based on 
[200] [202] [204] [205] [206] [208] [209] [210] [211] [212] [213] [214]. 
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It gets clear that miR-574-5p plays a role in a variety of diseases and cellular processes by 
direct interaction with various targets (see Figure 7). Besides the direct base pairing with a 
mRNA, miR-574-5p was recently described to interact with the RBP CUGBP1 [196]. By this 
mechanism, miR-574-5p has an impact on lipid metabolism and tumor progression which will 
be discussed in the next two chapters. 
 
1.2 mPGES-1-derived PGE2 in cancer development 
In 2011, alteration in lipid metabolites was announced a hallmark of cancer [215]. Metabolic 
reprogramming of lipid mediators obviously also includes prostanoids such as prostaglandin 
E2 (PGE2). The metabolite PGE2 is a bioactive lipid mediator which shows great importance in 
the regulation of a variety of physiological and pathophysiological processes, such as 
inflammation, pain and tumorigenesis [216] [217] [218] [219]. It is generated in a first step by 
the enzymes cyclooxygenase (COX)-1 or COX-2 by converting arachidonic acid to PGH2.This 
instable intermediate is then further converted by microsomal prostaglandin E2 synthase 1 
(mPGES-1) [220]. The generated PGE2 is secreted by the cell and elicits a wide range of pro-
tumorigenic functions by binding to the EP1-4 receptors. High levels of mPGES-1 could be 
observed in various types of cancers including colon [221], prostate [222] and lung cancer 
[223]. Increased levels of COX-2 as well as mPGES-1 are further associated with a poor overall 
survival rate [224]. MPGES-1 activity does not only have an impact on pain and inflammation 
in the tumor microenvironment but also enhances the progression of the tumor itself. Moreover, 
PGE2 is responsible for the crosstalk of cancer and stromal cells within the tumor tissue. The 
result is a highly efficient immune evasion, which facilitates further tumor growth [219]. One 
example is cervical cancer-derived PGE2 which was observed to induce monocyte 
differentiation into tumor-associated macrophages (TAMs) [225]. Furthermore, PGE2 not only 
suppresses an anti-tumorigenic immune response but also facilitates tumor growth directly 
[226]. In the case of breast cancer, PGE2 leads to lymph angiogenesis while the EP4 receptor 
seems to be the most important one in that context [227]. Also in lung cancer, EP4 is the crucial 
receptor, leading to enhanced tyrosine kinase c-Src activation and subsequently to an 
increased tumor growth as well as metastasis [228].  
Overall, there are numerous publications describing the influence of PGE2 on tumor 
progression (for reviews see [218] [229] [230] [231]). Therefore, it is no surprise that the pro-
tumorigenic properties of PGE2 attracted great attention to potential pharmacological inhibition 
of its synthesis. However, current approved medication to interfere with the negative effects of 
PGE2 comprise only inhibitors of the COX enzymes. Especially in long time treatment, these 
therapeutic approaches show severe side effects like increased cardiovascular events or 
gastrointestinal bleeding [232] [233] [234] [235] [236]. With inhibition of the COXs, other 
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prostanoids like PGD2, prostacyclin (PGI2) and thromboxane (TXA) are also impaired (see 
Figure 08). For this reason, it would be much more reasonable to target mPGES-1 rather than 
COX-2 [237]. Inhibition of mPGES-1 would minimize side effects [238] and hypothetically also 
cause a shift towards PGI2 and PGD2, which would be beneficial for the cardiovascular system. 
[239] [240]. Several studies have shown that genetic deletion or pharmacological inhibition of 
mPGES-1 is indeed a promising tool against tumor growth [222]. 
  
 
Figure 8: Prostanoid biosynthesis. 
Arachidonic acid is converted by either COX-1 or COX-2. The resulting instable intermediate 
PGH2 is then further processed by respective synthases to generate the prostanoids PGE2, 
PGI2, TXA2, PGD2 or PGF2a. NSAIDs inhibit COX enzymes and therefore all prostanoids 
downstream of PGH2. Therefore, inhibition of only PGE synthase (mPGES-1) by 
CUGBP1/miR-574 decoy would be more beneficial and should not affect other prostanoids. 
Modified from [241]. 
 
However, most of the developed mPGES-1 inhibitors have a problematic limitation: they do 
not work in mouse or rat models, since mPGES-1 is not conserved in rodents [242]. As murine 
and human mPGES-1 differ in three amino acids near the active site of the enzyme [243], the 
majority of human inhibitors does not repress the murine enzyme activity. Therefore, any kind 
of pre-clinical study is impossible, due to a lack of established animal models. An exception is 
Compound III which inhibits both human and murine mPGES-1 [244] [245] [246] [247] and was 
already shown in pre-clinical studies to be an efficient tool against neuroblastoma [246]. 
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Besides pharmacological inhibition of mPGES-1, recently a post-transcriptional regulation 
mechanism was unravelled which will be described more closely in the next chapter. 
 
1.2.1 Regulation of mPGES-1 by the miR-574-5p/CUGBP1 decoy mechanism in human 
lung cancer 
Recently, the PGE2-generating synthase mPGES-1 was found to be regulated in a non-
canonical way [196]. Until then, it was not much known about post-transcriptional regulation of 
mPGES-1. In its 3’UTR there are two long GREs which represent binding sites for the RBP 
CUGBP1. A similar sequence can be found in miR-574-5p. In an inflammatory environment 
like stimulation with IL-1β, miR-574-5p is able to sequester CUGBP1 away from the mPGES-1 
mRNA (see Figure 9). This eliminates the negative influence of the RBP and additionally 
results in an AS event. The mPGES-1 3’UTR is spliced which removes a conserved ALU 
element in between the two GREs. The shorter splice variant has a higher translational rate. 
Therefore, the decoy has an overall enhancing effect on mPGES-1 gene expression [196].  
 
 
 
Figure 9: Regulation of mPGES-1 gene expression via the miR-574-5p/CUGBP1 decoy 
mechanism.  
CUGBP1 binds to two GREs within the mPGES-1 3’UTR. Upon IL-1β simulation, miR-574-5p 
acts as decoy to CUGBP1, preventing it from binding to the GREs. This results in an AS event 
creating a shorter 3’UTR isoform with a higher translational rate. As a result, mPGES-1 levels 
and PGE2 synthesis are increased as well as subsequent tumor growth in vivo. Modified from 
[196]. 
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The increased mPGES-1 protein level then leads to a higher level of its enzymatic product 
PGE2. As described above, PGE2 has a crucial influence on the progression of cancer. In a 
xenograft mouse model, it could be demonstrated that this decoy mechanism has a 
tremendous impact on lung tumor growth. When miR-574-5p overexpressing lung cancer cells 
were injected into nude mice hind flanks, it was revealed that they displayed a strongly 
increased proliferation. The tumor weight and volume was significantly increased compared to 
control tumors. Moreover, urinary PGE-M levels linked this to enhance PGE2 formation. 
Interestingly, progression of miR-574-5p overexpressing tumors was reduced back to control 
level with the simultaneous administration of the mPGES-1 inhibitor Compound III. This proved 
that the pro-tumorigenic effects of miR-574-5p were solely caused by the decoy-mediated 
mPGES-1 induction [196]. This conclusion is consequential because a delayed growth of 
murine xenograft tumors was already observed upon mPGES-1 knockdown in an earlier study 
[222]. Hence, this new non-canonical mPGES-1 regulation mechanism is an intriguing 
research topic in the context of future lung cancer research. 
 
1.3 Aim of the study 
With the discovery of the new decoy mechanism in human lung cancer, it would be possible 
for the first time to regulate mPGES-1 expression on mRNA level. In order to further 
characterize the miR-574-5p/CUGBP1 decoy in lung cancer, a TMT-based proteomics study 
was used to unravel the overall impact on cellular protein levels. It should be revealed if the 
miR-574-5p/CUGBP1 decoy has a global impact similar to the miR-328/hNRNP E2 decoy or 
if mPGES-1 could be the only target. In that case, this would open up new options for NSCLC 
patients. Not all patients benefit from a treatment with medication that aims to reduce PGE2 
levels [248] [249]. Potentially, because not all lung adenocarcinomas are comparably PGE2-
dependent. Therefore, levels of miR-574-5p could be used as stratification marker in order to 
identify those patients with higher mPGES-1 and PGE2 levels. For this subgroup, a treatment 
with COX inhibitors could be highly beneficial in the fight against NSCLC. 
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2. Materials and Methods 
2.1 Cell culture methods 
2.1.1 Cell culture conditions 
The human cell line A549 (ATCC Manassas, VA, USA) is derived from a 58-year old male with 
lung adenocarcinoma. Cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Life 
technologies) supplemented with 10% (v/v) fetal calf serum (FCS; Life technologies), 
100 U/mL penicillin (PAA the Cell Culture Company) 100 µg/mL streptomycin (PAA the Cell 
Culture Company) and 1 mM sodium pyruvate (PAA the Cell Culture Company) (= fully 
complemented medium). Cells were grown in T75 cell culture flasks under standard growth 
conditions (humidified atmosphere of 5% CO2 at 37°C). When the cells reached a confluence 
of ~ 70-90%, medium was aspirated and cells were washed with pre-warmed phosphate 
buffered saline (PBS). Then, they were detached using pre-warmed Trypsin-EDTA (Invitrogen) 
at 37°C for 5 min. Reaction was stopped adding pre-warmed full culture medium (1:1) to the 
cells and number of viable cells was examined by trypan blue staining and counted using Bio-
Rad TC10 automated cell counter (both Bio-Rad Laboratories). Approximately 1 million cells 
were transferred into a new T75 culture flask. For all experiments, cells were seeded in 6-well 
plates à 5x105 cells per well in 2 mL medium. Except for RIP assays, where 3 x 106 A549 cells 
were seeded in 10-cm dishes in 10 mL medium. 
For preparation of liquid nitrogen stocks, A549 cells were detached as described above and 
resuspended in medium containing 10% (v/v) DMSO (Carl Roth). The suspension was 
transferred into cryo vials (VWR) and stored at -80°C for 2 days. Afterwards, cryo vials were 
transferred into a liquid nitrogen tank until further use. In order to thaw cells again, the cryo 
vials were carefully pre-warmed at room temperature until suspension began to thaw. Then, 
pre warmed medium was added and the cryo vial was rinsed until the whole suspension was 
thawed and transferred in a 50 mL reaction tube. Cells were precipitated in a centrifuge for 5 
min at 1,200 rpm (Eppendorf Centrifuge 5702), to remove DMSO. Supernatant was discarded, 
the cell pellet was resuspended in fresh pre-warmed medium and transferred in a T75 cell 
culture flask. 
 
2.1.2 Depletion of CUGBP1 using RNA interference 
By using siRNA oligonucleotides, CUGBP1 was transiently knocked down. Therefore, a 
previously published siRNA (5´-GCUGUUUAUUGGUAUGAUU-3´) was used. 24 h prior to 
transfection, A549 cells were seeded in a 6-well plate as described above. For transfection, 
20 pmol/µL siRNA oligonucleotides were transfected using Lipofectamin2000® (Invitrogen) 
according to manufacturer’s instructions. A siRNA against GFP, naturally not expressed, was 
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designed (5´-UCUCUCACAACGGGCAUUU-3´) and used as negative control. After 24 h, cells 
were stimulated with 5 ng/mL interleukin (IL)-1β (Sigma-Aldrich). Further 24 h later, the 
samples were harvested using 500 µL pre-warmed Trypsin-EDTA (Invitrogen) as described 
above. Transfection efficiency was tested by Western blot analysis (see chapter 2.3.3 SDS-
PAGE and Western Blot). 
 
2.1.3 Overexpression of miR-574-5p 
For transient overexpression (oe) of miR-574-5p, the miRIDIAN hsa-miR-574-5p mimic 
(HMI0794, Sigma-Aldrich) and negative control (HMC0002, Sigma-Aldrich) were used. A549 
cells were seeded 24 h prior to transfection in a 6-well plate. 20 pmol/µL per well of the mimics 
or control were transfected using Lipofectamin2000® (Invitrogen) according to the 
manufacturer´s instructions. After 24 h, cells were stimulated with 5 ng/mL IL-1β (Sigma-
Aldrich). Further 24 h later, the samples were harvested using 500 µL pre-warmed Trypsin-
EDTA (Invitrogen) as described above. The efficiency was assessed by qRT-PCR analysis 
(see chapter 2.2.2 mRNA or miR quantification by qRT-PCR) as stated in [196]. 
For stable overexpression of miR-574-5p, the lentiviral particles Mission® lenti miR-574-5p 
(HLMIR0794, Sigma-Aldrich) or Mission® lenti control (NCLMIR001, Sigma-Aldrich) were 
used. A549 cells were seeded at a density of 5 x 105 per well in a 6-well plate 24 h prior to 
transduction. Lenti viral particles were rapidly thawn and added to the cells at a MOI of 0.83 
for spinoculation (875 x g, at 32°C for 60 min). Transduced cells were incubated for 24 h in 
fully complemented DMEM before 10 µg/mL puromycin (Sigma-Aldrich) were added for four 
days to select the transduced clones. These stable A549 miR-574-5p overexpression and 
control cell lines were generously provided by Stefan Stein, Georg-Speyer Haus, Frankfurt 
[196]. The transduction efficiency was verified by qRT-PCR (see chapter 2.2.2 mRNA or miR 
quantification by qRT-PCR). 
 
2.1.4 Depletion of miR-574-5p by LNA™ inhibitors 
Transient depletion of miR-574-5p was achieved using LNAs™ from Exiqon (miR-574-5p-
LNA™ inhibitor and negative control MIMAT0004795). A549 were seeded 24 h prior to 
transfection at a density of 5 x 105 cells in a 6-well plate. 40 pmol/µL per well was transfected 
using Lipofectamin2000® (Invitrogen) according to manufacturer’s instructions. After 24 h, cells 
were stimulated with 5 ng/mL IL-1β (Sigma-Aldrich). Further 24 h later, the samples were 
harvested using 500 µL pre-warmed Trypsin-EDTA (Invitrogen) as described above. Efficiency 
of the knockdown was measured by qRT-PCR analysis (see chapter 2.2.2 mRNA or miR 
quantification by qRT-PCR) as stated in [196].  
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2.1.5 Wound healing assay 
For determination of migratory behavior of A549 cells, wound healing assays were performed 
with stable A549 miR-574-5p overexpression and control cells. Therefore, cells were seeded 
in 6-well plates as described above. In order to minimize proliferation, cells were pre-starved 
for 24h in Opti-MEM (Life technologies). Each condition was assessed in duplicates. 
Scratching was performed in the middle of the well using a 10 µL pipette tip. Remaining cell 
debris was washed away with pre-warmed PBS, before reduced culture medium was applied 
(only containing 2% FCS). Images were taken immediately after scratching at time point t0 and 
after 24 h as described in chapter 2.6.2 Wound healing assay images. 
 
2.1.6 Trans-well migration assay 
Trans-well assay, also called Boyden chamber assay, was performed with stable A549 
miR-574-5p overexpression and control cells. Cultured cells were detached as described 
above and sedimented for 5 min at 1,200 rpm (Eppendorf Centrifuge 5702). The cell pellet was 
then resuspended in serum-free culture medium without any FCS. 5 x 104 cells were seeded 
in a volume of 100 µL in a 24-well cell culture insert (Corning, Cat. No. 353097). Those inserts 
have a membrane on the bottom with 8 µm pores to enable migration of A549 cells. The inserts 
were placed in a 24-well plate and cells were allowed to adhere for 20 min at room temperature. 
Subsequently, the bottom of the wells was filled with 700 µL of full complemented culture 
medium to encourage migratory behavior (see Figure 10). As negative control, one well was 
filled with serum-free medium which restrains migration.  
Samples were cultured for 5 h at 37°C. Then, the inserts were washed in PBS. Non-migrated 
cells that were still on the inside of the insert were removed by swiping. Migrated cells on the 
bottom of the insert were fixed for 3 min at room temperature by placing the inserts in new 
wells filled with 700 µL of methanol (VWR). Afterwards, cells were stained with 0.5% crystal 
violet (Carl Roth) for 10 min at room temperature. Residual dye was remove by washing the 
inserts with autoclaved Millipore water (MQ) followed by an additional swiping step to remove 
cells from the inside of the insert. The membranes were then cut out using a scalpel and were 
mounted on cover slides with Pertex® (VWR). Number of violet migrated cells was counted 
under a light microscope using a manual cell counter. The protocol was kindly provided by Dr. 
Kati Turkowski and PD Dr. Rajkumar Savai, Max-Planck-Institute for Heart and Lung 
Research, Bad Nauheim. 
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Figure 10: Boyden chamber set-up. 
Cells are seeded in a cell culture insert with a 
membranous bottom (pore size 8 µm) and migrate 
towards an increased FCS concentration. After 
5 h, migrated cells on the bottom of the membrane 
can be fixed, stained and counted under a light 
microscope. 
 
  
 
2.2 RNA methods 
2.2.1 RNA extraction  
Total RNA was extracted using TRIzol Reagent (Invitrogen) performing a standard phenol 
chloroform protocol. In short, cell pellets were resuspended in an appropriate amount of TRIzol 
and incubated for 5 min. Then, 200 µL Chloroform (Carl Roth) were added and samples were 
thoroughly mixed before incubation on ice for 15 min. After centrifugation for 15 min at 4°C 
with 17,000 x g, the upper aqueous phase containing the RNA was transferred to a fresh tube 
and 500 µL isopropanol (VWR), 5 µL 3M sodium acetate (pH 6.5) (Carl Roth) and 1 µL 
GlycoBlue™ (Thermo Fisher Scientific) were added and mixed. Samples were incubated 
further 15 min on ice before another centrifugation step was performed. The precipitated RNA 
pellet was then dissolved in an appropriate amount of MQ. The RNA was then treated with 
Turbo DNase (Ambion) for 5 min according to the manufacturer’s instructions to remove 
residual DNA. DNase digested RNA was incubated for 30 min at -80°C together with 100 µL 
ethanol (VWR), 2 µL 3 M sodium acetate (pH 6.5) and 1 µL Glyco blue™. RNA was then 
precipitated for 30 min at 17,000 x g at 4°C. The pellet was washed with 70% ice-cold ethanol 
by rinsing the pellet and a subsequent centrifugation for 5 min at 17,000 x g at 4°C. The RNA 
pellet was air dried for 5 min at room temperature and resuspended in an appropriate amount 
of MQ.  RNA concentration and purity were then measured by UV spectroscopic measurement 
using the NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific). 
 
2.2.2 mRNA or miR quantification by qRT-PCR 
For mRNA quantification, 1 µg of DNase-treated RNA was used for reverse transcription. 
Therefore, the High-Capacity RNA-to-cDNA Kit (Applied Biosystems) was used according to 
manufacturer's instructions. Generally, 10 µL 2x RT buffer and 1 µL RT enzyme were added 
to a RNA mix in 9 µL. Reverse transcription was conducted in a thermo cycler (Bio-Rad 
Laboratories) for 1 h at 37°C and 5 min at 95°C. Real-time PCR was then performed with the 
StepOne Plus™ Real-Time PCR System (Applied Biosystem) using Power Syber Green PCR 
Master Mix (Applied Biosystems).  The PCR program can be found in Table 2. In general, one 
reaction contained 10 µL 10x Sybr Green Mastermix, 3.75 µL forward Primer (2 µM diluted in 
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MQ), 3.75 µL reverse Primer (2 µM diluted in MQ), 1.5 µL MQ and 1 µL cDNA (1:2 diluted in 
MQ). Each sample was set up in duplicates. To normalize variations in cDNA quantities 
throughout the samples, β-Actin was used as housekeeping gene. Fold inductions were 
calculated using the 2(-∆Ct) method. A list of primers can be found in Table 3.  
 
Table 2. PCR program for mRNA quantification 
Step Temperature Time Repeats 
Initial denaturation 95°C 20 s x 
Denaturation 95°C 3 s 
40 cycles 
Annealing & Elongation 60°C 30 s 
 95°C 15 s x 
Melt curve 
60°C 1 min x 
95°C 15 s x 
 
Table 3. Primer used for qRT-PCR 
Target forward primer sequence  reverse primer sequence 
β-Actin CGGGACCTGACTGACTAC CTTCTCCTTAATGTCACGCACG 
cJun  TCG ACA TGG AGT CCC AGG A GGC GAT TCT CTC CAG CTT CC 
SMAD2  GGGATGCTTCAGGTAGGACA TCTCTTTGCCAGGAATGCTT 
SMAD3   CGCAGAACGTCAACACCAAG GGCGGCAGTAGATGACATGA 
COX-2 CCGGGTACAATCGCACTTAT GGCGCTCAGCCATACAG 
NDUFS2 GTTTTGCCCATCTGGCTGGT CATGCCATGGCCTATGGTGAA 
mPGES-1 GAAGAAGGCCTTTGCCAAC CCAGGAAAAGGAAGGGGTAG 
UBE2R2 ATGTGGCACCCCAACATT TCCACCTTTCAGAAGGCAGT 
CEP41 ACAGAACCCAAGATACCAGCATAT GGGAGCTGGTAAGATACACACA 
SLC39A6 GCACTTACTGCTGGCTTATTCA CGGCTACATCCATGGTCACT 
PAIP2  CCATTTGCAGAGTACATGTGGA CCGTACTTCACCCCAGGAAC 
GTF2E2  CCATGCAGGAATCTGGACCA AATCCTTCAGCACTCCAGCC 
LEO1  ACTGCCCAACTTTCTCAGTGT AGATGATTGTGGTCGCCCTG 
 
For miR quantification, the Qiagen miScript system was used according to manufacturer’s 
instructions. One reverse transcription reaction comprised of 4 µL 5x miScript HiSpec Buffer, 
2 µL 10x miScript Nucleic Acid Mix, 2 µL reverse transcriptase and 1 µg DNase digested RNA 
in MQ ad 20 µL. The reverse transcription was performed for 1 h at 37°C and 5 min at 95°C 
using the thermo cycler (Peqlab Biotechnologie GmbH, advanced primus 25). CDNA was 
diluted 1:2 in MQ afterwards. Following, real time PCR was performed using either the miR-
574-5p specific primer (MS00043617, Qiagen) or miR-16-5p (MS0031493, Qiagen). Real-time 
PCR was performed according to the manufacturer’s instructions (see Table 4). Generally, a 
mix for one reaction contained 12.5 µL QuantiTect Syber Green Mastermix, 2.5 µL 10x miScript 
Universal primer, 2.5 µL specific primer, 1 µL miScript cDNA and 6.5 µL MQ. Fold inductions 
were calculated as described above. 
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Table 4. PCR program for miR quantification 
Step Temperature Time Repeats 
Initial denaturation 94°C 15 s x 
Denaturation 94°C 15 s 
40 cycles Annealing  55°C 30 s 
Elongation 70°C 30 s 
 94°C 15 s x 
Melt curve 
60°C 1 min x 
95°C 15 s x 
 
2.2.3 RNA immunoprecipitation (RIP) 
The RIP protocol was kindly provided by Prof. Michaela Müller-McNicoll, Goethe University 
Frankfurt. In order to precipitate CUGBP1, the GammaBind Plus Sepharose beads (GE 
Healthcare) were used. In preparation, the beads were blocked with blocking buffer containing 
0.2 mg/mL bovine serum albumine (BSA) in PBS (Sigma-Aldrich) and 0.1 mg/mL yeast tRNA 
for 90 min at 4°C. Then, beads were washed with PBS and stored at 4°C until further use. 
A549 cells were seeded at a density of 3 x 106 in a 10-cm dish and incubated overnight. In 
case of stimulation, 5 ng/mL IL-1β were added for further 24 h. In order to harvest the cells, 
they were washed with 5 mL of ice-cold PBS and scraped in 5 mL PBS complemented with 
protease inhibitor EDTA-free (Roche). Cells were spinned down for 5 min and 400 x g at 4°C 
and resuspended in 1 mL lysis buffer (see Table 5). The suspension was incubated 10 min on 
ice and then sonicated 4 times for 10 seconds on 30% amplitude, with 20 sec pause (Branson 
Sonifier 250). Then, cell debris was spinned down for 10 min at 10,000 x g at 4°C. The 
supernatant was transferred into a fresh tube and 10% were taken as input sample.  
Before usage, the blocked beads were washed 3 times with lysis buffer and were centrifuged 
at 300 x g for 5 min. Beads and antibodies were linked by mixing 50 µL bead suspension with 
10 µg of CUGBP1 antibody (05-621 clone3B1, Merck) or normal mouse IgG antibody (12-371, 
Merck) followed by incubation for 30-60 min at 4°C. Afterwards, immunoprecipitation (IP) was 
conducted by dividing the lysate equally to the CUGBP1- /IgG-bead mixture and incubating for 
2 h at 4°C. Then, samples were washed with each wash buffer B1-B3 (composition see Table 
5) for 5 min in the cold room, with centrifugation steps of 5 min and 300 x g in between. After 
the last washing step, 10% of each precipitate was taken for Western blot analysis in order to 
validate the immunoprecipitation (see chapter 2.3.3 SDS-PAGE and Western Blot). The 
remaining precipitates were resuspended in 500 µL TRIzol reagent (Invitrogen) and RNA was 
isolated as described above (see chapter 2.2.1 RNA extraction). Thereby, it was important to 
take the exact same volume of aqueous phase from each sample, since the complete isolated 
RNA was then used for reverse transcription. 
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Since there was no housekeeping gene for analysis of the real time PCR, data analysis was 
conducted without building a difference to a Ct of a housekeeping gene. After calculating the 
2(-Ct), the Input value was multiplied by 10 to even out that it was 10% of the total cell lysate, 
while IgG-IP and CUGBP1-IP values were multiplied by 1.11 since 10% were taken for 
Western blot analysis and 90% were left. Then, a x-fold was calculated to obtain the RNA 
enrichment and the yield. The yield describes the amount of precipitated RNA in percent 
compared to the input, while the enrichment shows the specificity of CUGBP1-IP in comparison 
to IgG-IP. In this thesis, the graphs will depict the enrichment, as it gives the information if a 
certain RNA is indeed bound by CUGBP1. 
𝑦𝑖𝑒𝑙𝑑 =
2−𝐶𝑇 𝑜𝑓 𝐼𝑃 × 1.11
2−𝐶𝑇 𝑜𝑓 10%𝐼𝑛𝑝𝑢𝑡 × 10
 
 
𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =
2−𝐶𝑡 𝑜𝑓 𝐶𝑈𝐺𝐵𝑃1 × 1.11
2−𝐶𝑇 𝑜𝑓 𝐼𝑔𝐺 × 1.11
 
Table 5. RIP buffer composition 
Buffer End concentration Reagent 
Hypotonic lysis 
buffer 
10 mM  Tris-HCl pH 7.5 (Sigma-Aldrich) 
10 mM  KCl (Sigma-Aldrich) 
1.5 mM  MgCl2 (Sigma-Aldrich) 
0.5 mM  Ll fac (Carl Roth) 
0.9% NP-40 (Igepal) (Sigma-Aldrich) 
1x  Protease inhibitor cocktail (Roche) 
 40 U/µL Ribonuclease Inhibitor 
Ad 10 mL MQ 
Wash buffer B1 20 mM  Tris-HCl pH 7.5 (Sigma-Aldrich) 
150 mM NaCl (Sigma-Aldrich) 
2 mM  EDTA (Roche) 
0.1%  SDS (Carl Roth) 
1%  Triton X-100 (Carl Roth) 
1x Protease inhibitor cocktail (Roche) 
Ad 10 mL MQ 
Wash buffer B2 20 mM  Tris-HCl pH 7.5 (Sigma-Aldrich) 
500 mM NaCl (Sigma-Aldrich) 
2 mM  EDTA (Roche) 
0.1%  SDS (Carl Roth) 
1%  Triton X-100 (Carl Roth) 
1x Protease inhibitor cocktail (Roche) 
Ad 10 mL MQ 
Wash buffer B3 10 mM  Tris-HCl pH 7.5 (Sigma-Aldrich) 
250 mM  LiCl (Sigma-Aldrich) 
1 mM  EDTA (Roche) 
1%  Na Deoxycholate (Sigma-Aldrich) 
1%  NP-40 (Igepal) (Sigma-Aldrich) 
1x Protease inhibitor cocktail (Roche) 
Ad 10 mL MQ 
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2.3 Protein methods 
2.3.1 Soluble and microsomal fraction preparation 
As described in [250] [195], cell pellets of A549 cells were resuspended in 1 mL 
homogenization buffer (0.1 M potassium phosphate (Carl Roth) pH 7.4, 0.25 M sucrose 
(Scharlau), and EDTA-free protease inhibitor (Roche)). The suspension was then sonicated 4 
x 10 seconds on ice with 20 seconds pause (Branson Sonifier 250). To remove all debris, 
samples were centrifuged with 5,000 x g at 4°C for 10 min and the supernatant was transferred 
in ultracentrifugation tubes. Then, samples were centrifuged at 100,000 x g at 4°C for 1 h 
(using Beckmann Optima XL-100K). The resulting supernatants contained the soluble fractions 
and were stored at -80°C while, the pellets were mixed with 500 µL 2.5 M NaBr (Sigma-Aldrich) 
and incubated for 45 min on ice with shaking. Another centrifugation step was performed at 
4°C for 1 h at 100 000 x g. The supernatant containing membrane associated fraction was 
discarded, while the pellets resembled the microsomal protein fraction. They were 
resuspended in PBS supplemented with EDTA-free protease inhibitor (Roche) and sonicated 
on ice to improve dissolving of the proteins. All samples were stored at -80°C until further use. 
Concentration for Western blot analysis was measured using Bradford assay (Bio-Rad 
Laboratories) (see next chapter) while for proteomics samples the protein amount was 
determined by Pierce BCA Protein Assay (Thermo Fisher Scientific) following manufacturing 
instructions. 
 
2.3.2 Determination of protein concentration  
Concentration of the protein solution was determined by Bradford assay (Bio-Rad 
Laboratories) according to manufacturer's instructions. A standard curve with bovine serum 
albumin (BSA) concentrations of 50-500 µg/mL was used. 10 μL of the different BSA solutions 
or protein samples (diluted 1:20 in MQ) were mixed in a 96-well plate and 190 μL of Bradford 
reagent (diluted 1:5 in MQ) was added. Each sample and standards were measured in 
duplicates. The absorption at a wavelength of 595 nm was measured at a Tecan Infinte M 200 
(Tecan Group). The protein concentration was calculated according to the standard curve. 
 
2.3.3 SDS-PAGE and Western Blot 
Proteins were separated by Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Depending on the approach, either 80 µg of soluble/microsomal proteins or for RIP 
samples 20 µL were mixed with 5 µL 4x protein loading buffer containing 50% glycerine, 1.5% 
bromphenol blue, 4% SDS, 15% β-Mercaptoethanol (all Carl Roth). Samples were then boiled 
for 5 min at 95°C in order to denature proteins and loaded on a 12% SDS-Gel (composition 
see Table 6). As a marker the Precision Plus Protein™ All Blue Standard (Bio-Rad 
Materials and Methods 
__________________________________________________________________________ 
 
39 
 
Laboratories) was also applied and the gel ran for ca. 1 h at 120 V. Afterwards, proteins were 
transferred to a HyBond ECL nitrocellulose membrane (Amersham) with 230 mA for 80 min. 
Subsequently, membranes were blocked with Odyssey blocking buffer (LI-COR® Bioscience) 
for 1 h at room temperature. Then, they were incubated over night at 4°C with primary 
antibodies (see Table 7). The next day, membranes were washed 3 times with PBS pH 7.4 
complemented with Tween20 0.1% (v/v) (Carl Roth) (PBS-T) to remove residual unbound 
antibody. Then an infrared dye conjugated secondary antibody (IRDye®, LI-COR® 
Bioscience) directed against the certain host animal, was incubated on the membranes for 
45 min at room temperature. Membranes were washed three times with PBS-T before 
visualization. Detection and quantification were performed using the Odyssey Infrared Imaging 
System (LI-COR® Biosciences) and the Image Studio Software.  
Table 6. Gel composition for SDS-PAGE 
Stacking gel (7.4 %) Separating gel (12%) 
MQ 1.2 mL MQ 1.6 mL 
Acrylamide 30% (w/v) 266 µL Acrylamide 30% (w/v) 2 mL 
Tris-HCl, 0.5 M, pH 6.8 500 µL Tris-HCl, 1.5 M, pH 8.8 1.3 mL 
SDS 10% (w/v) 20 µL SDS 10% (w/v) 50 µL 
APS 10% (w/v) 12 µL APS 10% (w/v) 50 µL 
TEMED 3 µL TEMED 4 µL 
 
Table 7. Primary antibodies for Western blot analysis 
Target Host Supplier (order no.)  
β-Actin goat Santa cruz (sc-1616) 
CUGBP1 mouse Abcam (ab9549) 
mPGES-1 rabbit Cayman (cay160140) 
NDUFS2 rabbit Abcam (ab96160) 
SMAD2 goat Santa cruz (sc-6200) 
SMAD3 rabbit Abcam (ab28379) 
SMAD4 mouse Abcam (ab3219) 
P38 goat Santa cruz (sc-535-g) 
CUGBP1 (RIP-Western blot) rabbit Abcam (ab129115) 
 
2.3.4 TMT labelling and mass spectrometry 
Soluble or microsomal proteins (see chapter 2.3.1 Soluble and microsomal fraction 
preparation) were solubilized in 50 μl buffer containing 0.05 M triethylammonium bicarbonate, 
4 M Urea, 0.01 % SDS and 1 mg RapiGest SF Surfactant (Waters). From each sample 50 µg 
were taken for further preparation.  Disulfide reduction was conducted for 30 min at 56°C by 
adding 5 μl 1 M DTT. Afterwards, sulfhydryl alkylation was performed by adding 4 μl 1 M 
iodoacetamide solution, while samples were incubated at room temperature for 1 h in the dark. 
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Trypsin (modified sequencing grade, Promega) was added in a ratio of 1:30 (trypsin: protein). 
Then, samples were incubated at 37°C overnight. By using tandem mass tags (TMT 6-plex) 
according to manufacturer's instructions (ThermoFisher Scientific), peptides were labelled. 
Using an SCX-cartridge (Phenomenex), excess reagents could be removed from the samples. 
Liquid chromatography tandem mass spectrometry (MS) of a TMT-labeled sample was 
performed on QExactive mass spectrometer (ThermoFisher Scientific).  
Peptide pre-fractionation was conducted as previously described in [251]. TMT-labeled protein 
samples were separated over a 60-minute gradient (3-55 % B) on a 2.1 × 250 mm XBridge 
BEH300 C18 column (Waters) using a flow rate of 200 µL/min. Buffers A contained 20 mM 
ammonia in MQ, whereas buffer B contained 20 mM ammonia in 80 % acetonitrile. The specific 
fractions were collected every minute and the fractions covering the peptide elution range were 
concatenated to yield 12 final pooled fractions. These fractions were evaporated to dryness by 
vacuum drying and stored at -20°C until nano Liquid chromatography-mass spectrometry (LC-
MS) data capture. A Q-Exactive mass spectrometer (Thermo Scientific) was used to performe 
online LC-MS measurements. Peptide samples were trapped on an Acclaim PepMap trap 
column (C18, 3 µm, 100Å, 75 µm x 20 mm). Separation took place on a 15-cm long C18 picofrit 
column with 100 μm internal diameter and 5 μm bead size (Nikkyo Technos) which was 
installed onto a nano-electrospray ionization source.  Solvent A was 97% water, 3% 
acetonitrile, 0.1% formic acid; and solvent B was 5% water, 95% acetonitrile, 0.1% formic acid. 
At a constant flow of 0.25 μl/min, the curved gradient went from 3% solvent B up to 48% solvent 
B in 50 min. Fourier transform mass analyzers (FTMS) master scans with 70,000 resolutions 
(and mass range 400-1200 m/z) were followed by data-dependent MS/MS (17,500 resolution) 
on the top 10 ions using higher energy collision dissociation (HCD) at 31% normalized collision 
energy. Precursors were isolated with a 2 m/z window. Automatic gain control (AGC) targets 
were 3e6 for MS1 and 2e5 for MS2. Maximum injection times were 250 ms for MS1 and 200 
ms for MS2. Dynamic exclusion was used with 20 s duration. Precursors were excluded when 
they showed unassigned charge state or charge state of 1. An underfill ratio of 1% was used.  
 
2.4. Bioinformatical methods 
2.4.1 3’UTR analysis 
For the analysis of splice patterns, proteins that were upregulated at least 1.5-fold in response 
to ΔCUGBP1 in the mass spectrometry dataset were taken into account. This list of 399 
proteins was then analyzed concerning their 3’UTRs. All described 3’UTR isoform sequences 
were downloaded from ensemble biomart (Human, GRCh38.p12 Ensembl variation resources 
[252]), resulting in a list of 1916 transcripts. Those sequences were then aligned with 42 known 
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binding motifs of CUGBP1 downloaded from the online tool Splice Aid F [109] [104]. Alignment 
was kindly conducted by Tobias Saul. 
For the high stringency analysis, three criteria were applied: (I) the binding sites should be of 
39 or 46 nt length, (II) there should at least be 2 binding sites and (III) those binding sites 
should span a potential intron of at least 1000 nt. For a second less stringent approach 
(referred to as low stringency analysis), the three criteria were mitigated: (I) the binding sites 
should at least be of 8 nt length, (II) there should be 2 or more binding sites and (III) those 
binding sites should span a potential intron of minimum 100 nt. Analysis was performed with 
Microsoft Excel 2016. 
 
2.4.2 Mass Spectrometry data analysis 
Acquired MS raw files were searched using Sequest-Percolator under the software platform 
Proteome Discoverer 1.4.1.14 (Thermo Fisher Scientific) against human Uniprot database 
(release 01.12.2015 [89]) and filtered to a 1% false discovery rate (FDR) cut off. A precursor 
ion mass tolerance of 10 ppm was used as well as product ion mass tolerances of 0.02 Da for 
HCD-FTMS and 0.8 Da for collision induced dissociation Ion Trap Mobility Spectroscopy (CID-
ITMS). The algorithm considered tryptic peptides with maximum 2 missed cleavages; 
carbamidomethylation (C), TMT 6-plex (K, N-term) as fixed modifications and oxidation (M) as 
dynamic modifications. Quantification of reporter ions was done by Proteome Discoverer on 
HCD-FTMS tandem mass spectra using an integration window tolerance of 10 ppm. Only 
unique peptides in the data set were used for quantification. Fold values were calculated 
comparing proteins from ΔCUGBP1 to Scramble, ΔmiR-574-5p to negative control LNA and 
miR-574-5p oe to negative control mimic. Fold values of +1.5/-1.5 were considered up- or 
downregulated.  
 
2.4.3 Ingenuity pathway analysis (IPA) 
Most genes are regulated by a variety of upstream regulators or transcription factors with often 
opposing effects. As it is unknown which will dominate in this specific system, predictions 
become difficult. Therefore, a statistical approach was used. A quantity “z‐score” was 
calculated that rates whether an upstream regulator has significantly more “activated” 
predictions than “inhibited” predictions (z > 0). The other way around, when there are more 
inhibited predictions than activating predictions, the z-score will be negative. All regulated 
proteins in soluble as well as microsomal fractions from all three conditions were analyzed 
using IPA (Ingenuity Systems, www.ingenuity.com). The 5 most affected canonical pathways 
were predicted. The canonical pathways with p-values ≤0.05 were defined as significant.  
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2.5 Fluorescent labeling techniques  
To find if the two binding partners CUGBP1 and miR-574-5p co-localize within the cell, 
immunostaining as well as in situ hybridization techniques were performed by Julia Wellstein. 
 
2.5.1 Immunostaining 
Immunofluorescent stainings were performed to visualize CUGBP1. Therefore, A549 cells 
were seeded at a density of 2.5 x 105 per well in a 6-well plate on glass cover slips (12 mm, 
Neolab) and cultured overnight. Medium was removed and cells were washed with PBS, before 
fixation for 10 min with 4% formaldehyde (FA, Carl Roth). After 3 PBS washing steps for 3 min 
to remove residual FA, cells were permeabilized for 10 min with 0.5% Triton X-100 (Sigma-
Aldrich) diluted in PBS. Subsequently, cells were blocked for 20 min with a 2% BSA solution 
(Sigma-Aldrich) in PBS. The CUGBP1 primary antibody (ab9549, Abcam) was diluted 1:500 
in blocking solution applied on the cells and incubated for 1h at room temperature. Following, 
3 washing steps à 5 min with 0.01% Tween20 (Carl Roth) in PBS were performed. Then, cells 
were incubated for 45 min at room temperature with the secondary antibody goat anti-mouse 
IgG (Alexa Fluor® 594, ab150116, Abcam) diluted 1:500in blocking solution. Finally, cells were 
washed with 0.01% Tween20 (Carl Roth) in PBS, counterstained for 5 min with 4′,6-diamidine-
2′-phenylindole dihydrochloride (DAPI 1µg/ mL in PBS), Sigma-Aldrich) and mounted in Mowiol 
4-88 mounting medium (Sigma-Aldrich).   
 
2.5.2 Fluorescence in situ hybridization (FISH) 
To visualize miR-574-5p within the cells, FISH was performed with A549. To that end, 2.5x105 
A549 cells were seeded on glass cover slips (12 mm, Neolab) in 6-well plates and cultured for 
24 h. Cells were washed with PBS and prefixed with 1% FA in PBS for 10 min. After 3 washing 
steps of 3 min with PBS, cells were permeabilized with 0.5% Triton X-100 in PBS for 20 min 
on ice. After additional 3 PBS washing steps of 3 min, cells were refixed for 10 min with 4% 
FA. Then, 3 further washing steps with PBS were followed by prehybridization for 30 min at 40 
°C in microRNA ISH buffer (Qiagen). Then, hybridization took place at 54°C with 100 nM 
double digoxigenin (DIG) labeled miR-574-5p probe (Qiagen) diluted to final concentration of 
100 nM in microRNA ISH buffer for 1 h. Afterwards, cells were washed twice for 5 min with 2x 
saline-sodium citrate buffer (Gibco) at 54°C and once at room temperature. Blocking was then 
performed with 2% BSA in PBS for 20 min. The rabbit anti-DIG antibody (9H27L19, Invitrogen, 
Thermo Fisher Scientific) was diluted 1:40 in blocking solution and cultured on the cells at 
room temperature for 1 h. Residual antibody was removed by washing with 0.01% Tween20 
in PBS 3 times for 5 min. Secondary antibody goat anti-rabbit IgG (Alexa Fluor® 594, 111-585-
144, Jackson ImmunoResearch) diluted 1:300 in blocking solution was incubated on the cells 
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for 45 min at room temperature. Finally, cells were washed with 0.01% Tween20 in PBS, 
counterstained with DAPI and mounted as described above. 
 
2.6 Microscopy and image acquisition 
2.6.1 Immunostaining and FISH images 
In order to take confocal images of immunofluorescence and FISH samples, the Leica TCS 
SPE confocal point scanner mounted on a Leica DMi8 stand equipped with an oil immersion 
63x Apochromat was used. In all cases, the 405 and 561 nm laser lines were used to perform 
excitation. Images were analyzed using the ImageJ software (http://imagej.nih.gov/ij/) and 
show one focal plane of the middle of the nucleus. 
 
2.6.2 Wound healing assay images 
Images were acquired with 10 x magnitude using Axiovert 200 (Zeiss) with the LSM 510 Meta 
(Zeiss) image-processing software. One image was taken per well at the exact same 
localization immediately after scratching (t0) and 24 h later. Analysis of the images was 
performed using ImageJ software (http://imagej.nih.gov/ij/). Therefore, the width of the scratch 
was measured at 3 random sites within each picture. Since there were two wells per condition, 
this resulted in 6 values per time point which were used to build a mean value.  
 
2.7 Statistics 
Results are given as mean +SEM of at least three independent experiments. Statistical 
analysis was carried out by Student's paired or unpaired t-test (two-tailed), respectively, using 
GraphPad Prism 5.0. Differences were considered as statistically significant for p≤0.05 
(indicated as * for p≤0.05, ** for p≤0.01 and ***for p≤0.001). 
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3. Results 
In the center of this thesis is the non-canonical decoy mechanism of CUGBP1 binding to miR-
574-5p. This mechanism was recently described to regulate the expression of the CUGBP1 
target mPGES-1 [196]. Therefore, the first steps were to proof the interaction of CUGBP1 with 
the mPGES-1 mRNA and with miR-574-5p. 
 
3.1 Verification of CUGBP1 binding via RIP 
In order to proof the interaction of CUGBP1 with mPGES-1 and especially miR-574-5p, RIP 
assays were conducted. Thereby, CUGBP1 was precipitated from a whole cell lysate of 
unstimulated or IL-1β-stimulated A549 cells with a specific antibody that was coupled to 
sepharose beads. As mock control, a normal mouse IgG antibody was used for precipitation. 
CUGBP1 protein as well as the RNAs bound by CUGBP1 could then be quantified via Western 
blot and qRT-PCR, respectively. Binding was assumed, if the specific mRNA showed an 
enrichment in CUGBP1-IP, compared to IgG-IP.   
 
3.1.1 Establishment of CUGBP1 RIP protocol 
In a first validation step, the precipitation of CUGBP1 had to be confirmed via Western blot 
analysis. Therefore, 10% of the input, as well as IgG- and CUGBP1-IP samples were applied 
on a SDS-Gel. The Western blot membrane was then incubated with a CUGBP1 antibody from 
another host animal than the RIP antibody. Otherwise the images were not evaluable, because 
the sepharose beads could not be removed from the samples and create a smear. The 
Western blot images demonstrated that a clear CUGBP1 band was detected in the CUGBP1-
IP sample at 48 kDa but not in the IgG sample (see Figure 11A). Hence, precipitation was 
indeed successful. Naturally, the CUGBP1 band with the highest intensity was detected in the 
Input sample. The amount of precipitated CUGBP1 was calculated based on the input, 
revealing that 33.2% (±5.5 SEM) of total CUGBP1 were recovered.  
Following, verification of RNA co-precipitation was necessary. Therefore, the first described 
CUGBP1 target cJUN was measured performing qRT-PCR [253]. Indeed, qRT-PCR results 
revealed a significant 2.4-fold enrichment compared to IgG-IP (see Figure 11B). Together with 
the Western blot analyses, this ensured the accuracy of the RIP experiments, allowing for 
quantification of other potential CUGBP1 targets in following experiments. 
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Figure 11: Validation of RIP protocol.  
RIP of A549 cells with antibodies against CUGBP1 or normal mouse IgG. (A) Precipitated 
CUGBP1 protein was analyzed via Western blot analysis. Quantification was performed with 
Odyssey Infrared Imaging System (LI-COR® Biosciences).  Input was set as 100%. 
Percentage of precipitated CUGBP1 is given as mean +SEM. One representative image of 
n=4 independent experiments is shown. (B) Co-precipitated cJUN mRNA was quantified using 
qRT-PCR. Relative enrichment normalized to IgG is given as mean +SEM of n=4 experiments., 
t-test, **p ≤ 0.01, ****p ≤ 0.0001 
 
 
3.1.2 CUGBP1 binds to miR-574-5p and mPGES-1 mRNA 
Previous work from our lab provided first evidence that the RBP CUGBP1 can bind miR-574-
5p under inflammatory conditions, which prevents it from binding to its actual target, the 
mPGES-1 mRNA [196]. Within this thesis, the binding of CUGBP1 to both mPGES-1 and miR-
574-5p needed to be confirmed. RIP of unstimulated A549 cells was conducted and in fact, 
mPGES-1 mRNA was significantly enriched in CUGBP1-IP in comparison to IgG-IP samples 
(see Figure 12A). As negative control, COX-2 was tested as it does not have any binding sites 
for CUGBP1 [196] and therefore was not enriched in the CUGBP1-IP samples. These findings 
further confirmed the interaction of CUGBP1 with mPGES-1 mRNA. 
For miRs, IL-1β-stimulated A549 cells were used to initiate the decoy. MiR-16-5p served as 
negative control and was certainly not bound by CUGBP1. MiR-574-5p however, depicts a 
sequence homology to CUGBP1 binding motifs [196]. In fact, miR-574-5p was strongly 
enriched 22-fold in the CUGBP1-IP samples which proves the interaction (see Figure 12B). 
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Figure 12: CUGBP1 binding to mPGES-1 mRNA and miR-574-5p in RIP assays. 
RIP of A549 cells with antibodies against CUGBP1 or normal mouse IgG. Co-precipitated 
RNAs were quantified using qRT-PCR. (A) mRNA quantification of mPGES-1 and COX-2 in 
unstimulated A549 cell IP samples. (B) miR quantification of miR-574-5p and miR-16-5p in IP 
samples of A549 cells stimulated with IL-1β for 24 h. Relative enrichment normalized to IgG is 
given as mean +SEM of n=3 (A) or n=7 (B) experiments, t-test, *p ≤ 0.05. 
 
These results further confirmed the existence of a decoy mechanism of miR-574-5p and 
CUGBP1. Thus, it was intriguing to further characterize this novel miR function and investigate 
if it influences the proteome of A549 cells in a broader way. 
 
3.2. TMT-based proteomics study of IL-1β-stimulated A549 cells 
A549 cells were cultured by Dr. Isabel Baumann, stimulated with 5 ng/mL IL-1β and transfected 
with siRNA, LNA or mimics, respectively. Cells with ΔCUGBP1, ΔmiR-574-5p or miR-574-5p 
oe were compared to their corresponding controls. Knockdown and overexpression of miR-
574-5p were previously established by Dr. Isabell Baumann and revealed a significant ~ 80% 
decrease of miR-574-5p, while miR-574-5p was ~ 300-fold upregulated as quantified via qRT-
PCR as stated in [196]. Knockdown of CUGBP1 was validated via Western blot analysis and 
showed a reduction of 67% in the soluble fraction and 83% in the microsomal fraction of A549 
cells (see Figure 13).  
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Figure 13: Quantification of CUGBP1 knockdown. 
siRNA-mediated knockdown of CUGBP1 in A549 cells was followed by 24 h stimulation with 
IL-1β. Fractionation resulted in a soluble and a microsomal protein fraction which were 
analyzed via Western blot. One representative blot is shown from n=3 independent 
experiments. β-Actin was used as loading control. Quantification was performed with Odyssey 
Infrared Imaging System (LI-COR® Biosciences). Fold inductions compared to control are 
given as mean +SEM. t-test, **p ≤ 0.01. 
 
In order to identify gene expression changes, A549 cells stimulated with IL-1β were used for a 
TMT-based LC/MS-MS study which was conducted by the group of Per-Johan Jakobsson, KI, 
Sweden (see Figure 14). Cell lysates were fractionated to separate soluble and microsomal 
proteins. All LC-MS/MS samples were then digested and labeled with TMT 6-plex to allow 
quantitative protein comparison. This technique facilitates a sensitive multiplex analysis and 
controls for technical variations [254]. TMT quantification is conducted by analyzing the 
intensities of fragment reporter ions released from the labels in the tandem MS mode (MS2) 
during peptide fragmentation. In the full scan mode (MS1) to be fragmented, precursor ions 
were selected.  
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Figure 14: TMT based proteomics approach. 
A549 cells were transfected creating ΔCUGBP1, ΔmiR-574-5p or miR-574-5p oe as well as 
respective controls and stimulated with IL-1β for 24 h. Fractionation of the cell lysates resulted 
in soluble and microsomal protein fractions which were separately analyzed. All samples were 
trypsin digested, labelled with Tandem mass tags (TMT) and analyzed by LC-MS/MS. Data 
were analyzed concerning fold-changes of protein levels compared to each control. 
 
3.2.1 Proteome changes in A549 upon ΔCUGBP1, ΔmiR-574-5p and miR-574-5p oe 
In the soluble fraction a total amount of 2441 proteins was detected in the ΔCUGBP1 samples, 
while in the ΔmiR-574-5p cells 2449 and in miR-574-5p oe samples a total number of 2450 
proteins were measured. Whereas in the microsomal fraction a significantly higher number of 
proteins was detected: 3970 proteins in ΔCUGBP1 samples, 3967 proteins in ΔmiR-574-5p 
and 3968 proteins in miR-574-5p oe samples. Accordingly, roughly the same numbers of total 
proteins were identified throughout the three conditions. Besides the high numbers of total 
proteins, only small percentages of them exhibited up- or downregulation in comparison to the 
corresponding control samples (see Figure 16). In general, a protein was considered as 
Results 
__________________________________________________________________________ 
 
49 
 
upregulated starting from a TMT ratio of ≥ 1.5 (fold change ≥ 1.5) and as downregulated with 
a TMT ratio of ≤ 0.5 (fold change ≤ -1.5).  
Canonical CUGBP1 targets, as well as decoy targets, as a subpopulation of those, were 
supposed to show an upregulation in response to the knockdown (see Figure 15), while 
downregulation potentially indicated a secondary effect. In fact, 2% of the proteins detected in 
the soluble fraction were upregulated (61 proteins), while 8% (187 proteins) showed a 
decreased expression level (see Table 8). In the microsomal fraction, more proteins were up- 
than downregulated: 9% (338 proteins) exhibited an increased protein level, whereas only 4% 
(152 proteins) showed a reduced one. As described, decoy targets could not certainly be 
identified in the ΔCUGBP1 samples as they are thought to show the same regulation like 
canonical CUGBP1 targets. Thus, the two miR conditions were more relevant in that regard.  
 
 
 
Figure 15: Expected regulations in the proteomics study. 
Discrimination of canonical CUGBP1/ miR-574-5p and decoy targets via expected regulation 
on protein level. ↑ indicates increased protein level, ↓ indicates decreased protein level. 
 
In miR-574-5p oe samples, decoy targets were expected to be increased in response to high 
miR-574-5p levels, whereas reduced protein levels would refer to canonical miR targets (see 
Figure 15). Vice versa, the opposite could be assumed for the ΔmiR-574-5p condition. In the 
soluble fraction of miR-574-5p oe samples, 2% (40 proteins) were up- and 3% (78 proteins) 
were downregulated. While 8% of microsomal proteins (303 proteins) were decreased upon 
the overexpression, only 3% of protein levels were elevated (124 proteins) (see Table 8).  
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In the soluble fraction, 1% (29 proteins) of the total protein amount was increased upon ΔmiR-
574-5p, while 14 proteins showed a decrease. However, the microsomal proteins showed 
higher percentages, 9% were upregulated (345 proteins), while even 13% (504 proteins) 
showed a downregulation (see Table 8).   
 
Table 8. Numbers of increased (↑) and decreased (↓) proteins in each fraction and each 
condition of the proteomics study compared to their respective controls. 
  Soluble fraction Microsomal fraction 
ΔCUGBP1 
↑ 61 338 
↓ 187 152 
miR-574-5p oe 
↑ 40 124 
↓ 78 303 
ΔmiR-574-5p 
↑ 29 345 
↓ 14 504 
 
 
Proteins which showed increased levels upon ΔCUGBP1 were analyzed for CUGBP1 binding 
sites in their 3’UTRs. Sequences of the 3´UTRs of the specific proteins were downloaded from 
the database “UCSC Genome Browser” (Dec. 2013 GRCh38/hg38 https://genome.ucsc.edu/) 
[255]. Followed by identification of potential CUGBP1 binding motifs with the online tool 
“SpliceAid 2” (www.introni.it/spliceaid.html [256]). The algorithm recognizes GREs and other 
binding motives (e.g. CUGUCUG) in the provided 3’UTR sequences.  
It was demonstrated that an excessive amount of the upregulated proteins does have a 
potential CUGBP1 binding site: in the soluble fraction 69% (42 proteins) and in the microsomal 
fraction 73% (246 proteins) of all detected proteins in the proteomics study (see Figure 16). 
This indicates that many primary effects were observed herein. Preliminary analysis of 
canonical miR-574-5p targets was accomplished by the microRNA.org. online tool [257]. 
Proteins that were upregulated upon ΔmiR-574-5p or downregulated upon miR-574-5p oe 
were analyzed for miR-574-5p seed regions in their 3’UTRs. On average, only 16% of them 
have a seed region, which strongly implies that there are many secondary effects observed in 
this study (see Figure 16). 
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Figure 16: Numbers of proteins differentially expressed upon ΔCUGBP1, ΔmiR-574-5p 
or miR-574-5p oe in soluble and microsomal fraction of the proteomics study. 
Cut-offs were set to 1.5-fold for upregulation (grey) and -1.5-fold for downregulation (black). 
CUGBP1 binding sites of upregulated proteins upon ΔCUGBP1 were predicted using splice 
aid [256]. MiR-574-5p seed regions were identified with the online tool microrna.org [257] of 
proteins revealing an upregulation upon ΔmiR-574-5p or a downregulation upon miR-574-5p 
oe. 
 
 
Table 9 presents a list of the overlap of potential miR-574-5p targets from soluble and 
microsomal fraction as well as from the ΔmiR-574-5p and miR-574-5p oe samples. However, 
as the focus of this project was clearly on canonical CUGBP1 and decoy targets, this approach 
was not continued or further experimentally examined. 
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Table 9. Potential canonical miR-574-5p targets. 
 
Fraction Description Gene name 
Microsomal Isoform 2 of Protein transport protein Sec24B SEC24B  
Microsomal Mitochondrial inner membrane protein OXA1L OXA1L  
Microsomal Isoform 2 of Methionine synthase  MTR  
Microsomal Isoform 2 of Phosphatidylinositol 5-phosphate 4-kinase 
type-2 gamma  
PIP4K2C 
Microsomal Sterol O-acyltransferase 1  SOAT1  
Microsomal Transportin-3  TNPO3  
Microsomal Transmembrane protein 33  TMEM33 
Overlap analysis of proteins from the proteomics study that were upregulated upon ΔmiR-574-5p (65 
proteins) and downregulated upon miR-574-5p oe (59 proteins) and which have a seed region in their 
3’UTR. From the microsomal fraction seven proteins were left, while no proteins in the soluble fraction 
fulfilled these criteria. 
 
To summarize, these results demonstrate that on average 11% of all analyzed proteins could 
be somehow regulated by CUGBP1, whereas 9.7% of all detected proteins depict a regulation 
related to miR-574-5p. However, the distribution of the miR-574-5p regulated proteins varies 
considerably depending on the protein fraction.   
 
3.2.2 Validation of TMT proteomics study using Western blot analysis 
For validation, the mass spectrometry data needed to be confirmed via Western blot analysis. 
Distinct proteins were selected and it was examined whether they show the same regulation 
upon ΔCUGBP1, ΔmiR-574-5p and miR-574-5p oe in Western blot data than in the proteomics 
data. The proteomics study was a highly complex study with different conditions and fractions 
(see Figure 14), which is why validation is not necessarily based on physiologically connected 
proteins.  
The first protein to be analyzed was NADH-Ubiquinone Oxidoreductase Core Subunit S2 
(NDUFS2) which is a postulated CUGBP1 target in HeLa cells [84]. In the soluble fraction of 
the proteomics study, NDUFS2 showed a trend towards a slight upregulation in response to 
ΔCUGBP1 (1.3-fold) and miR-574-5p oe (1.4-fold). Western blot data proofed this regulation, 
revealing a fold change of 1.6-fold upon miR-574-5p oe and even 2.2-fold in response to 
ΔCUGBP1 (see Figure 17A, C). In ΔmiR-574-5p samples, NDUFS2 protein level seemed to 
be slightly decreased (0.8-fold) in the proteomics data. This could also be confirmed using 
Western blot analysis, where NDUFS2 was significantly reduced 0.8-fold in ΔmiR-574-5p 
samples as well (see Figure 17B). In the microsomal fraction, NDUFS2 revealed no strong 
changes in expression. For example, in response to ΔmiR-574-5p it showed a fold change of 
1.1 in the proteomics data. This invariable protein level could also be demonstrated using 
Western blot analysis, revealing a fold change of 1.1 (see Figure 17D).  
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Apart from that, SMAD3 (Mothers against decapentaplegic homolog 3) was another protein 
which was investigated. It was clearly downregulated (0.5-fold) in response to ΔCUGBP1 in 
the soluble fraction of the proteomics study. This trend was successfully validated via Western 
blot, where SMAD3 was downregulation as well (0.6-fold) (see Figure 17F). In the microsomal 
fraction of the proteomics study, SMAD3 was only slightly regulated by 1.1-fold in response to 
ΔmiR-574-5p. Western blot data showed a stronger effect although it was not significant, 
revealing a tendency for an upregulation of 1.4-fold (see Figure 17G).  
SMAD2, another member of the same protein family [89] [258], was also detected in the 
proteomics study. In the soluble fraction, SMAD2 levels were increased 1.2-fold upon miR-
574-5p oe which was validated with a significant upregulation of 1.2-fold concerning Western 
blot data (see Figure 17E). In order to complete the protein family, it was logical to analyzed 
SMAD4, which was the only other SMAD detected in the proteomics study. However, neither 
in the proteomics study nor in the Western Blot images, it did depict any regulation upon 
ΔCUGBP1 (see Figure 17H) which validated the mass spectrometry data, but excluded 
SMAD4 as interesting potential target.  
Finally, p38 (Mitogen-Activated Protein Kinase 14, MAPK14) was examined as it was one of 
the strongest downregulated proteins (0.3-fold) upon ΔCUGBP1 in the soluble fraction of the 
proteomics study. This strong decrease of p38 protein was confirmed using Western blot 
analysis which revealed a significant 0.5-fold reduction (see Figure 17I). Nevertheless, this 
seems to be a secondary effect, because CUGBP1 targets are supposed to be upregulated in 
response to the knockdown. 
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Figure 17: Proteomics validation using Western blot analysis. 
Western blot analysis (black bars) of NDUFS2 (A-D), SMAD2 (E), SMAD3 (F, G), SMAD4 (H) 
and p38 (I) in microsomal or soluble protein fraction of IL-1β-stimulated A549 cells upon 
ΔCUGBP1, ΔmiR-574-5p or miR-574-5p oe as indicated. One representative blot is shown of 
n=3-6 independent experiments. β-Actin was used as loading control. Quantification was 
performed with Odyssey Infrared Imaging System (LI-COR® Biosciences). Fold inductions 
compared to control are given as mean +SEM. t-test, *p ≤ 0.05. TMT ratios of the respective 
proteins in the proteomics study are depicted in grey bars (n=1). 
 
In summary, these Western blot results have clearly confirmed the proteomics study. Since 
the accuracy of the mass spectrometry data was assured, this allowed for further analyses of 
the data. 
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3.3 Physiological impact 
3.3.1 Pathway analysis predicts canonical pathways, upstream regulators and 
biological functions 
In a next step, all proteins in soluble as well as microsomal fraction were analyzed with the 
help of IPA (Ingenuity Systems, www.ingenuity.com). This tool uses the list of detected proteins 
and predicts canonical pathways and upstream regulators that could also be affected. 
Canonical pathways with p-values ≤ 0.05 were termed as significant. Analysis was conducted 
by the group of Per-Johan Jakobsson, KI Sweden. It was revealed that the five most affected 
canonical pathways in the soluble fraction were: Eukaryotic Initiation Factor 2 (eIF2) Signaling, 
Regulation of Eukaryotic Initiation Factor 4 (eIF4) and 70 kDa ribosomal S6 kinase (p70S6K) 
Signaling, tRNA Charging, Protein Ubiquitination Pathway and mechanistic Target of 
Rapamycin (mTOR) Signaling (see Table 14; appendix). Top regulated pathways in the 
microsomal fraction were: eIF2 Signaling, Protein Ubiquitination Pathway, Mitochondrial 
Dysfunction, Regulation of eIF4 and p70S6K Signaling as well as Oxidative Phosphorylation.  
For the upstream regulators, IPA predicted: Hepatocyte Nuclear Factor 4 Alpha (HNF4A), 
Cystatin D (CST5), Rapamycin-Insensitive Companion of mTOR (RICTOR), MYC Proto-
Oncogene, MYCN Proto-Oncogene, microtubule associated protein tau (MAPT) and p53 (see 
Table 15; appendix), which further underlines the influence of CUGBP1 and miR-574-5p on 
cancer development. Interestingly, in the IPA prediction of influenced biological functions in 
the soluble fraction, it was revealed that cancer metastasis could be highly affected by 
CUGBP1 and miR-574-5p.  
As presented in Figure 18, migration-related processes were on position four, seven and eight 
under the top ten regulated bio functions. With help of an activation Z-score, likely regulated 
molecules could be predicted based on a pattern match of up- and downregulation [259]. 
Further, it gives a hint in which direction the respective process is regulated. Thus, it was 
predicted that migration is diminished upon ΔCUGBP1 and miR-574-5p oe, whereas ΔmiR-
574-5p cells could possibly show a higher migration potential.  
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3.3.2 Influence of miR-574-5p and mPGES-1 on migratory behavior of A549 cells 
Following the IPA, migration of cancer cells became an intriguing topic to work on within this 
project. With two different techniques, the influence of miR-574-5p on lung cancer cell 
migration was investigated. Therefore, a stable miR-574-5p oe cell line was used [196]. In so-
called wound healing or scratch assays, the ability of A549 cells to migrate into a previously 
scraped scratch within the cell monolayer was studied. Therefore, cells were starved to 
minimize proliferative effects. Microscope images were taken right after scratching and 24 h 
later. The width of the remaining scratch was measured with ImageJ software to calculate the 
migrated area. It turned out that there was no measurable difference between miR-574-5p oe 
and control cells concerning their migratory behavior (see Figure 19A). However, wound 
healing assays are controversially discussed in literature, as a proliferative effect can never be 
fully excluded. Indeed, miR-574-5p has a positive influence on proliferation of A549 cells as 
stated in [196]. Therefore, the system was switched to Boyden chamber assays. The same 
stable cell line was used and seeded in transwell inlays with a porous membrane on the 
bottom. Additionally, the influence of mPGES-1 was investigated. Therefore, cells were 
stimulated with IL-1β to induce mPGES-1 expression, whose activity was supposed to be 
repressed with the application of a selective inhibitor Compound III (CIII). Migrated cells were 
stained and counted under a light microscope. However, the numbers of migrated miR-574-5p 
oe and control cells were nearly the same, although high standard deviations were observed 
(see Figure 19B, black bars). Moreover, stimulation with CIII did not change migration of any 
of the cell lines (see Figure 19B, grey bars). Apparently, neither miR-574-5p nor mPGES-1 
had any impact on migration of A549 cells. 
Figure 18: Top ten regulated 
biological processes predicted by 
IPA. 
IPA analysis of soluble proteins from 
the proteomics study after ΔCUGBP1, 
ΔmiR-574-5p and miR-574-5p oe in 
IL-1β-stimulated A549 cells. Activation 
Z-Score indicates predicted direction 
of regulation.  
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Figure 19: Migration assays. 
A549 cells with stable miR-574-5p oe or control cells were analyzed concerning migratory 
behavior. (A) Wound healing assay showed no difference between migrated area of miR-574-
5p oe or control cells after 24 h. (B) Boyden chamber assay of IL-1β-stimulated A549 miR-
574-5p oe or control cells stimulated with 10 µM Compound III (CIII) or vehicle (DMSO) 
revealed equal numbers of migrated cells after 5 h. Results are given as mean +SEM of n=3 
different experiments. 
 
3.4 Identification of new CUGBP1 targets 
3.4.1 Western blot analysis of microsomal proteins upon ΔCUGBP1 
New canonical CUGBP1 targets were determined based on their expression levels in 
proteomics as well as Western blot data. It was assumed that CUGBP1 targets should exhibit 
increased protein level, when the inhibitory influence of CUGBP1 is missing after knockdown. 
As depicted in Figure 13, CUGBP1 protein was mainly found in the microsomal fraction. In 
consequence, the focus was set on that fraction for further analyses. The previously described 
CUGBP1 target and decoy target mPGES-1 served as positive control. Indeed, mPGES-1 did 
show a significant 1.4-fold increased protein level in response to ΔCUGBP1 (see Figure 20A). 
NDUFS2, another postulated CUGBP1 target was further analyzed via Western blot. Although 
it did not show strong changes in the microsomal fraction of the proteomics study, NDUFS2 
revealed a clear induction of 1.4-fold upon ΔCUGBP1 via Western blot analysis (see Figure 
20B). This confirmed it as a CUGBP1 target, despite the fact that further experiments were 
needed as final proof. 
Since physiological experiments concerning cancer migration were conducted within this 
project, associated SMAD proteins came into the focus. Therefore, the SMAD protein family 
was analyzed more deeply. A variety of family members such as SMAD2, SMAD3 and SMAD4 
were in fact found in the mass spectrometry data. SMAD4 did not exhibit any regulation upon 
ΔCUGBP1 though, neither in the proteomics study, nor in the Western blot images. For this 
reason, it was excluded as potential CUGBP1 target. The remaining SMADs however, were 
promising candidates. SMAD2 and SMAD3 both exhibit multiple binding motifs all over their 
3’UTRs as determined with SpliceAid 2 [256]. Moreover, Western blot analysis revealed 
obvious changes in expression levels upon ΔCUGBP1. Compared to control samples, SMAD2 
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was significantly increased by 4-fold in response to the knockdown (see Figure 20C). Although 
this strong regulation was not measured in the mass spectrometry, the IPA also predicted that 
SMAD2 expression would be enhanced. Thus, the Western blot data validated this prediction 
successfully, making SMAD2 a promising CUGBP1 target. SMAD3 depicted slightly weaker 
regulation in response to ΔCUGBP1, as it was upregulated by 2.2-fold according to Western 
blot analysis (see Figure 20D). Again, this perfectly fitted IPA data that predicted SMAD3 levels 
to be increased 2.3-fold upon knockdown of CUGBP1. 
 
 
Figure 20: Protein levels of potential CUGBP1 targets in IL-1β-stimulated A549 cells with 
manipulated CUGBP1 levels. 
A549 cells with or without ΔCUGBP1 were stimulated with IL-1β for 24 h. Microsomal fraction 
was analyzed via Western blot concerning (A) mPGES-1, (B) NDUFS2, (C) SMAD2 and (D) 
SMAD3 protein levels. One representative blot is shown of n=3-4 independent experiments. 
β-Actin was used as loading control. Quantification was performed with Odyssey Infrared 
Imaging System (LI-COR® Biosciences). Fold inductions compared to control are given as 
mean +SEM. t-test, ***p ≤ 0.001. 
 
Taken together, these data provide first evidence that SMAD2, SMAD3 and NDUFS2 could be 
canonical CUGBP1 targets in A549 cells.  
 
3.4.2 Binding of CUGBP1 to mRNAs of novel canonical targets 
In order to further validate the newly postulated targets SMAD2, SMAD3, NDUFS2 as well as 
mPGES-1, binding of CUGBP1 to the respective mRNAs needed to be confirmed. Therefore, 
RIP assays were performed. After immunoprecipitation of CUGBP1, the bound mRNAs could 
be quantified via qRT-PCR. Binding of CUGBP1 was assumed, if the mRNA was enriched in 
CUGBP1-IP, compared to IgG-IP. Indeed, a significant enrichment could be observed for 
NDUFS2 and SMAD2 mRNAs (see Figure 21). While NDUFS2 was 2.2-fold enriched, SMAD2 
showed a strong 6.4-fold enrichment compared to IgG. This confirms the interaction of 
CUGBP1 with the respective mRNAs. However, SMAD3 showed no enrichment in CUGBP1-
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IP samples (see Figure 21) although it contains a binding site in the 3’UTR. This indicates that 
SMAD3 mRNA is not bound by CUGBP1 under the conditions examined herein.  
 
 
 
Overall, CUGBP1 binding to two of the three postulated targets was confirmed: SMAD2 and 
NDUFS2. Since decoy targets were assumed to be a subpopulation of CUGBP1 targets, the 
next step was to investigate if these new candidates were also regulated by miR-574-5p. 
 
3.5 Identification of novel miR-574-5p/CUGBP1 decoy targets 
3.5.1 Investigating a “decoy regulation pattern” via Western blot analysis 
In order to find new targets of the miR-574-5p/CUGBP1 decoy mechanism, the proteomics 
data were further analyzed in regard to a stringent “decoy regulation pattern” in the three 
conditions: (I) ΔCUGBP1, (II) ΔmiR-574-5p and (III) miR-574-5p oe:  
(I) As subpopulation of canonical CUGBP1 targets, decoy targets are supposed to be 
increased in response to ΔCUGBP1 just as canonical CUGBP1 targets. With a reduced 
CUGBP1 level, the inhibitory influence on gene expression of the target is missing, leading to 
an upregulation on protein level (see Figure 22A). Without presence of CUGBP1, the level of 
miR-574-5p should not have an impact on the decoy targets. However, decoy targets cannot 
be distinguished from canonical CUGBP1 targets only by looking at the ΔCUGBP1 condition. 
To clearly identify targets of the decoy mechanism, the two miR conditions are more intriguing. 
(II) Potentially, decoy targets are supposed to be downregulated upon ΔmiR-574-5p. In theory, 
lower intracellular levels of miR-574-5p allow higher binding capacity of CUGBP1. As CUGBP1 
binding has mostly negative effects on the protein level, the respective decoy target should be 
downregulated (see Figure 22B). 
(III) Vice versa, miR-574-5p oe should lead to an upregulation of potential decoy targets. 
Simply more miRs are accessible to prevent binding of CUGBP1 (see Figure 22C). 
Figure 21: Binding of CUGBP1 to potential 
new target mRNAs. 
RIP of A549 cells with antibodies against 
CUGBP1 or normal mouse IgG. Co-precipitated 
RNAs were quantified using qRT-PCR. mRNA 
quantification of NDUFS2, SMAD2 and SMAD3 
in unstimulated A549 cell IP samples. Relative 
enrichment normalized to IgG is given as mean 
+SEM of n=3-4 experiments, t-test, *p ≤ 0.05. 
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Figure 22: Schematic overview of the decoy mechanism. 
Expected cellular processes in the three conditions: (A) ΔCUGBP1, (B) ΔmiR-574-5p and (C) 
miR-574-5p oe and their effects on potential decoy targets. 
 
In a first analysis, proteins were included even if they only had a tendency for the “decoy 
regulation pattern” in the proteomics data. Such as only two conditions that met the criteria, 
with the third condition potentially not matching, but also not contradicting the “decoy regulation 
pattern”. For instance, High-mobility group AT-hook 2 (HMGA2) protein was strongly 
upregulated upon ΔCUGBP1 (2.4-fold) and downregulated upon ΔmiR-574-5p (0.6-fold) but 
showed only a 1.1-fold TMT ratio in response to miR-574-5p oe. The newly postulated 
CUGBP1 target proteins and several other candidates were then analyzed via Western blot. 
As positive control, the previously described decoy target mPGES-1 was used.  
The analysis demonstrated that mPGES-1 protein levels did indeed react as predicted: It was 
1.4-fold upregulated upon ΔCUGBP1, significantly 0.6-fold downregulated upon ΔmiR-574-5p 
and 1.4-fold enriched in response to miR-574-5p oe (see Figure 23D). From the list of potential 
candidates, HMGA2, Glyoxalase Domain Containing 4 (GLOD4) or PABP-Interacting Protein 
2 (PAIP2) were just a few examples that were only expressed on very basal level by A549 
cells. Thus, many proteins could not be detected since the sensitivity of the Western blot 
system was too low compared to mass spectrometry. NDUFS2 however, was sufficiently 
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expressed, although it just showed a slight tendency for the “decoy regulation pattern” in the 
proteomics data. In the analyzed Western blot images, NDUFS2 levels did not change upon 
manipulated miR-574-5p levels (see Figure 23A). This indicated that it is just a canonical 
CUGBP1 target but not affected by the decoy with miR-574-5p.  
SMAD3, although not bound by CUGBP1 in RIP assays, was still included here. As already 
described, SMAD3 levels were increased upon ΔCUGBP1. Surprisingly, in the two miR 
conditions SMAD3 depicted the opposite regulation than expected for a decoy target. It was 
slightly upregulated upon ΔmiR-574-5p and downregulated in response to miR-574-5p oe (see 
Figure 23B). The same regulation was observed for SMAD2 which showed significant 
reduction in response to miR-574-5p oe (see Figure 23C). This would have been an indication 
for canonical miR targets, however neither SMAD3 nor SMAD2 have a miR-574-5p seed 
region in their 3’UTRs. Nevertheless, both of them were excluded as potential decoy targets. 
 
 
Figure 23: Investigating a “decoy regulation pattern” via Western blot analysis. 
Western blot analysis of (A) NDUFS2, (B) SMAD3, (C) SMAD2, (D) mPGES-1 in microsomal 
fraction of IL-1β-stimulated A549 cells upon ΔCUGBP1, ΔmiR-574-5p or miR-574-5p oe. One 
representative blot is shown of n=3-6 independent experiments. β-Actin was used as loading 
control. Quantification was performed with Odyssey Infrared Imaging System (LI-COR® 
Biosciences). Fold inductions compared to control are given as mean +SEM. t-test, *p ≤ 0.05, 
***p ≤ 0.001.  
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Taken together, for none of the detectable proteins the “decoy regulation pattern” could be 
elucidated via Western blot analysis. Neither SMAD2, SMAD3 or NDUFS2 showed the 
adequate pattern concerning the two miR conditions (see Figure 23). While other candidates, 
such as GLOD4 or HMGA2 which were found in the mass spectrometry data, were not 
detectable via Western blot. Thus, only mPGES-1 was left as CUGBP1/miR-574-5p decoy 
target.  
 
3.5.2 Stringent “decoy regulation pattern” in the proteomics study 
As the rather loose criteria in the first approach led to inconclusive results, the proteomics data 
were re-analyzed with more stringent criteria to find if the decoy mechanism is as global as 
expected. A closer look was taken on how many proteins exactly depicted the perfect “decoy 
regulation pattern” i.e. showed an upregulation of ≥1.5-fold in response to ΔCUGBP1, a 
downregulation of at least 0.5-fold after ΔmiR-574-5p and at least an upregulation of ≥1.5 fold 
in response to miR-574-5p oe.  
It was revealed that, as expected, in the soluble fraction zero proteins matched all three criteria 
(see Figure 24A). This further underlines the hypothesis that the decoy mechanism mainly 
takes place in the microsomal fraction. Concentrating on the microsomal fraction, from 
originally 3970 proteins, only seven proteins (0.2%) matched this perfect “decoy regulation 
pattern” in all three conditions (see Figure 24B):  
 
 Ubiquitin Conjugating Enzyme E2 R2 (UBE2R2) 
 Centrosomal Protein of 41 kDa (CEP41) 
 RNA polymerase-associated protein LEO1 (LEO1) 
 General Transcription Factor IIE Subunit 2 (GTF2E2) 
 Polyadenylate-Binding Protein-Interacting Protein 2 (PAIP2) 
 Solute carrier family 39 member 6 (SLC39A6) 
 GRIP1 Associated Protein 1 (GRIPAP1) 
 
Of note, mPGES-1 was not under the seven proteins, since it did not depict the exact pattern 
in the proteomics data either. Although it displayed the “decoy regulation pattern” in Western 
blot images, it was not so prominent in the mass spectrometry data. This underlines that mass 
spectrometry data need to be validated, as artefacts can be detected and it therefore not 
necessarily reveals an accurate representation of the actual proteome within the cells. 
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Figure 24: Proteins with a stringent “decoy regulation pattern” in the proteomics study. 
Venn diagram with numbers of proteins that exhibit a very stringent “decoy regulation pattern” 
in (A) soluble and (B) microsomal fraction of the proteomics study. ↑ indicates increased protein 
level, ↓ indicates decreased protein level. 
 
This small number of proteins provided first evidence that the CUGBP1/miR-574-5p decoy 
seems to be a very specific mechanism and does not affect an extensive amount of proteins. 
 
3.5.3 Binding analysis of potential decoy targets 
The seven potential decoy targets were then further analyzed concerning binding behavior of 
CUGBP1. GRIPAP1 was the only exception, as it has no described 3’UTR according to 
ensemble database. The remaining six 3’UTRs were analyzed concerning CUGBP1 binding 
motifs [256]. It was found that all of them had at least one binding site in their 3’UTR. 
Subsequently, binding of CUGBP1 to the mRNAs was investigated by RIP assay. It turned out 
that none of the mRNAs was enriched in the CUGBP1-IP compared to mock control (see 
Figure 25).  
 
 
 
Figure 25: Binding of CUGBP1 to potential decoy targets. 
RIP of A549 cells with antibodies against CUGBP1 or normal mouse IgG. Co-precipitated 
RNAs were quantified using qRT-PCR. mRNA quantification of UBE2R2, CEP41, LEO1, 
GTF2E2, PAIP2 and SLC39A6 in unstimulated A549 cell IP samples. Relative enrichment 
normalized to IgG is given as mean +SEM of n=3 experiments. 
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Although it cannot be excluded that one of the seven mRNAs is bound under different 
conditions or in a different cell type, they were excluded as interesting candidates.  
 
3.6 Subcellular localization of CUGBP1 and miR-574-5p in A549 cells 
Since the search for new decoy targets seemed to have an end at that point of the study, a 
different approach was needed to further characterize the decoy mechanism. As a next step, 
it was necessary to elucidate where exactly in the cell the interaction of CUGBP1 and miR-
574-5p takes place. Therefore, subcellular localization of the two binding partners in A549 cells 
was visualized by performing immunofluorescence staining and FISH assay, respectively. 
Localization of miR-574-5p was determined by using a specific DIG-labeled LNA probe and a 
DIG binding antibody. Whereas immunofluorescence staining with a specific primary antibody 
was performed in order to localize CUGBP1. As control, the well-established nuclear marker 
DAPI was used. Interestingly, with these techniques it was demonstrated that both, CUGBP1 
and miR-574-5p were mainly located in the nuclei of A549 cells (see Figure 26). Nearly no 
cytosolic signals were detected for miR-574-5p, which is quite unusual for a miR. CUGBP1 
exhibited stronger cytoplasmic signals but was still predominantly located in the nucleus. IL-1β 
stimulation had no influence on subcellular localization of both CUGBP1 and miR-574-5p. All 
staining experiments were kindly performed by Julia Wellstein using established protocols. 
 
Figure 26: Subcellular localization of CUGBP1 and miR-574-5p in A549 cells. 
(A) FISH assay and (B) immunofluorescence staining of A549 cells with or without IL-1β-
stimulation for 24 h. miR-574-5p FISH was performed using DIG-labelled miRCURY LNA 
probes (green). Immunofluorescence staining with specific antibody visualized subcellular 
localization of CUGBP1 (red). Nuclei were counterstained with DAPI (blue). Scale bar = 10 µm. 
One representative image of n=3 independent experiments is shown. 
 
Hence, it was concluded that the decoy mechanism mainly takes place in the nucleus, 
especially during the experiments performed herein. In case miR-574-5p interfered solely with 
CUGBP1’s nuclear functions, this would shift the focus of this project from protein level 
regulation more to the direction of splicing regulation.  
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3.7 Bioinformatical analysis of 3’UTR splicing patterns 
The main nuclear function of CUGBP1 is regulation of AS. Thus, it was consequential to 
continue with investigations concerning splicing. As the only known decoy target of CUGBP1 
and miR-574-5p, mPGES-1 served as model, especially since it represents a very unique case. 
CUGBP1 binds to two binding sites in the mPGES-1 3’UTR and influences AS which creates 
a shorter 3’UTR isoform [196]. This was used as a paradigm, meaning other potential decoy 
candidates were analyzed in regard of this specific splicing pattern. For this comprehensive 
analysis, all 399 proteins which showed an upregulation in response to ΔCUGBP1 in soluble 
or microsomal fraction of the proteomics study were included. 3’UTR sequences from all 
described isoforms were downloaded, using ensemble biomart (GRCh38/.p12, version 91, 
[252]). This resulted in a list of 1916 3’UTR sequences which were then aligned with 42 
described CUGBP1 binding motifs (see Table 10, using the online tool Splice Aid F [109]).  
 
Table 10. List of potential binding motifs of CUGBP1 
No. Motif Length (nt) 
1 
CUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUU
GCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCU
UGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUGCUUG 
151 
2 
CAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGAC
AGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACAGACA
GACAGACAGACAGACAGACAGA 
127 
3 
UCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCU
GUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUCUGUC
UGUCUGUCUGUCUGUCUGUCUGUCUG 
127 
4 
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC
AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA
GCAGCAGCAGCAGCAGCAG 
122 
5 
CGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACGG
ACGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACGGACG
GACGGACGGACGGACGGA 
119 
6 
UCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCC
GUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUCCGUC
CGUCCG 
107 
7 
CCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCG
CCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCG  
90 
8 
CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG
GCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
90 
9 
CCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCC
GCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCG  
84 
10 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG  48 
11 CUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUG  33 
12 UGUGUGUGUGUGUGUGUGUGUGUGUGUUUUU  31 
13 CUCUCUCUCUCUCUCUCUCUCUCUCUCUCU  30 
14 CUGCUGCUGCUGCUGCUGCUGCUGCUGCUG  30 
15 GUUGGUUGGUUGGUUGGUUGGUUGGUUGGU  30 
16 UAUGUAUGUAUGUAUGUAUGUAUGUAUGUA  30 
17 UGGUGGUGGUGGUGGUGGUGGUGGUGGUGG  30 
18 UGUGUGUGUGUGUAUGUGUGUGUGUGUGUG  30 
19 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG  30 
20 UUGUUGUUGUUGUUGUUGUUGUUGUUGUUG  30 
21 UGUGUGUGUGUGUGUGUGUGUGUGUUUUU  29 
22 CAUGCAUGCAUGCAUGCAUGCAUGCAUG  28 
23 CCUGCCUGCCUGCCUGCCUGCCUGCCUG  28 
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24 UAUGUAUGUAUGUAUGUAUGUAUGUAUG  28 
25 UGUGUGUGUGUGUGUGUGUGUGUUUUU  27 
26 GUGUUUGUGUUUGUGUGUGUUUGUU  25 
27 CUGCUGCUGCUGCUGCUGCUGCUG  24 
28 CUGCUGCUGCUGCUGCUGCUGCUG  24 
29 GUUUGUUUGUUUGUUUGUUUGUUU  24 
30 UUUUUUUGUUGUGUUUUUUCCUU  23 
31 UUUCUUGUUUGUUUGUUUGGGU  22 
32 UGUUGUGUGUGUGUGU  16 
33 UGUGUUGUGUGU  12 
34 UGUGUGUGUGU  11 
35 UGUGUGUGUG  10 
36 UGUGUGUGU  9 
37 UGUGUGUG  8 
38 CUGUCUG  7 
39 UGUGUGU  7 
40 UGUUUGU  7 
41 UGUGUG  6 
42 UGUGU  5 
According to Splice Aid F; used in the bioinformatical 3’UTR analysis [109]. 
 
In a first step, a high stringency analysis was performed, looking for the exact splicing pattern 
of mPGES-1 (see Figure 27A). However, it turned out that none of the transcripts exhibits this 
exact pattern with two very long binding sites and a 1000 nt intron in between. Therefore, it 
was considered that the splicing pattern might not be identical.  
In a second low stringency analysis, criteria were loosened, screening for transcripts 
containing 2 or more binding sites of at least 8 nt length and with at least 100 nt in between 
(see Figure 27B).  
 
 
Figure 27: High stringency and low stringency approach in bioinformatical 3‘UTR 
analysis. 
All 3’UTRs of potential CUGBP1 targets were analyzed concerning a (A) high stringency/ 
mPGES-1 splice pattern or (B) low stringency pattern with two or more CUGBP1 binding sites 
(≥ 8 nucleotides), with potential intron (≥ 100 nucleotides). 
 
As listed in Table 11, 575 transcripts resembling 30% of the originally 1914 3’UTRs, contained 
a CUGBP1 binding site. Restricting it to binding sites that were 8 nt or longer, only 118 
transcripts (6%) were left, as a lot of them were shorter (see number 38-42 in Table 10). By 
applying the criterion that at least 2 distinct binding sites of at least 8 nt length should be in the 
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sequence, only 33 transcripts were left (1.7%). Eventually, by looking for an additional intron 
of at least 100 nt in between the binding sites, only 11 transcripts (0.6%) fulfilled all the criteria. 
Due to the binding motifs of CUGBP1 which often are repeats of only two nt (e.g. UG/TG) the 
last step also removed transcripts that had several UG-repeat binding motives but only 2 nt 
apart, meaning that these were actually the same binding sites. For instance, the 3’UTR of 
Lysosome-associated membrane protein 2 harbors a 40-nt UG-repeat, which is why it was 
predicted to have 17 CUGBP1 binding sites (of number 37, Table 10). However, when looking 
at the exact positions within the 3’UTR sequence, it becomes clear that these predicted distinct 
binding sites are at position 420, 422, 424 etc., belonging to the same 40-nt UG-repeat. 
Therefore, the last criterion was not only used to find potential introns but also to support the 
second criterion of two distinct binding sites. 
 
Table 11. Number of transcripts fulfilling the low stringency analysis criteria. 
Criterion I Criterion II Criterion III  
Binding site length Number of 
binding sites 
Space between 
binding sites 
Number of 
transcripts left 
All All All 575 
binding site of ≥8 nt All All 118 
binding site of ≥8 nt ≥2 binding sites All 33 
binding site of ≥8 nt ≥2 binding sites ≥ 100 nt intron 11 
 
Those 11 transcripts that were finally left, belong to 9 different genes (see Figure 28, and Table 
17; appendix)  
 MAF BZIP Transcription Factor K (MAFK) 
 UBX Domain Protein 2B (UBXN2B) 
 Complexin 2 (CPLX2) 
 UBE2R2 
 Superoxide dismutase 2 (SOD2) 
 CUB domain-containing protein 1 (CDCP1) 
 CEP41 
 RNA Binding Motif Protein 23 (RBM23) 
 SET Domain Containing Lysine Methyltransferase 7 (SETD7) 
 
In ten of the 3’UTRs, exactly two CUGBP1 binding sites were found, while the 3’UTR of CPLX2 
harbors three distinct binding sites. However, the first and the second one at position 1233 and 
1250 do not span a potential intron of ≥ 100 nt. Binding motifs were mostly 8 nt long (number 
37 in Table 10), except for CEP41 which harbors a 9 nt binding motif (number 36 in Table 10) 
and SOD2 which harbors a 11 nt binding motif (number 34 in Table 10). The potential introns 
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in between the two binding sites range from rather small 199 nt for CEP41 up to 7537 nt for 
SOD2 (for more details see Table 17; appendix).  
 
 
 
Figure 28: Transcripts from low stringency 3’UTR analysis. 
Transcripts which harbor two (in case of CPLX2 three) CUGBP1 binding sites in the 3’UTR. 
For more details, see Table 17; appendix. All transcripts are protein coding except for MAFK 
ENST00000343242 which is predicted to be an NMD target. Downloaded from ensemble 
Human (GRCh38.p12). 
 
 
Of these, only CEP41 and UBE2R2 depicted the “decoy regulation pattern” in the mass 
spectrometry data. However, they were not bound by CUGBP1 in the RIP assay of A549 cells 
(see Figure 25) and therefore excluded as novel decoy targets. This small number of proteins, 
together with the fact that the high stringency analysis did not provide any hits, strongly 
indicated that it is a very exceptional splice pattern and the decoy mechanism must be very 
specific.  
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4. Discussion 
When it was revealed in 2010 that miRs can act as decoy to RBPs [193], this opened up a 
whole new field of miR research. Recently, the decoy mechanism was also described for 
CUGBP1 and miR-574-5p [196]. The resulting regulation of mPGES-1 expression and PGE2 
levels in non-small cell lung cancer gives hope for the development of novel therapeutic 
approaches and might even allow the use of miR-574-5p as a biomarker for lung cancer patient 
stratification. 
 
4.1 Insights into the proteome of A549 lung cancer cells 
A mass spectrometry-based proteomics study was conducted in order to elucidate existence 
and global distribution of novel targets of CUGBP1 and miR-574-5p. To this end, A549 lung 
cancer cells with manipulated levels of CUGBP1 or miR-574-5p were used. Of note, the 
proteomics study was used as shotgun procedure. It gives first indications which proteins might 
be regulated but does not always depict the exact expression changes. The regulation of 
mPGES-1 is a simple example for that. It was not regulated upon ΔCUGBP1 in the mass 
spectrometry data, although it is a described CUGBP1 target. Therefore, it was necessary that 
any information drawn from the data set was validated. Experimentally, the regulation of 
distinct proteins was successfully validated via Western blot analysis. Moreover, published 
data sets of CUGBP1 and miR-574-5p targets were compared with lists of potential targets 
from the proteomics study. For instance, a published Clip Seq (cross-linking 
immunoprecipitation-high-throughput sequencing) data set of Tonqueze et al. revealed a 25% 
overlap (102 proteins) with potential CUGBP1 targets [260]. For canonical miR-574-5p targets, 
a similar approach was conducted: 130 (20%) of them were also found in a list of predicted 
targets from the database targetscan.org [261]. Finally, one of the strongest downregulated 
proteins upon ΔCUGBP1 in the microsomal fraction was CUGBP1 itself (-3.1-fold), which 
validates the knockdown as well as the mass spectrometry data (see Table 16). With that the 
accuracy of the proteomics study was assured, both experimentally and by comparison to 
literature and databases.  
In order to broaden the insights in compartment specific post-transcriptional regulation, 
proteins from soluble and microsomal fraction were separately analyzed in the proteomics 
study [250]. It is generally assumed that soluble proteins are translated from free ribosomes in 
the cytosol, whereas the microsomal fraction is associated with ribosomes of the rough 
endoplasmic reticulum [262]. Indeed, differential regulation between fractions was observed 
for many proteins. Concerning mass spectrometry data, 78 proteins were observed showing 
opposite regulation in soluble and microsomal fraction, thereof 48 in the two miR conditions 
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and 30 in the CUGBP1 condition. Using Western blot analysis during proteomics validation, 
the R-SMADs SMAD2 and SMAD3 were also observed to show opposite regulation in the two 
fractions. This underlines the theory that RBPs may allow different translational efficiencies 
concerning free and endoplasmic reticulum-bound ribosomes [263] [264]. 
The microsomal fraction appears to be of greater importance compared to the soluble fraction. 
On the one hand, there was a broader diversity of proteins detected (60% more different 
proteins than in the soluble fraction). Compared to other proteomics studies, this result is 
unusual. Since its establishment in 2008, the microsomal fractionation protocol has been used 
in a variety of proteomics studies [250].  For monocytic MM6 cells and A549 lung cancer cells, 
it was demonstrated in the last years that the soluble and microsomal fractions contained 
roughly the same amount of different proteins [265] [195] [266]. Thus, the discrepancy to this 
thesis could be potentially caused by technical variances such as differences in digestion 
protocol, labelling and buffer composition [265]. 
Another point to consider is that there was a higher percentage of microsomal proteins that 
actually revealed a regulation in response to the oe or knockdowns.  An explanation could be 
that CUGBP1 exerts its functions more in the microsomal protein fraction. This hypothesis is 
supported by the fact that CUGBP1 protein itself can be found predominantly in the microsomal 
fraction as confirmed by Western blot analysis. Furthermore, it was previously shown that the 
decoy targets of miR-328 and hnRNP E2 are also predominantly found in the microsomal 
fraction of MM6 cells [195]. 
In conclusion, it can be assumed that effects of CUGBP1 and the decoy with miR-574-5p are 
more prominently found in the microsomal protein fraction. Hence, special emphasis was 
placed on this fraction in the course of this project. 
 
4.2. Discovery and verification of new canonical CUGBP1 targets  
In order to screen for potential new targets of CUGBP1, different approaches were combined. 
Concerning the mass spectrometry data, around 72% of the upregulated proteins were found 
to have a CUGBP1 binding site. Comparing this to total protein amounts, 4.5% of all detected 
proteins could potentially be CUGBP1 targets. This fits the general assumption that CUGBP1 
is a multifunctional RBP, as a lot of transcripts contain its binding motif. Nevertheless, CUGBP1 
is described to bind those potential targets strictly context specific [267]. Not only the binding 
alone but also the outcome is context specific, as CUGBP1 can influence a variety of mRNA 
processing steps, from AS [111] [112] in the nucleus to translation in the cytoplasm [133] [134] 
[135]. Furthermore, these assumptions are based on the repressive functions of CUGBP1. In 
specific cases CUGBP1 was also observed to have a positive impact  on its targets [136] [137]. 
Therefore, the downregulated proteins in response to ΔCUGBP1 could potentially also be 
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positively regulated by CUGBP1. Moreover, CUGBP1 binding sites were only analyzed in 
3’UTR sequences within this study. This was consequential, as most of the time CUGBP1 is 
described to bind to 3’UTRs of target mRNAs and additionally mPGES-1 was used as a model 
for a decoy target. Of note, in some rare cases CUGBP1 was also observed to bind to exon-
intron boundaries within the CDS [268] or 5’UTR sequences [269] [270]. Therefore, the actual 
number of targets might be even higher. 
The NADH-ubiquinone NDUFS2 was mentioned as potential CUGBP1 target in HeLa cells for 
the first time in a study by Rattenbacher et al. [84]. NDUFS2 is part of the core subunit of the 
mitochondrial membrane respiratory chain NADH dehydrogenase (mitochondrial complex I) 
[271] [272]. This complex is an assembly of at least 43 different subunits, while NDUFS2 
belongs to a group of 7 iron-sulfur metalloproteins which stabilize the early intermediate 
complex [273]. In order to investigate the diverse binding motifs of CUGBP1, Rattenbacher et 
al. performed immunoprecipitation and subsequently microarray analysis. This resulted in a 
list of 613 potential CUGBP1 targets including their specific sequences. NDUFS2 was 
identified as one of 477 transcripts that were solely found in the CUGBP1-IP. With a short 
3’UTR of only 202 nt, NDUFS2 contains a 31 nt long GU-repeat at position 77 that serves as 
binding site for CUGBP1. This motif was additionally present in 17% of the other detected 
transcripts in the study and has a 7% prevalence in the whole genome [84]. Furthermore, they 
could show that by binding of CUGBP1, the NDUFS2 mRNA as well as any other mRNA 
containing the specific motif was rapidly degraded, hinting towards a CUGBP1-mediated decay 
mechanism. This hypothesis does also match the results within this thesis. In A549 cells, 
CUGBP1 also seems to have a negative impact on NDUFS2 gene expression. However, 
NDUFS2 did not show the “decoy regulation pattern”. Therefore, it cannot be considered as 
decoy target but only as canonical CUGBP1 target. It is described that mutations in the 
NDUFS2 gene go along with the autosomal recessive Mitochondrial Complex I Deficiency 
[274] [275] [276]. This heterogeneous disease can have a variety of phenotypes from lethal 
neonatal disease to adult-onset neurodegenerative disorders, cardiomyopathy or impaired 
liver function [277] [278] [279]. By influencing a protein of the respiratory chain, it can be 
assumed that CUGBP1 could have an impact on cellular energy supply as well as associated 
diseases. 
Another protein family that was investigated are the SMADs. Functionally, they act as signal 
transducers for the Transforming growth factor (TGF)-β signaling pathway. They can be 
divided in the so-called receptor (R-) SMADs (SMAD1-3, SMAD5 and SMAD8-9), the Co-
SMAD (SMAD4) and the inhibitory (I-) SMADs (SMAD6-7) [280] [281] [282]. Upon TGF-β 
receptor activation, two R-SMADs get phosphorylated by the receptor kinase and build a 
complex with a Co-SMAD [283] [284]. The trimer then translocates to the nucleus, where it 
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acts as transcription factor. As a result, upregulation of certain response genes like Snail 
Family Transcriptional Repressor 1 (Snail1), Zinc Finger E-Box Binding Homeobox 1 (ZEB1) 
and Twist Family BHLH Transcription Factor 1 (Twist1) [285] [286] [287] has been observed. 
As those are all associated with EMT, SMAD proteins are considered being essential for tumor 
metastasis throughout a variety of cancer types [288]. 
Thus, SMAD proteins were an interesting objective within this project, as metastasis was 
predicted by IPA and also some SMADs were detected in the proteomics study. It was verified 
that SMAD2 is a canonical target of CUGBP1. SMAD3 was another promising candidate, but 
the mRNA was not bound by CUGBP1, at least under the conditions investigated here. This 
does not necessarily exclude SMAD3 as CUGBP1 target. Potentially, binding of SMAD3 
mRNA only occurs under certain conditions e.g. with a certain stimulus like TGF-β, some 
culture conditions like starvation or simply in another cell type [267]. Interestingly, another 
family member, SMAD7 was not detected in the proteomics study. Nevertheless, it is described 
as CUGBP1 target in C2C12, a murine myoblast cell line [110]. In a publication by Lee et al. 
RIP assays proved the interaction of CUGBP1 with SMAD7 mRNA. It was further elucidated 
that binding led to a destabilization of the SMAD7 transcript, while knockdown of CUGBP1 
increased the stability of the mRNA [110]. This fits to the general assumption that CUGBP1 is 
a destabilizing factor. In A549 cells, SMAD7 is barely expressed, which might explain why it 
was not detected in the proteomics study. However, it is interesting that several members of 
the SMAD family seem to be affected by CUGBP1. In a similar way, this is already described 
for the signal recognition particles (SRP) [117] which underlines the existence of CUGBP1 
regulons. 
 
4.3 Decoy target search 
One of the main aims of this project was it to investigate if the decoy mechanism affects other 
targets of CUGBP1 or if it is strictly specific for mPGES-1. In that regard, a first approach was 
it to screen for a “decoy regulation pattern” on protein level. 
(I) CUGBP1 has generally negative effects on its targets, based on its role as a translational 
repressor or decay mediator. Therefore, it can be hypothesized that the majority of decoy and 
canonical CUGBP1 targets should react to the knockdown with an increased protein level.  
(II) Taking a closer look at the miR-574-5p oe condition, it becomes clear that this also should 
have a positive effect on protein levels of the decoy targets. Similar to the ΔCUGBP1 condition, 
little to no CUGBP1 can bind to the binding sites as miR-574-5p acts as competitive inhibitor 
and sequesters CUGBP1 away from its target. Hence, an increased mPGES-1 protein level 
can be observed. 
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(III) In the ΔmiR-574-5p samples, CUGBP1 can easily bind its targets. Decoy target proteins 
were expected to be decreased compared to control, while canonical CUGBP1 targets should 
not be affected by the miR-574-5p levels. In the case of mPGES-1, binding of CUGBP1 leads 
to a lower amount of the 3’UTR splice variant and thus to a lower protein level. 
When the proteomics data were analyzed concerning stringent criteria for this “decoy 
regulation pattern”, it was revealed that only 7 microsomal proteins (0.1% of total proteins) did 
resemble this perfect pattern that matched all three criteria. In Western blot analyses, no 
proteins were found to reveal this “decoy regulation pattern” except for mPGES-1. The 
analyzed CUGBP1 targets NDUFS2, SMAD2 and SMAD3 did also not show the expected 
pattern. Unfortunately, the Odyssey Western blot system provided too little sensitivity for the 
detection of some weakly expressed proteins like HMGA2. Nevertheless, concerning the 
decoy target search on protein level it could be assumed that the decoy mechanism does not 
have a global impact on A549 proteome. This was especially intriguing, as it was initially 
assumed that the decoy mechanism would influence the expression of a variety of genes. In a 
recent study, it was shown that numerous proteins could be regulated by the decoy function of 
miR-328 and hnRNP E2 [195]. Therefore, it would have been reasonable that the miR-574-
5p/CUGBP1 decoy would also have a global impact. However, the data within this thesis 
indicate the opposite. 
Overall, it can be assumed that the CUGBP1 and miR-574-5p decoy mechanism would not 
promiscuously affect a lot of proteins. 
 
4.4 Bioinformatical 3’UTR analysis revealed unique splice pattern 
As it was demonstrated that both CUGBP1 and miR-574-5p were located predominantly in the 
nucleus, the CUGBP1 function as splicing factor came into focus. It was reasonable, as it was 
already described that mPGES-1 mRNA was alternatively spliced [196]. In fact, mPGES-1 
mRNA is spliced in the 3’UTR creating a shorter isoform. Thereby, a 3’UTR ALU element is 
removed as well as a myriad of miR and RBP binding sites which allow for a higher translational 
efficiency [196]. It is generally known that shorter 3’UTRs are beneficial for a higher expression 
profile due to a diminishment of binding sites [289].  
In a bioinformatical 3’UTR analysis it could be shown that the 3’UTR splicing pattern of 
mPGES-1 was not found in any other transcript and therefore was termed as being unique. 
This outcome was expected, as it was unlikely to find another 3’UTR with one 39 nt and one 
46 nt CUGBP1 binding motive, with a 1000 nt intron in between. In a low stringency analysis, 
it was screened for a similar pattern with two shorter CUGBP1 binding sites and with only 100 
nt in between. The resulting list of only 11 transcripts (0.5% of the analyzed transcripts) gave 
an additional hint that this was a quite specific pattern.  
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Of note, this approach only aimed to find potential other splice patterns in 3’UTRs, as the 
3’UTR splicing of mPGES-1 was used as a model. Conventional splicing processes were not 
considered herein, although CUGBP1 does also influence (alternative) splicing in the CDS 
[111] [112]. Further, it has to be mentioned that CUGBP1 cannot only bind in 3’UTR sequences 
but also in CDS and 5’UTRs [268] [269]. Therefore, this bioinformatical study was just a first 
approach and needs to be followed by additional analyses like bioinformatical extension to 
CDS or experimental analysis of splice events.  
Moreover, as two of the low stringency transcripts were not bound by CUGBP1 in RIP assays, 
further experiments need to be conducted. It is likely that with an additional stimulus or other 
cellular conditions the binding of CUGBP1 could be triggered. Unfortunately, as CUGBP1 
binds strictly context specific and is described to function in various steps of mRNA processing 
this would have exceeded this project.  
 
Overall, the screening for new decoy targets using several different approaches did not result 
in any conclusive hits. This highly complex proteomics study provided a broad insight into the 
proteome of A549 lung cancer cells, including compartment-specific regulation and new 
canonical targets of CUGBP1 but did not provide any new targets regulated by the interaction 
of CUGBP1 and miR-574-5p. Hence, it is assumable that in A549 cells mPGES-1 is the only 
protein regulated by the CUGBP1/miR-574-5p decoy mechanism. 
 
4.5 Physiological impact 
In order to investigate the overall physiological functions of CUGBP1, miR-574-5p and the 
decoy mechanism, a pathway analysis was performed that predicted biological functions, 
canonical pathways and upstream regulators based on the mass spectrometry data. As 
metastasis and migration were among the top ten predictions, it was an intriguing research 
topic.  
 
4.5.1 Influence of miR-574-5p on metastasis 
In wound healing and trans-well assays, surprisingly, no significant effects were measured with 
miR-574-5p oe cells compared to control cells. This clearly contradicts literature, where miR-
574-5p was described as being pro-metastatic in small cell and non-small cell lung cancer 
cells, respectively [209] [210]. In these two publications from the same research lab, they 
investigated the influence of miR-574-5p on the migration of A549 cells with the same two 
methods described within this thesis but with a different outcome. However, there were 
differences in the procedures. For the wound healing assays within this project, cells were pre-
starved, before the actual assay in order to minimize proliferation of the cells. This step was 
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skipped in the publications by Zhou et al.. Further, they performed trans-well assays for 24 h. 
This opens up the possibility of further proliferation of the migrated cells on the bottom of the 
membrane, as A549 cells are described to have a doubling time of around 18-22 h [290]. 
Indeed, transient miR-574-5p oe has a pro-proliferative effect on A549 cells [196] which could 
explain why they measured enhanced number of cells which potentially were falsely 
considered as migrated cells. 
Another possible explanation could be that within this project a stable miR-574-5p oe cell line 
was used. Compared to a transient transfection, stable integration is dependent on position, 
copy number and site of integration. Potentially the viral particle transduction could have 
caused other variances in the cell, besides the miR-574-5p oe and therefore caused a different 
migratory behavior. An example that underlines this theory is that A549 cells transiently 
overexpressing miR-574-5p show an increased proliferation, while stable miR-574-5p oe cells 
do not [291]. In order to exclude those variances, it would be necessary to repeat the wound 
healing and trans-well assays with a transient overexpression or knockdown of the miR.  
Another point to mention is that IPA predicted metastasis to be diminished with miR-574-5p 
oe, which does not fit the results of the migration assays and additionally stands in contrast to 
the two publications about the enhancing effects of miR-574-5p on migration [209] [210]. 
However, in this context, it has to be mentioned that the IPA is based on the mass spectrometry 
results which were performed with transient miR-574-5p oe (300-fold oe), while the migration 
assays were performed with a stable miR-574-5p oe (15-fold oe) [196]. 
What supports the IPA is the fact that it also predicted metastasis to be decreased upon 
ΔCUGBP1. Especially metastasis of breast cancer cells was predicted in that context. This 
underlines the recently published positive impact of CUGBP1 on EMT-proteins and tumor 
metastasis of breast cancer cells [136] [137].  
Overall, the migration assays do not give any conclusive results and further experiments are 
needed to exclude any influence of miR-574-5p and CUGBP1 on tumor metastasis. 
 
4.5.2 Influence of mPGES-1 on metastasis 
In a further approach, the influence of mPGES-1 was investigated. A previous study showed 
that the pro-proliferative effect of miR-574-5p was solely caused by its influence on mPGES-1. 
Therefore, this was also an interesting point to investigate in the context of tumor migration. 
The fact that mPGES-1 did not affect migration in the experiments within this thesis is 
controversial. Two publications describe mPGES-1 as promoter of cancer metastasis in vivo 
[292] [293]. Both injected tumor cells intravenously in wild type or mPGES-1 knockout mice 
and determined metastases of the lung by number and weight of the whole organ. Although 
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this is a common procedure, it does not fully cover the physiological background of tumor 
metastasis. 
In general, to undergo metastasis the cancer cells do have to go through a process called EMT 
[294]. It includes an extensive phenotypical change from an epithelial to a more mesenchymal 
cell type. Thereby, the cells lose their cell-cell-adhesion and acquire migratory abilities, 
accompanied by a mayor change in the protein profile. This transition is crucial for invasion, 
meaning that the tumor cells gain the ability to enter the vascular system. Only then, the cells 
can migrate to distant sites within the body. Then, the migrated cells have to undergo the 
reverse process, called mesenchymal epithelial transition to regain their adhesive properties 
and form new metastases [295] [296].  
By injecting tumor cells directly in the blood system, the metastasis process is tremendously 
facilitated. Further, in vivo models are only basally comparable with trans-well and wound 
healing assay in cell culture systems. Nevertheless, it is odd that mPGES-1 does not render 
migration of the lung cancer cells at all. Therefore, it could be interesting to perform further 
experiments in that regard. For example, invasion assays with 3D cell culture would provide a 
more physiological environment and potentially could reveal new insights. 
 
4.6 Outlook 
This thesis provided first evidence that the decoy mechanism of miR-574-5p and CUGBP1 
could be specifically regulating mPGES-1. Using different screening approaches, no other 
target could be found that was regulated by the interaction of the miR and the RBP.  
However, the decoy mechanism itself is still not fully understood. In the future it could be an 
intriguing research topic to investigate how the interaction of miR-574-5p and CUGBP1 is 
triggered. Until now it is described to happen in the presence of IL-1β. What exactly causes 
miR-574-5p to bind to CUGBP1 still remains unclear. The phosphorylation status of CUGBP1 
could be the key, as it is a known regulator of CUGBP1 function [120] [121] [122] [123] [119]. 
Further, the existence of binding partners or chaperones could also be possible. Additionally, 
the exact impact of IL-1β is of great interest. Signaling downstream of the IL-1β receptor 
involves recruitment of myeloid differentiation primary response gene 88 (MyD88) and/or Toll-
interleukin receptor domain containing adaptor-inducing interferon-β (TRIF) [297]. 
Interestingly, miR-574-5p is also described to act as TLR8 ligand and activate this exact 
signaling pathway, which provides a promising connection [184] [185] [186] [187].   
Finally, specificity of the decoy mechanism is an interesting question. Until now, the 
mechanism is only described for two pairs: miR-328/hnRNP E2 and miR-574-5p/CUGBP1 
[193] [196]. It would be interesting to investigate if there are more miR/RBP pairs or if the given 
ones can also interact with other partners. CUGBP1 could potentially bind other GU-rich miRs. 
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Vice versa, miR-574-5p is described to be bound by Transactive response DNA binding 
protein43 kDa (TDP-43) [298], an RBP which facilitates pri-miR processing and builds a 
complex with Drosha [299]. Further GU-binding RBPs are Nova-1 [300] and CUGBP2 [301] 
which could also potentially bind to miR-574-5p. Clearly, future experiments are needed to fully 
elucidate this topic. 
The fact that the miR-574-5p/CUGBP1 decoy is specific for mPGES-1 was initially surprising. 
Eventually, the discovery of the unique 3’UTR splice pattern provided a possible explanation. 
Moreover, it has to be taken into account that the miR-574-5p effects on tumor progression 
were also based solely on mPGES-1 [196]. This was probably the first hint for this kind of 
specificity. Although one can never fully exclude each and every potential option, the results 
within this thesis clearly support the postulation that mPGES-1 is the only protein regulated by 
the miR-574-5p/CUGBP1 decoy in A549 cells. This would open up new options for NSCLC 
patients. It is well-known that not all patients benefit from a treatment with medication that aims 
to reduce PGE2 levels [248] [249]. Presumably, because not all lung adenocarcinomas are 
dependent on PGE2. Therefore, the miR-574-5p levels could serve as stratification marker to 
identify the subgroup with high mPGES-1 and PGE2 levels. For those patients, treatment with 
NSAIDs could be a beneficial tool in the fight against NSCLC. 
 
 
  
References 
__________________________________________________________________________ 
 
78 
 
References 
[1] P. W. B Alberts, A Johnson, J Lewis, M Raff, K Roberts, Molecular Biology of the cell, 
Fifth edit. Garland Science, 2008. 
[2] F. Uchiumi, Ed., Gene Expression and Regulation in Mammalian Cells - Transcription 
From General Aspects. InTech, 2018. 
[3] D. L. Bentley, “Coupling mRNA processing with transcription in time and space.,” Nat. 
Rev. Genet., vol. 15, no. 3, pp. 163–75, 2014. 
[4] T. Glisovic, J. L. Bachorik, J. Yong, and G. Dreyfuss, “RNA-binding proteins and post-
transcriptional gene regulation.,” FEBS Lett., vol. 582, no. 14, pp. 1977–86, Jun. 2008. 
[5] A. H. Corbett, “Post-transcriptional regulation of gene expression and human disease.,” 
Curr. Opin. Cell Biol., vol. 52, pp. 96–104, 2018. 
[6] M. Stewart, “Polyadenylation and nuclear export of mRNAs.,” J. Biol. Chem., vol. 294, 
no. 9, pp. 2977–2987, 2019. 
[7] H. A. Meijer et al., “A novel method for poly(A) fractionation reveals a large population 
of mRNAs with a short poly(A) tail in mammalian cells.,” Nucleic Acids Res., vol. 35, no. 
19, p. e132, 2007. 
[8] K. Buiting, C. Körner, B. Ulrich, E. Wahle, and B. Horsthemke, “The human gene for the 
poly(A)-specific ribonuclease (PARN) maps to 16p13 and has a truncated copy in the 
Prader-Willi/Angelman syndrome region on 15q11-->q13.,” Cytogenet. Cell Genet., vol. 
87, no. 1–2, pp. 125–31, 1999. 
[9] K. C. M. Moraes, C. J. Wilusz, and J. Wilusz, “CUG-BP binds to RNA substrates and 
recruits PARN deadenylase.,” RNA, vol. 12, no. 6, pp. 1084–91, Jun. 2006. 
[10] W. S. Lai, E. Carballo, J. R. Strum, E. A. Kennington, R. S. Phillips, and P. J. Blackshear, 
“Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation 
and destabilization of tumor necrosis factor alpha mRNA.,” Mol. Cell. Biol., vol. 19, no. 
6, pp. 4311–23, Jun. 1999. 
[11] K. Leppek, J. Schott, S. Reitter, F. Poetz, M. C. Hammond, and G. Stoecklin, “Roquin 
promotes constitutive mRNA decay via a conserved class of stem-loop recognition 
motifs.,” Cell, vol. 153, no. 4, pp. 869–81, May 2013. 
[12] W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, “Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight?,” Nat. Rev. Genet., 
vol. 9, no. 2, pp. 102–14, Feb. 2008. 
[13] M. Brengues, D. Teixeira, and R. Parker, “Movement of eukaryotic mRNAs between 
polysomes and cytoplasmic processing bodies.,” Science, vol. 310, no. 5747, pp. 486–
9, Oct. 2005. 
[14] M. Kulkarni, S. Ozgur, and G. Stoecklin, “On track with P-bodies.,” Biochem. Soc. 
Trans., vol. 38, no. Pt 1, pp. 242–51, Feb. 2010. 
[15] S. N. Bhattacharyya, R. Habermacher, U. Martine, E. I. Closs, and W. Filipowicz, “Relief 
of microRNA-mediated translational repression in human cells subjected to stress.,” 
Cell, vol. 125, no. 6, pp. 1111–24, Jun. 2006. 
[16] A. Nordheim and R. Knippers, Eds., Molekulare Genetik. Stuttgart: Georg Thieme 
Verlag, 2015. 
[17] S. Gerstberger, M. Hafner, and T. Tuschl, “A census of human RNA-binding proteins,” 
References 
__________________________________________________________________________ 
 
79 
 
Nat. Rev. Genet., vol. 15, no. 12, pp. 829–845, 2014. 
[18] P. J. Wittkopp and G. Kalay, “Cis-regulatory elements: molecular mechanisms and 
evolutionary processes underlying divergence.,” Nat. Rev. Genet., vol. 13, no. 1, pp. 
59–69, Dec. 2011. 
[19] U. Dettmer, M. Folkerts, E. Kächler, and A. Sönnichsen, Intensivkurs Biochemie. 2005. 
[20] F. E. Baralle and J. Giudice, “Alternative splicing as a regulator of development and 
tissue identity.,” Nat. Rev. Mol. Cell Biol., vol. 18, no. 7, pp. 437–451, 2017. 
[21] A. Kalsotra and T. A. Cooper, “Functional consequences of developmentally regulated 
alternative splicing.,” Nat. Rev. Genet., vol. 12, no. 10, pp. 715–29, Sep. 2011. 
[22] E. S. Lander et al., “Initial sequencing and analysis of the human genome.,” Nature, vol. 
409, no. 6822, pp. 860–921, Feb. 2001. 
[23] Q. Pan, O. Shai, L. J. Lee, B. J. Frey, and B. J. Blencowe, “Deep surveying of alternative 
splicing complexity in the human transcriptome by high-throughput sequencing.,” Nat. 
Genet., vol. 40, no. 12, pp. 1413–5, Dec. 2008. 
[24] E. T. Wang et al., “Alternative isoform regulation in human tissue transcriptomes.,” 
Nature, vol. 456, no. 7221, pp. 470–6, Nov. 2008. 
[25] M. L. Tress, F. Abascal, and A. Valencia, “Alternative Splicing May Not Be the Key to 
Proteome Complexity.,” Trends Biochem. Sci., vol. 42, no. 2, pp. 98–110, 2017. 
[26] M. L. Tress, F. Abascal, and A. Valencia, “Most Alternative Isoforms Are Not 
Functionally Important.,” Trends Biochem. Sci., vol. 42, no. 6, pp. 408–410, 2017. 
[27] J. Tazi, N. Bakkour, and S. Stamm, “Alternative splicing and disease.,” Biochim. 
Biophys. Acta, vol. 1792, no. 1, pp. 14–26, Jan. 2009. 
[28] Y. Lee and D. C. Rio, “Mechanisms and Regulation of Alternative Pre-mRNA Splicing.,” 
Annu. Rev. Biochem., vol. 84, pp. 291–323, 2015. 
[29] D. L. Black, “Mechanisms of alternative pre-messenger RNA splicing.,” Annu. Rev. 
Biochem., vol. 72, pp. 291–336, 2003. 
[30] L. P. Iñiguez and G. Hernández, “The Evolutionary Relationship between Alternative 
Splicing and Gene Duplication.,” Front. Genet., vol. 8, p. 14, Feb. 2017. 
[31] A. Hegele et al., “Dynamic protein-protein interaction wiring of the human spliceosome.,” 
Mol. Cell, vol. 45, no. 4, pp. 567–80, Feb. 2012. 
[32] M. S. Jurica and M. J. Moore, “Pre-mRNA Splicing,” Mol. Cell, vol. 12, no. 1, pp. 5–14, 
Jul. 2003. 
[33] Y. Shi, “Mechanistic insights into precursor messenger RNA splicing by the 
spliceosome.,” Nat. Rev. Mol. Cell Biol., vol. 18, no. 11, pp. 655–670, Nov. 2017. 
[34] R. Martinez-Contreras, P. Cloutier, L. Shkreta, J.-F. Fisette, T. Revil, and B. Chabot, 
“hnRNP proteins and splicing control.,” Adv. Exp. Med. Biol., vol. 623, pp. 123–47, 2007. 
[35] J. C. Long and J. F. Caceres, “The SR protein family of splicing factors: master 
regulators of gene expression.,” Biochem. J., vol. 417, no. 1, pp. 15–27, Jan. 2009. 
[36] A. J. Matlin, F. Clark, and C. W. J. Smith, “Understanding alternative splicing: towards 
a cellular code.,” Nat. Rev. Mol. Cell Biol., vol. 6, no. 5, pp. 386–98, May 2005. 
[37] M. C. Wahl, C. L. Will, and R. Lührmann, “The spliceosome: design principles of a 
References 
__________________________________________________________________________ 
 
80 
 
dynamic RNP machine.,” Cell, vol. 136, no. 4, pp. 701–18, Feb. 2009. 
[38] A. N. Ladd and T. A. Cooper, “Finding signals that regulate alternative splicing in the 
post-genomic era.,” Genome Biol., vol. 3, no. 11, p. reviews0008, Oct. 2002. 
[39] R. B. Voelker and J. A. Berglund, “A comprehensive computational characterization of 
conserved mammalian intronic sequences reveals conserved motifs associated with 
constitutive and alternative splicing.,” Genome Res., vol. 17, no. 7, pp. 1023–33, Jul. 
2007. 
[40] K. Kruger, P. J. Grabowski, A. J. Zaug, J. Sands, D. E. Gottschling, and T. R. Cech, 
“Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening 
sequence of Tetrahymena.,” Cell, vol. 31, no. 1, pp. 147–57, Nov. 1982. 
[41] Dominic W. S. Wong, The ABCs of Gene Cloning. Boston, MA: Springer US, 2006. 
[42] W. Janning and E. Knust, Allgemeine Genetik Molekulare Genetik Entwicklungsgenetik, 
no. Isbn 9783131287724. 2004. 
[43] R. Sandberg, J. R. Neilson, A. Sarma, P. A. Sharp, and C. B. Burge, “Proliferating cells 
express mRNAs with shortened 3’ untranslated regions and fewer microRNA target 
sites.,” Science, vol. 320, no. 5883, pp. 1643–7, Jun. 2008. 
[44] C. Mayr and D. P. Bartel, “Widespread shortening of 3’UTRs by alternative cleavage 
and polyadenylation activates oncogenes in cancer cells.,” Cell, vol. 138, no. 4, pp. 673–
84, Aug. 2009. 
[45] O. Isken and L. E. Maquat, “Quality control of eukaryotic mRNA: safeguarding cells from 
abnormal mRNA function.,” Genes Dev., vol. 21, no. 15, pp. 1833–56, Aug. 2007. 
[46] H. Le Hir, D. Gatfield, E. Izaurralde, and M. J. Moore, “The exon-exon junction complex 
provides a binding platform for factors involved in mRNA export and nonsense-mediated 
mRNA decay.,” EMBO J., vol. 20, no. 17, pp. 4987–97, Sep. 2001. 
[47] C. Cenik, A. Derti, J. C. Mellor, G. F. Berriz, and F. P. Roth, “Genome-wide functional 
analysis of human 5’ untranslated region introns.,” Genome Biol., vol. 11, no. 3, p. R29, 
2010. 
[48] L. G. Wilming, J. G. R. Gilbert, K. Howe, S. Trevanion, T. Hubbard, and J. L. Harrow, 
“The vertebrate genome annotation (Vega) database.,” Nucleic Acids Res., vol. 36, no. 
Database issue, pp. D753-60, Jan. 2008. 
[49] J. L. Ashurst et al., “The Vertebrate Genome Annotation (Vega) database.,” Nucleic 
Acids Res., vol. 33, no. Database issue, pp. D459-65, Jan. 2005. 
[50] O. Anczuków and A. R. Krainer, “Splicing-factor alterations in cancers.,” RNA, vol. 22, 
no. 9, pp. 1285–301, 2016. 
[51] M. Ladomery, “Aberrant alternative splicing is another hallmark of cancer.,” Int. J. Cell 
Biol., vol. 2013, p. 463786, 2013. 
[52] R. Holmila, C. Fouquet, J. Cadranel, G. Zalcman, and T. Soussi, “Splice mutations in 
the p53 gene: case report and review of the literature.,” Hum. Mutat., vol. 21, no. 1, pp. 
101–2, Jan. 2003. 
[53] Z. Kalnina, P. Zayakin, K. Silina, and A. Linē, “Alterations of pre-mRNA splicing in 
cancer.,” Genes. Chromosomes Cancer, vol. 42, no. 4, pp. 342–57, Apr. 2005. 
[54] M. Roy, Q. Xu, and C. Lee, “Evidence that public database records for many cancer-
associated genes reflect a splice form found in tumors and lack normal splice forms.,” 
References 
__________________________________________________________________________ 
 
81 
 
Nucleic Acids Res., vol. 33, no. 16, pp. 5026–33, 2005. 
[55] I. Shmulevich and W. Zhang, Computational and Statistical Approaches to Genomics. 
Boston, MA: Springer US, 2006. 
[56] J. P. Venables, “Aberrant and alternative splicing in cancer.,” Cancer Res., vol. 64, no. 
21, pp. 7647–54, Nov. 2004. 
[57] K. Musunuru, “Cell-specific RNA-binding proteins in human disease.,” Trends 
Cardiovasc. Med., vol. 13, no. 5, pp. 188–95, Jul. 2003. 
[58] I. Vlasova-St Louis and P. R. Bohjanen, “Post-transcriptional regulation of cytokine 
signaling by AU-rich and GU-rich elements.,” J. Interferon Cytokine Res., vol. 34, no. 4, 
pp. 233–41, Apr. 2014. 
[59] I. Vlasova-St Louis and P. R. Bohjanen, “Post-transcriptional regulation of cytokine and 
growth factor signaling in cancer.,” Cytokine Growth Factor Rev., vol. 33, pp. 83–93, 
2017. 
[60] G. Dreyfuss, V. N. Kim, and N. Kataoka, “Messenger-RNA-binding proteins and the 
messages they carry.,” Nat. Rev. Mol. Cell Biol., vol. 3, no. 3, pp. 195–205, Mar. 2002. 
[61] M. Müller-McNicoll and K. M. Neugebauer, “How cells get the message: dynamic 
assembly and function of mRNA-protein complexes.,” Nat. Rev. Genet., vol. 14, no. 4, 
pp. 275–87, Apr. 2013. 
[62] R. J. Jackson, C. U. T. Hellen, and T. V Pestova, “The mechanism of eukaryotic 
translation initiation and principles of its regulation.,” Nat. Rev. Mol. Cell Biol., vol. 11, 
no. 2, pp. 113–27, Feb. 2010. 
[63] J. R. Buchan and R. Parker, “Eukaryotic stress granules: the ins and outs of translation.,” 
Mol. Cell, vol. 36, no. 6, pp. 932–41, Dec. 2009. 
[64] R. Parker and U. Sheth, “P bodies and the control of mRNA translation and 
degradation.,” Mol. Cell, vol. 25, no. 5, pp. 635–46, Mar. 2007. 
[65] M. W. Hentze, A. Castello, T. Schwarzl, and T. Preiss, “A brave new world of RNA-
binding proteins.,” Nat. Rev. Mol. Cell Biol., vol. 19, no. 5, pp. 327–341, 2018. 
[66] V. Marchand, I. Gaspar, and A. Ephrussi, “An intracellular transmission control protocol: 
assembly and transport of ribonucleoprotein complexes.,” Curr. Opin. Cell Biol., vol. 24, 
no. 2, pp. 202–10, Apr. 2012. 
[67] C. E. Holt and S. L. Bullock, “Subcellular mRNA localization in animal cells and why it 
matters.,” Science, vol. 326, no. 5957, pp. 1212–6, Nov. 2009. 
[68] C. Y. Chen and A. B. Shyu, “AU-rich elements: characterization and importance in 
mRNA degradation.,” Trends Biochem. Sci., vol. 20, no. 11, pp. 465–70, Nov. 1995. 
[69] G. Shaw and R. Kamen, “A conserved AU sequence from the 3’ untranslated region of 
GM-CSF mRNA mediates selective mRNA degradation.,” Cell, vol. 46, no. 5, pp. 659–
67, Aug. 1986. 
[70] S. S. Peng, C. Y. Chen, N. Xu, and A. B. Shyu, “RNA stabilization by the AU-rich element 
binding protein, HuR, an ELAV protein.,” EMBO J., vol. 17, no. 12, pp. 3461–3470, Jun. 
1998. 
[71] I. A. Vlasova et al., “Conserved GU-Rich Elements Mediate mRNA Decay by Binding to 
CUG-Binding Protein 1,” Mol. Cell, vol. 29, no. 2, pp. 263–270, 2008. 
[72] A. S. Halees et al., “Global assessment of GU-rich regulatory content and function in 
References 
__________________________________________________________________________ 
 
82 
 
the human transcriptome.,” RNA Biol., vol. 8, no. 4, pp. 681–691, 2011. 
[73] L. Paillard, F. Omilli, V. Legagneux, T. Bassez, D. Maniey, and H. B. Osborne, “EDEN 
and EDEN-BP, a cis element and an associated factor that mediate sequence-specific 
mRNA deadenylation in Xenopus embryos.,” EMBO J., vol. 17, no. 1, pp. 278–87, Jan. 
1998. 
[74] J. Delaunay et al., “The Drosophila Bruno paralogue Bru-3 specifically binds the EDEN 
translational repression element.,” Nucleic Acids Res., vol. 32, no. 10, pp. 3070–82, 
2004. 
[75] N. Charlet-B, R. S. Savkur, G. Singh, A. V Philips, E. A. Grice, and T. A. Cooper, “Loss 
of the muscle-specific chloride channel in type 1 myotonic dystrophy due to 
misregulated alternative splicing.,” Mol. Cell, vol. 10, no. 1, pp. 45–53, Jul. 2002. 
[76] A. Sureau, J. Sauliere, A. Expert-Bezancon, and J. Marie, “CELF and PTB proteins 
modulate the inclusion of the beta-tropomyosin exon 6B during myogenic 
differentiation.,” Exp. Cell Res., vol. 317, no. 1, pp. 94–106, Jan. 2011. 
[77] V. A. Barron, H. Zhu, M. N. Hinman, A. N. Ladd, and H. Lou, “The neurofibromatosis 
type I pre-mRNA is a novel target of CELF protein-mediated  splicing regulation.,” 
Nucleic Acids Res., vol. 38, no. 1, pp. 253–264, Jan. 2010. 
[78] Z. Chen, T. L. Eggerman, and A. P. Patterson, “ApoB mRNA editing is mediated by a 
coordinated modulation of multiple apoB mRNA editing enzyme components.,” Am. J. 
Physiol. Gastrointest. Liver Physiol., vol. 292, no. 1, pp. G53-65, Jan. 2007. 
[79] S. Anant et al., “Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. 
CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with 
apobec-1 and ACF, the apobec-1 complementation factor.,” J. Biol. Chem., vol. 276, no. 
50, pp. 47338–51, Dec. 2001. 
[80] S. Millevoi et al., “An interaction between U2AF 65 and CF I(m) links the splicing and 3’ 
end processing machineries.,” EMBO J., vol. 25, no. 20, pp. 4854–64, Oct. 2006. 
[81] F. Rigo and H. G. Martinson, “Functional coupling of last-intron splicing and 3’-end 
processing to transcription in vitro: the poly(A) signal couples to splicing before 
committing to cleavage.,” Mol. Cell. Biol., vol. 28, no. 2, pp. 849–62, Jan. 2008. 
[82] P. Hilleren, T. McCarthy, M. Rosbash, R. Parker, and T. H. Jensen, “Quality control of 
mRNA 3’-end processing is linked to the nuclear exosome.,” Nature, vol. 413, no. 6855, 
pp. 538–42, Oct. 2001. 
[83] P. Iakova et al., “Competition of CUGBP1 and calreticulin for the regulation of p21 
translation determines cell fate.,” EMBO J., vol. 23, no. 2, pp. 406–417, Jan. 2004. 
[84] B. Rattenbacher et al., “Analysis of CUGBP1 targets identifies GU-repeat sequences 
that mediate rapid mRNA decay.,” Mol. Cell. Biol., vol. 30, no. 16, pp. 3970–80, 2010. 
[85] I. Vlasova-St Louis and P. R. Bohjanen, “Coordinate regulation of mRNA decay 
networks by GU-rich elements and CELF1.,” Curr. Opin. Genet. Dev., vol. 21, no. 4, pp. 
444–451, Aug. 2011. 
[86] L. Paillard and H. B. Osborne, “East of EDEN was a poly(A) tail.,” Biol. cell, vol. 95, no. 
3–4, pp. 211–9. 
[87] H. B. Osborne et al., “Post-transcriptional regulation in Xenopus embryos: role and 
targets of EDEN-BP.,” Biochem. Soc. Trans., vol. 33, no. Pt 6, pp. 1541–3, Dec. 2005. 
[88] A. N. Ladd, N. Charlet, and T. A. Cooper, “The CELF family of RNA binding proteins is 
References 
__________________________________________________________________________ 
 
83 
 
implicated in cell-specific and developmentally regulated alternative splicing.,” Mol. Cell. 
Biol., vol. 21, no. 4, pp. 1285–96, Feb. 2001. 
[89] “UniProt: a worldwide hub of protein knowledge,” Nucleic Acids Res., vol. 47, no. D1, 
pp. D506–D515, Jan. 2019. 
[90] D. K. Choi, T. Ito, F. Tsukahara, M. Hirai, and Y. Sakaki, “Developmentally-regulated 
expression of mNapor encoding an apoptosis-induced ELAV-type RNA binding 
protein.,” Gene, vol. 237, no. 1, pp. 135–42, Sep. 1999. 
[91] P. J. Good, Q. Chen, S. J. Warner, and D. C. Herring, “A family of human RNA-binding 
proteins related to the Drosophila Bruno translational regulator.,” J. Biol. Chem., vol. 
275, no. 37, pp. 28583–92, Sep. 2000. 
[92] D.-K. Choi, K.-W. Yoo, S.-K. Hong, M. Rhee, Y. Sakaki, and C.-H. Kim, “Isolation and 
expression of Napor/CUG-BP2 in embryo development.,” Biochem. Biophys. Res. 
Commun., vol. 305, no. 3, pp. 448–54, Jun. 2003. 
[93] C. Kress, C. Gautier-Courteille, H. B. Osborne, C. Babinet, and L. Paillard, “Inactivation 
of CUG-BP1/CELF1 causes growth, viability, and spermatogenesis defects in mice.,” 
Mol. Cell. Biol., vol. 27, no. 3, pp. 1146–57, Feb. 2007. 
[94] Y. Yang, C. L. Mahaffey, N. Bérubé, T. P. Maddatu, G. A. Cox, and W. N. Frankel, 
“Complex seizure disorder caused by Brunol4 deficiency in mice.,” PLoS Genet., vol. 3, 
no. 7, p. e124, Jul. 2007. 
[95] J. Wu, C. Li, S. Zhao, and B. Mao, “Differential expression of the Brunol/CELF family 
genes during Xenopus laevis early development.,” Int. J. Dev. Biol., vol. 54, no. 1, pp. 
209–14, 2010. 
[96] G. Singh, N. Charlet-B, J. Han, and T. A. Cooper, “ETR-3 and CELF4 protein domains 
required for RNA binding and splicing activity in vivo.,” Nucleic Acids Res., vol. 32, no. 
3, pp. 1232–41, 2004. 
[97] C. Barreau, L. Paillard, A. Méreau, and H. B. Osborne, “Mammalian CELF/Bruno-like 
RNA-binding proteins: molecular characteristics and biological functions.,” Biochimie, 
vol. 88, no. 5, pp. 515–25, May 2006. 
[98] I. Lubin et al., “Engraftment and development of human T and B cells in mice after bone 
marrow transplantation.,” Science, vol. 252, no. 5004, pp. 427–31, Apr. 1991. 
[99] A. Mankodi et al., “Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride 
channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.,” 
Mol. Cell, vol. 10, no. 1, pp. 35–44, Jul. 2002. 
[100] A. N. Ladd and T. A. Cooper, “Multiple domains control the subcellular localization and 
activity of ETR-3, a regulator of nuclear and cytoplasmic RNA processing events.,” J. 
Cell Sci., vol. 117, no. Pt 16, pp. 3519–29, Jul. 2004. 
[101] J. A. Dembowski and P. J. Grabowski, “The CUGBP2 splicing factor regulates an 
ensemble of branchpoints from perimeter binding sites with implications for 
autoregulation.,” PLoS Genet., vol. 5, no. 8, p. e1000595, Aug. 2009. 
[102] T. Dasgupta and A. N. Ladd, “The importance of CELF control: molecular and biological 
roles of the CUG-BP,  Elav-like family of RNA-binding proteins.,” Wiley Interdiscip. Rev. 
RNA, vol. 3, no. 1, pp. 104–121, Jan. 2012. 
[103] D. Mori, N. Sasagawa, Y. Kino, and S. Ishiura, “Quantitative analysis of CUG-BP1 
binding to RNA repeats.,” J. Biochem., vol. 143, no. 3, pp. 377–83, Mar. 2008. 
References 
__________________________________________________________________________ 
 
84 
 
[104] J. Marquis et al., “CUG-BP1/CELF1 requires UGU-rich sequences for high-affinity 
binding.,” Biochem. J., vol. 400, no. 2, pp. 291–301, Dec. 2006. 
[105] N. Takahashi, N. Sasagawa, K. Suzuki, and S. Ishiura, “The CUG-binding protein binds 
specifically to UG dinucleotide repeats in a yeast three-hybrid system.,” Biochem. 
Biophys. Res. Commun., vol. 277, no. 2, pp. 518–23, Oct. 2000. 
[106] J. R. Tollervey et al., “Characterizing the RNA targets and position-dependent splicing 
regulation by TDP-43.,” Nat. Neurosci., vol. 14, no. 4, pp. 452–8, Apr. 2011. 
[107] J. Fallmann, V. Sedlyarov, A. Tanzer, P. Kovarik, and I. L. Hofacker, “AREsite2: an 
enhanced database for the comprehensive investigation of AU/GU/U-rich elements.,” 
Nucleic Acids Res., vol. 44, no. D1, pp. D90-5, Jan. 2016. 
[108] L. T. Timchenko et al., “Identification of a (CUG)n triplet repeat RNA-binding protein and 
its expression in myotonic dystrophy.,” Nucleic Acids Res., vol. 24, no. 22, pp. 4407–
14, Nov. 1996. 
[109] M. Giulietti et al., “SpliceAid-F: A database of human splicing factors and their RNA-
binding sites,” Nucleic Acids Res., vol. 41, 2013. 
[110] J. E. Lee, J. Y. Lee, J. Wilusz, B. Tian, and C. J. Wilusz, “Systematic analysis of Cis-
elements in unstable mRNAS demonstrates that CUGBP1 is a key regulator of mRNA 
decay in muscle cells,” PLoS One, vol. 5, no. 6, 2010. 
[111] J. E. Lee and T. A. Cooper, “Pathogenic mechanisms of myotonic dystrophy.,” Biochem. 
Soc. Trans., vol. 37, no. Pt 6, pp. 1281–6, Dec. 2009. 
[112] A. Masuda et al., “CUGBP1 and MBNL1 preferentially bind to 3′ UTRs and facilitate 
mRNA decay,” Sci. Rep., vol. 2, no. 1, p. 209, Dec. 2012. 
[113] P. J. Webster, L. Liang, C. A. Berg, P. Lasko, and P. M. Macdonald, “Translational 
repressor bruno plays multiple roles in development and is widely conserved.,” Genes 
Dev., vol. 11, no. 19, pp. 2510–21, Oct. 1997. 
[114] N. Ezzeddine et al., “EDEN-dependent translational repression of maternal mRNAs is 
conserved between Xenopus and Drosophila.,” Proc. Natl. Acad. Sci. U. S. A., vol. 99, 
no. 1, pp. 257–62, Jan. 2002. 
[115] D. Beisang, P. R., and I. A. Vlasova-St. Louis, “CELF1, a Multifunctional Regulator of 
Posttranscriptional Networks,” Bind. Protein, 2012. 
[116] O. Le Tonquèze, B. Gschloessl, A. Namanda-Vanderbeken, V. Legagneux, L. Paillard, 
and Y. Audic, “Chromosome wide analysis of CUGBP1 binding sites identifies the 
tetraspanin CD9 mRNA as a target for CUGBP1-mediated down-regulation.,” Biochem. 
Biophys. Res. Commun., vol. 394, no. 4, pp. 884–9, Apr. 2010. 
[117] J. Russo et al., “The CELF1 RNA-Binding Protein Regulates Decay of Signal 
Recognition Particle mRNAs and Limits Secretion in Mouse Myoblasts.,” PLoS One, vol. 
12, no. 1, p. e0170680, 2017. 
[118] R. Pullmann et al., “Analysis of turnover and translation regulatory RNA-binding protein 
expression through binding to cognate mRNAs.,” Mol. Cell. Biol., vol. 27, no. 18, pp. 
6265–78, Sep. 2007. 
[119] B. Schoser and L. Timchenko, “Myotonic dystrophies 1 and 2: complex diseases with 
complex mechanisms.,” Curr. Genomics, vol. 11, no. 2, pp. 77–90, Apr. 2010. 
[120] I. Vlasova-St. Louis and P. Bohjanen, “Feedback Regulation of Kinase Signaling 
Pathways by AREs and GREs,” Cells, vol. 5, no. 1, p. 4, 2016. 
References 
__________________________________________________________________________ 
 
85 
 
[121] J. P. Orengo, P. Chambon, D. Metzger, D. R. Mosier, G. J. Snipes, and T. A. Cooper, 
“Expanded CTG repeats within the DMPK 3’ UTR causes severe skeletal muscle 
wasting in an inducible mouse model for myotonic dystrophy.,” Proc. Natl. Acad. Sci. U. 
S. A., vol. 105, no. 7, pp. 2646–51, Feb. 2008. 
[122] E. Salisbury et al., “Ectopic expression of cyclin D3 corrects differentiation of DM1 
myoblasts through activation of RNA CUG-binding protein, CUGBP1.,” Exp. Cell Res., 
vol. 314, no. 11–12, pp. 2266–78, Jul. 2008. 
[123] C. Huichalaf et al., “Expansion of CUG RNA repeats causes stress and inhibition of 
translation in myotonic dystrophy 1 (DM1) cells.,” FASEB J., vol. 24, no. 10, pp. 3706–
19, Oct. 2010. 
[124] M. Mahadevan et al., “Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ 
untranslated region of the gene.,” Science (80-. )., vol. 255, no. 5049, pp. 1253–5, Mar. 
1992. 
[125] C. Turner and D. Hilton-Jones, “The myotonic dystrophies: diagnosis and 
management.,” J. Neurol. Neurosurg. Psychiatry, vol. 81, no. 4, pp. 358–67, Apr. 2010. 
[126] D. S. Berger, M. Moyer, G. M. Kliment, E. van Lunteren, and A. N. Ladd, “Expression of 
a dominant negative CELF protein in vivo leads to altered muscle organization, fiber 
size, and subtype.,” PLoS One, vol. 6, no. 4, p. e19274, Apr. 2011. 
[127] A. N. Ladd, G. Taffet, C. Hartley, D. L. Kearney, and T. A. Cooper, “Cardiac tissue-
specific repression of CELF activity disrupts alternative splicing and causes 
cardiomyopathy.,” Mol. Cell. Biol., vol. 25, no. 14, pp. 6267–78, Jul. 2005. 
[128] T. Katoh, H. Hojo, and T. Suzuki, “Destabilization of microRNAs in human cells by 3’ 
deadenylation mediated by PARN and CUGBP1.,” Nucleic Acids Res., vol. 43, no. 15, 
pp. 7521–34, Sep. 2015. 
[129] C. J. Wilusz, M. Wormington, and S. W. Peltz, “The cap-to-tail guide to mRNA turnover.,” 
Nat. Rev. Mol. Cell Biol., vol. 2, no. 4, pp. 237–46, Apr. 2001. 
[130] C.-Y. A. Chen and A.-B. Shyu, “Mechanisms of deadenylation-dependent decay.,” Wiley 
Interdiscip. Rev. RNA, vol. 2, no. 2, pp. 167–83. 
[131] D. Beisang, C. Reilly, and P. R. Bohjanen, “Alternative polyadenylation regulates 
CELF1/CUGBP1 target transcripts following T cell activation.,” Gene, vol. 550, no. 1, 
pp. 93–100, Oct. 2014. 
[132] D. Beisang, B. Rattenbacher, I. A. Vlasova-St Louis, and P. R. Bohjanen, “Regulation 
of CUG-binding protein 1 (CUGBP1) binding to target transcripts upon T cell activation.,” 
J. Biol. Chem., vol. 287, no. 2, pp. 950–60, Jan. 2012. 
[133] N. A. Timchenko, P. Iakova, Z. J. Cai, J. R. Smith, and L. T. Timchenko, “Molecular 
basis for impaired muscle differentiation in myotonic dystrophy.,” Mol. Cell. Biol., vol. 21, 
no. 20, pp. 6927–38, Oct. 2001. 
[134] L. D. Horb and M. E. Horb, “BrunoL1 regulates endoderm proliferation through 
translational enhancement of cyclin A2 mRNA.,” Dev. Biol., vol. 345, no. 2, pp. 156–69, 
Sep. 2010. 
[135] A. Nakamura, K. Sato, and K. Hanyu-Nakamura, “Drosophila cup is an eIF4E binding 
protein that associates with Bruno and regulates oskar mRNA translation in oogenesis.,” 
Dev. Cell, vol. 6, no. 1, pp. 69–78, Jan. 2004. 
[136] A. Chaudhury et al., “CELF1 is an EIF4E binding protein that promotes translation of 
epithelial-mesenchymal transition effector mRNAs,” bioRxiv, p. 640300, Jan. 2019. 
References 
__________________________________________________________________________ 
 
86 
 
[137] A. Chaudhury et al., “CELF1 is a central node in post-transcriptional regulatory 
programmes underlying EMT,” Nat. Commun., vol. 7, no. 1, p. 13362, Dec. 2016. 
[138] R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14.,” Cell, vol. 75, no. 5, pp. 
843–54, Dec. 1993. 
[139] G. Ruvkun, “Molecular biology. Glimpses of a tiny RNA world.,” Science (80-. )., vol. 
294, no. 5543, pp. 797–9, Oct. 2001. 
[140] A. Rodriguez, S. Griffiths-Jones, J. L. Ashurst, and A. Bradley, “Identification of 
mammalian microRNA host genes and transcription units.,” Genome Res., vol. 14, no. 
10A, pp. 1902–10, Oct. 2004. 
[141] Y.-K. Kim and V. N. Kim, “Processing of intronic microRNAs.,” EMBO J., vol. 26, no. 3, 
pp. 775–83, Feb. 2007. 
[142] S. Baskerville and D. P. Bartel, “Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes.,” RNA, vol. 11, no. 3, pp. 241–
7, Mar. 2005. 
[143] X. Zhou, J. Ruan, G. Wang, and W. Zhang, “Characterization and identification of 
microRNA core promoters in four model species.,” PLoS Comput. Biol., vol. 3, no. 3, p. 
e37, Mar. 2007. 
[144] Y. Lee et al., “MicroRNA genes are transcribed by RNA polymerase II.,” EMBO J., vol. 
23, no. 20, pp. 4051–60, Oct. 2004. 
[145] X. Cai, C. H. Hagedorn, and B. R. Cullen, “Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs.,” RNA, vol. 10, 
no. 12, pp. 1957–66, Dec. 2004. 
[146] Y. Lee et al., “The nuclear RNase III Drosha initiates microRNA processing.,” Nature, 
vol. 425, no. 6956, pp. 415–9, Sep. 2003. 
[147] R. I. Gregory et al., “The Microprocessor complex mediates the genesis of microRNAs.,” 
Nature, vol. 432, no. 7014, pp. 235–40, Nov. 2004. 
[148] R. I. Gregory, T. P. Chendrimada, and R. Shiekhattar, “MicroRNA biogenesis: isolation 
and characterization of the microprocessor complex.,” Methods Mol. Biol., vol. 342, pp. 
33–47, 2006. 
[149] A. M. Denli, B. B. J. Tops, R. H. A. Plasterk, R. F. Ketting, and G. J. Hannon, “Processing 
of primary microRNAs by the Microprocessor complex.,” Nature, vol. 432, no. 7014, pp. 
231–5, Nov. 2004. 
[150] E. Berezikov, W.-J. Chung, J. Willis, E. Cuppen, and E. C. Lai, “Mammalian mirtron 
genes.,” Mol. Cell, vol. 28, no. 2, pp. 328–36, Oct. 2007. 
[151] E. P. Murchison and G. J. Hannon, “miRNAs on the move: miRNA biogenesis and the 
RNAi machinery.,” Curr. Opin. Cell Biol., vol. 16, no. 3, pp. 223–9, Jun. 2004. 
[152] C. Okada et al., “A high-resolution structure of the pre-microRNA nuclear export 
machinery.,” Science (80-. )., vol. 326, no. 5957, pp. 1275–9, Nov. 2009. 
[153] H. Zhang, F. A. Kolb, L. Jaskiewicz, E. Westhof, and W. Filipowicz, “Single processing 
center models for human Dicer and bacterial RNase III.,” Cell, vol. 118, no. 1, pp. 57–
68, Jul. 2004. 
[154] T. P. Chendrimada et al., “TRBP recruits the Dicer complex to Ago2 for microRNA 
References 
__________________________________________________________________________ 
 
87 
 
processing and gene silencing.,” Nature, vol. 436, no. 7051, pp. 740–4, Aug. 2005. 
[155] Z. Gao, Y. Dou, Y. Chen, and Y. Zheng, “MicroRNA roles in the NF- κB signaling 
pathway during viral infections.,” Biomed Res. Int., vol. 2014, p. 436097, 2014. 
[156] L. P. Garo and G. Murugaiyan, “Contribution of MicroRNAs to autoimmune diseases.,” 
Cell. Mol. life Sci., vol. 73, no. 10, pp. 2041–51, May 2016. 
[157] M. Tatsuguchi et al., “Expression of microRNAs is dynamically regulated during 
cardiomyocyte hypertrophy.,” J. Mol. Cell. Cardiol., vol. 42, no. 6, pp. 1137–41, Jun. 
2007. 
[158] T. Thum et al., “MicroRNAs in the human heart: a clue to fetal gene reprogramming in 
heart failure.,” Circulation, vol. 116, no. 3, pp. 258–67, Jul. 2007. 
[159] E. van Rooij et al., “A signature pattern of stress-responsive microRNAs that can evoke 
cardiac hypertrophy and heart failure.,” Proc. Natl. Acad. Sci. U. S. A., vol. 103, no. 48, 
pp. 18255–60, Nov. 2006. 
[160] Y. L. Phua, J. Y. S. Chu, A. K. Marrone, A. J. Bodnar, S. Sims-Lucas, and J. Ho, “Renal 
stromal miRNAs are required for normal nephrogenesis and glomerular mesangial 
survival.,” Physiol. Rep., vol. 3, no. 10, Oct. 2015. 
[161] A. Mencía et al., “Mutations in the seed region of human miR-96 are responsible for 
nonsyndromic progressive hearing loss.,” Nat. Genet., vol. 41, no. 5, pp. 609–13, May 
2009. 
[162] M. Acunzo, G. Romano, D. Wernicke, and C. M. Croce, “MicroRNA and cancer--a brief 
overview.,” Adv. Biol. Regul., vol. 57, pp. 1–9, Jan. 2015. 
[163] S. M. Hammond, “RNAi, microRNAs, and human disease.,” Cancer Chemother. 
Pharmacol., vol. 58 Suppl 1, pp. s63-8, Nov. 2006. 
[164] P. P. Medina, M. Nolde, and F. J. Slack, “OncomiR addiction in an in vivo model of 
microRNA-21-induced pre-B-cell lymphoma.,” Nature, vol. 467, no. 7311, pp. 86–90, 
Sep. 2010. 
[165] M.-L. Si, S. Zhu, H. Wu, Z. Lu, F. Wu, and Y.-Y. Mo, “miR-21-mediated tumor growth.,” 
Oncogene, vol. 26, no. 19, pp. 2799–803, Apr. 2007. 
[166] M. V Iorio et al., “MicroRNA gene expression deregulation in human breast cancer.,” 
Cancer Res., vol. 65, no. 16, pp. 7065–70, Aug. 2005. 
[167] A. J. Schetter et al., “MicroRNA expression profiles associated with prognosis and 
therapeutic outcome in colon adenocarcinoma.,” JAMA, vol. 299, no. 4, pp. 425–36, 
Jan. 2008. 
[168] J. Lu et al., “MicroRNA expression profiles classify human cancers.,” Nature, vol. 435, 
no. 7043, pp. 834–8, Jun. 2005. 
[169] J. M. Thomson, M. Newman, J. S. Parker, E. M. Morin-Kensicki, T. Wright, and S. M. 
Hammond, “Extensive post-transcriptional regulation of microRNAs and its implications 
for cancer.,” Genes Dev., vol. 20, no. 16, pp. 2202–7, Aug. 2006. 
[170] A. Wilczynska and M. Bushell, “The complexity of miRNA-mediated repression,” Cell 
Death Differ., vol. 22, no. 1, pp. 22–33, 2015. 
[171] A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, “Potent 
and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.,” 
Nature, vol. 391, no. 6669, pp. 806–11, Feb. 1998. 
References 
__________________________________________________________________________ 
 
88 
 
[172] B. P. Lewis, I. Shih, M. W. Jones-Rhoades, D. P. Bartel, and C. B. Burge, “Prediction of 
mammalian microRNA targets.,” Cell, vol. 115, no. 7, pp. 787–98, Dec. 2003. 
[173] I. Lee et al., “New class of microRNA targets containing simultaneous 5’-UTR and 3’-
UTR interaction sites.,” Genome Res., vol. 19, no. 7, pp. 1175–83, Jul. 2009. 
[174] J. J. Forman and H. A. Coller, “The code within the code: microRNAs target coding 
regions.,” Cell cycle, vol. 9, no. 8, pp. 1533–41, Apr. 2010. 
[175] S. M. Hammond, E. Bernstein, D. Beach, and G. J. Hannon, “An RNA-directed nuclease 
mediates post-transcriptional gene silencing in Drosophila cells.,” Nature, vol. 404, no. 
6775, pp. 293–6, Mar. 2000. 
[176] G. Meister, M. Landthaler, A. Patkaniowska, Y. Dorsett, G. Teng, and T. Tuschl, “Human 
Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.,” Mol. Cell, vol. 
15, no. 2, pp. 185–97, Jul. 2004. 
[177] J. Liu et al., “Argonaute2 is the catalytic engine of mammalian RNAi.,” Science (80-. )., 
vol. 305, no. 5689, pp. 1437–41, Sep. 2004. 
[178] J. Martinez, A. Patkaniowska, H. Urlaub, R. Lührmann, and T. Tuschl, “Single-stranded 
antisense siRNAs guide target RNA cleavage in RNAi.,” Cell, vol. 110, no. 5, pp. 563–
74, Sep. 2002. 
[179] G. Hutvágner and P. D. Zamore, “A microRNA in a multiple-turnover RNAi enzyme 
complex.,” Science (80-. )., vol. 297, no. 5589, pp. 2056–60, Sep. 2002. 
[180] R. I. Gregory, T. P. Chendrimada, N. Cooch, and R. Shiekhattar, “Human RISC couples 
microRNA biogenesis and posttranscriptional gene silencing.,” Cell, vol. 123, no. 4, pp. 
631–40, Nov. 2005. 
[181] J. B. Preall, Z. He, J. M. Gorra, and E. J. Sontheimer, “Short interfering RNA strand 
selection is independent of dsRNA processing polarity during RNAi in Drosophila.,” Curr. 
Biol., vol. 16, no. 5, pp. 530–5, Mar. 2006. 
[182] M. R. Fabian, N. Sonenberg, and W. Filipowicz, “Regulation of mRNA translation and 
stability by microRNAs.,” Annu. Rev. Biochem., vol. 79, pp. 351–79, 2010. 
[183] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions.,” Cell, vol. 136, 
no. 2, pp. 215–33, Jan. 2009. 
[184] M. Fabbri et al., “MicroRNAs bind to Toll-like receptors to induce prometastatic 
inflammatory response,” Proc. Natl. Acad. Sci., vol. 109, no. 31, pp. E2110–E2116, 
2012. 
[185] W. A. He, F. Calore, P. Londhe, A. Canella, D. C. Guttridge, and C. M. Croce, 
“Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via 
TLR7.,” Proc. Natl. Acad. Sci. U. S. A., vol. 111, no. 12, pp. 4525–9, Mar. 2014. 
[186] Z.-J. Zhang et al., “TLR8 and its endogenous ligand miR-21 contribute to neuropathic 
pain in murine DRG,” J. Exp. Med., vol. 215, no. 12, pp. 3019–3037, Dec. 2018. 
[187] K. B. Challagundla et al., “Exosome-mediated transfer of microRNAs within the tumor 
microenvironment and neuroblastoma resistance to chemotherapy.,” J. Natl. Cancer 
Inst., vol. 107, no. 7, Jul. 2015. 
[188] S. M. Lehmann et al., “An unconventional role for miRNA: let-7 activates Toll-like 
receptor 7 and causes neurodegeneration.,” Nat. Neurosci., vol. 15, no. 6, pp. 827–35, 
Jun. 2012. 
References 
__________________________________________________________________________ 
 
89 
 
[189] R. F. Place, L.-C. Li, D. Pookot, E. J. Noonan, and R. Dahiya, “MicroRNA-373 induces 
expression of genes with complementary promoter sequences.,” Proc. Natl. Acad. Sci. 
U. S. A., vol. 105, no. 5, pp. 1608–13, Feb. 2008. 
[190] D. G. Zisoulis, Z. S. Kai, R. K. Chang, and A. E. Pasquinelli, “Autoregulation of 
microRNA biogenesis by let-7 and Argonaute.,” Nature, vol. 486, no. 7404, pp. 541–4, 
Jun. 2012. 
[191] R. Tang et al., “Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the 
posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system.,” 
Cell Res., vol. 22, no. 3, pp. 504–15, Mar. 2012. 
[192] S. W. Chi, J. B. Zang, A. Mele, and R. B. Darnell, “Argonaute HITS-CLIP decodes 
microRNA-mRNA interaction maps.,” Nature, vol. 460, no. 7254, pp. 479–86, Jul. 2009. 
[193] A. M. Eiring et al., “miR-328 functions as an RNA decoy to modulate hnRNP E2 
regulation of mRNA translation in leukemic blasts.,” Cell, vol. 140, no. 5, pp. 652–65, 
Mar. 2010. 
[194] M. J. Saul, S. Stein, M. Grez, P.-J. Jakobsson, D. Steinhilber, and B. Suess, “UPF1 
regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 
balance.,” Sci. Rep., vol. 6, no. 1, p. 31995, 2016. 
[195] M. J. Saul et al., “Mass Spectrometry-Based Proteomics Approach Characterizes the 
Dual Functionality of miR-328 in Monocytes.,” Front. Pharmacol., vol. 10, p. 640, 2019. 
[196] M. J. Saul et al., “miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor 
growth by mPGES-1 induction.,” FASEB J., vol. 33, no. 6, pp. 6933–6947, Jun. 2019. 
[197] M. Boucquey et al., “Noxp20 and Noxp70, two new markers of early neuronal 
differentiation, detected in teratocarcinoma-derived neuroectodermic precursor cells.,” 
J. Neurochem., vol. 99, no. 2, pp. 657–69, Oct. 2006. 
[198] R. Edgar, M. Domrachev, and A. E. Lash, “Gene Expression Omnibus: NCBI gene 
expression and hybridization array data repository.,” Nucleic Acids Res., vol. 30, no. 1, 
pp. 207–10, Jan. 2002. 
[199] T. Barrett et al., “NCBI GEO: archive for functional genomics data sets--update.,” 
Nucleic Acids Res., vol. 41, no. Database issue, pp. D991-5, Jan. 2013. 
[200] T. Ku et al., “NF-κB-regulated microRNA-574-5p underlies synaptic and cognitive 
impairment in response to atmospheric PM2.5 aspiration.,” Part. Fibre Toxicol., vol. 14, 
no. 1, p. 34, 2017. 
[201] W. Zhang et al., “Amyloid precursor protein regulates neurogenesis by antagonizing 
miR-574-5p in the developing cerebral cortex.,” Nat. Commun., vol. 5, p. 3330, Mar. 
2014. 
[202] C. Li et al., “Non-coding RNA MFI2-AS1 promotes colorectal cancer cell proliferation, 
migration and invasion through miR-574-5p/MYCBP axis.,” Cell Prolif., vol. 52, no. 4, p. 
e12632, Jul. 2019. 
[203] P.-S. Wang et al., “A novel long non-coding RNA linc-ZNF469-3 promotes lung 
metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.,” Oncogene, 
vol. 37, no. 34, pp. 4662–4678, 2018. 
[204] X. Wang, X. Lu, Z. Geng, G. Yang, and Y. Shi, “LncRNA PTCSC3/miR-574-5p Governs 
Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin 
Signaling.,” J. Cell. Biochem., vol. 118, no. 12, pp. 4745–4752, 2017. 
References 
__________________________________________________________________________ 
 
90 
 
[205] S. Ji et al., “miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling 
and the development of colorectal cancer.,” Gut, vol. 62, no. 5, pp. 716–26, 2013. 
[206] Z. Zhang, X. Li, Q. Xiao, and Z. Wang, “MiR-574-5p mediates the cell cycle and 
apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the 
expression of Quaking proteins.,” Oncol. Lett., vol. 15, no. 4, pp. 5841–5848, Apr. 2018. 
[207] X. Zhou et al., “Quaking-5 suppresses aggressiveness of lung cancer cells through 
inhibiting β-catenin signaling pathway.,” Oncotarget, vol. 8, no. 47, pp. 82174–82184, 
Oct. 2017. 
[208] Z. Cui, J. Tang, J. Chen, and Z. Wang, “Hsa-miR-574-5p negatively regulates MACC-1 
expression to suppress colorectal cancer liver metastasis.,” Cancer Cell Int., vol. 14, no. 
1, p. 47, 2014. 
[209] R. Zhou et al., “MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by 
targeting PTPRU.,” Sci. Rep., vol. 6, p. 35714, 2016. 
[210] R. Zhou et al., “Tumor invasion and metastasis regulated by microRNA-184 and 
microRNA-574-5p in small-cell lung cancer.,” Oncotarget, vol. 6, no. 42, pp. 44609–22, 
Dec. 2015. 
[211] Q. Li et al., “MicroRNA-574-5p Was Pivotal for TLR9 Signaling Enhanced Tumor 
Progression via Down-Regulating Checkpoint Suppressor 1 in Human Lung Cancer,” 
PLoS One, vol. 7, no. 11, 2012. 
[212] Z. Lai et al., “MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells 
in the progression of coronary artery disease.,” Biomed. Pharmacother., vol. 97, pp. 
162–167, Jan. 2018. 
[213] M. Meyers-Needham et al., “Concerted functions of HDAC1 and microRNA-574-5p 
repress alternatively spliced ceramide synthase 1 expression in human cancer cells.,” 
EMBO Mol. Med., vol. 4, no. 2, pp. 78–92, Feb. 2012. 
[214] Y. Belarbi, N. Mejhert, H. Gao, P. Arner, M. Rydén, and A. Kulyté, “MicroRNAs-361-5p 
and miR-574-5p associate with human adipose morphology and regulate EBF1 
expression in white adipose tissue.,” Mol. Cell. Endocrinol., vol. 472, pp. 50–56, 2018. 
[215] D. Hanahan and R. a Weinberg, “Hallmarks of cancer: the next generation.,” Cell, vol. 
144, no. 5, pp. 646–74, Mar. 2011. 
[216] E. Ricciotti and G. A. FitzGerald, “Prostaglandins and inflammation.,” Arterioscler. 
Thromb. Vasc. Biol., vol. 31, no. 5, pp. 986–1000, May 2011. 
[217] P. Kalinski, “Regulation of Immune Responses by Prostaglandin E2,” J. Immunol., vol. 
188, no. 1, pp. 21–28, 2012. 
[218] M. Nakanishi and D. W. Rosenberg, “Multifaceted roles of PGE2 in inflammation and 
cancer,” Semin. Immunopathol., vol. 35, no. 2, pp. 123–137, 2013. 
[219] D. Wang and R. N. Dubois, “Eicosanoids and cancer.,” Nat. Rev. Cancer, vol. 10, no. 3, 
pp. 181–93, Mar. 2010. 
[220] W. L. Smith, Y. Urade, and P.-J. Jakobsson, “Enzymes of the cyclooxygenase pathways 
of prostanoid biosynthesis.,” Chem. Rev., vol. 111, no. 10, pp. 5821–65, Oct. 2011. 
[221] K. Yoshimatsu et al., “Inducible microsomal prostaglandin E synthase is overexpressed 
in colorectal adenomas and cancer.,” Clin. cancer Res., vol. 7, no. 12, pp. 3971–6, Dec. 
2001. 
References 
__________________________________________________________________________ 
 
91 
 
[222] H. Hanaka et al., “Microsomal prostaglandin E synthase 1 determines tumor growth in 
vivo of prostate and lung cancer cells.,” Proc. Natl. Acad. Sci. U. S. A., vol. 106, no. 44, 
pp. 18757–18762, 2009. 
[223] K. Yoshimatsu et al., “Inducible prostaglandin E synthase is overexpressed in non-small 
cell lung cancer.,” Clin. cancer Res., vol. 7, no. 9, pp. 2669–74, Sep. 2001. 
[224] Y.-C. Wu et al., “Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin 
E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.,” 
J. Thorac. Oncol., vol. 5, no. 8, pp. 1167–74, Aug. 2010. 
[225] M. Heusinkveld et al., “M2 macrophages induced by prostaglandin E2 and IL-6 from 
cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.,” J. 
Immunol., vol. 187, no. 3, pp. 1157–65, Aug. 2011. 
[226] P. Nandi, G. V Girish, M. Majumder, X. Xin, E. Tutunea-Fatan, and P. K. Lala, “PGE2 
promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor 
on lymphatic endothelial cells.,” BMC Cancer, vol. 17, no. 1, p. 11, 2017. 
[227] M. Majumder, P. Nandi, A. Omar, K. Ugwuagbo, and P. Lala, “EP4 as a Therapeutic 
Target for Aggressive Human Breast Cancer,” Int. J. Mol. Sci., vol. 19, no. 4, p. 1019, 
Mar. 2018. 
[228] J. I. Kim, V. Lakshmikanthan, N. Frilot, and Y. Daaka, “Prostaglandin E2 Promotes Lung 
Cancer Cell Migration via EP4- Arrestin1-c-Src Signalsome,” Mol. Cancer Res., vol. 8, 
no. 4, pp. 569–577, 2010. 
[229] V. Karpisheh et al., “Prostaglandin E2 as a potent therapeutic target for treatment of 
colon cancer.,” Prostaglandins Other Lipid Mediat., vol. 144, p. 106338, Oct. 2019. 
[230] E. Elwakeel, B. Brüne, and A. Weigert, “PGE2 in fibrosis and cancer: Insights into 
fibroblast activation.,” Prostaglandins Other Lipid Mediat., vol. 143, p. 106339, Aug. 
2019. 
[231] W. H. S. Nasry, J. C. Rodriguez-Lecompte, and C. K. Martin, “Role of COX-2/PGE2 
Mediated Inflammation in Oral Squamous Cell Carcinoma.,” Cancers (Basel)., vol. 10, 
no. 10, Sep. 2018. 
[232] R. S. Bresalier et al., “Cardiovascular events associated with rofecoxib in a colorectal 
adenoma chemoprevention trial.,” N. Engl. J. Med., vol. 352, no. 11, pp. 1092–102, Mar. 
2005. 
[233] J. A. Baron et al., “Cardiovascular events associated with rofecoxib: final analysis of the 
APPROVe trial.,” Lancet (London, England), vol. 372, no. 9651, pp. 1756–64, Nov. 
2008. 
[234] T. Grosser, S. Fries, and G. A. FitzGerald, “Biological basis for the cardiovascular 
consequences of COX-2 inhibition: therapeutic challenges and opportunities.,” J. Clin. 
Invest., vol. 116, no. 1, pp. 4–15, Jan. 2006. 
[235] Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, and G. A. Fitzgerald, 
“Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular 
function.,” J. Clin. Invest., vol. 116, no. 5, pp. 1391–9, May 2006. 
[236] H. T. Sørensen et al., “Risk of upper gastrointestinal bleeding associated with use of 
low-dose aspirin.,” Am. J. Gastroenterol., vol. 95, no. 9, pp. 2218–24, Sep. 2000. 
[237] K. Larsson and P.-J. Jakobsson, “Inhibition of microsomal prostaglandin E synthase-1 
as targeted therapy in cancer treatment.,” Prostaglandins Other Lipid Mediat., vol. 120, 
pp. 161–5, Jul. 2015. 
References 
__________________________________________________________________________ 
 
92 
 
[238] B. Samuelsson, R. Morgenstern, and P.-J. Jakobsson, “Membrane prostaglandin E 
synthase-1: a novel therapeutic target.,” Pharmacol. Rev., vol. 59, no. 3, pp. 207–24, 
Sep. 2007. 
[239] M. Wang, W.-L. Song, Y. Cheng, and G. A. FitzGerald, “Microsomal prostaglandin E 
synthase-1 inhibition in cardiovascular inflammatory disease,” J. Intern. Med., vol. 263, 
no. 5, pp. 500–505, May 2008. 
[240] M. Wang, A. M. Zukas, Y. Hui, E. Ricciotti, E. Pure, and G. A. FitzGerald, “Deletion of 
microsomal prostaglandin E synthase-1 augments prostacyclin and retards 
atherogenesis,” Proc. Natl. Acad. Sci., vol. 103, no. 39, pp. 14507–14512, Sep. 2006. 
[241] C. Cunningham and D. T. Skelly, “Non-steroidal anti-inflammatory drugs and cognitive 
function: are prostaglandins at the heart of cognitive impairment in dementia and 
delirium?,” J. neuroimmune Pharmacol., vol. 7, no. 1, pp. 60–73, Mar. 2012. 
[242] H.-H. Chang and E. J. Meuillet, “Identification and development of mPGES-1 inhibitors: 
where we are at?,” Future Med. Chem., vol. 3, no. 15, pp. 1909–34, Nov. 2011. 
[243] M. Korotkova and P.-J. Jakobsson, “Characterization of microsomal prostaglandin E 
synthase 1 inhibitors.,” Basic Clin. Pharmacol. Toxicol., vol. 114, no. 1, pp. 64–9, Jan. 
2014. 
[244] P. Leclerc et al., “Characterization of a human and murine mPGES-1 inhibitor and 
comparison to mPGES-1 genetic deletion in mouse models of inflammation,” 
Prostaglandins Other Lipid Mediat., vol. 107, pp. 26–34, Dec. 2013. 
[245] G. Ozen et al., “Inhibition of microsomal PGE synthase-1 reduces human vascular tone 
by increasing PGI2 : a safer alternative to COX-2 inhibition.,” Br. J. Pharmacol., vol. 174, 
no. 22, pp. 4087–4098, Nov. 2017. 
[246] A. Kock et al., “Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-
Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.,” EBioMedicine, vol. 
32, pp. 84–92, Jun. 2018. 
[247] N. Nishizawa et al., “Inhibition of microsomal prostaglandin E synthase-1 facilitates liver 
repair after hepatic injury in mice.,” J. Hepatol., vol. 69, no. 1, pp. 110–120, 2018. 
[248] H. Yokouchi and K. Kanazawa, “Revisiting the role of COX-2 inhibitor for non-small cell 
lung cancer.,” Transl. lung cancer Res., vol. 4, no. 5, pp. 660–4, Oct. 2015. 
[249] M. J. Edelman et al., “Randomized, double-blind, placebo-controlled, multicenter phase 
II study of the efficacy and safety of apricoxib in combination with either docetaxel or 
pemetrexed in patients with biomarker-selected non-small-cell lung cancer.,” J. Clin. 
Oncol., vol. 33, no. 2, pp. 189–94, Jan. 2015. 
[250] H. Eriksson et al., “Quantitative membrane proteomics applying narrow range peptide 
isoelectric focusing for studies of small cell lung cancer resistance mechanisms,” 
Proteomics, vol. 8, no. 15, pp. 3008–3018, Aug. 2008. 
[251] Z. Cao, H.-Y. Tang, H. Wang, Q. Liu, and D. W. Speicher, “Systematic comparison of 
fractionation methods for in-depth analysis of plasma proteomes.,” J. Proteome Res., 
vol. 11, no. 6, pp. 3090–100, 2012. 
[252] S. E. Hunt et al., “Ensembl variation resources,” Database (Oxford)., vol. 2018, no. 8, 
pp. 1–12, 2018. 
[253] S. S. Peng, C. Y. Chen, and A. B. Shyu, “Functional characterization of a non-AUUUA 
AU-rich element from the c-jun proto-oncogene mRNA: evidence for a novel class of 
AU-rich elements.,” Mol. Cell. Biol., vol. 16, no. 4, pp. 1490–1499, Apr. 1996. 
References 
__________________________________________________________________________ 
 
93 
 
[254] A. Sandberg, R. M. M. Branca, J. Lehtiö, and J. Forshed, “Quantitative accuracy in mass 
spectrometry based proteomics of complex samples: The impact of labeling and 
precursor interference,” J. Proteomics, vol. 96, pp. 133–144, Jan. 2014. 
[255] W. J. Kent et al., “The human genome browser at UCSC.,” Genome Res., vol. 12, no. 
6, pp. 996–1006, Jun. 2002. 
[256] F. Piva, M. Giulietti, L. Nocchi, and G. Principato, “SpliceAid: a database of experimental 
RNA target motifs bound by splicing proteins in humans.,” Bioinformatics, vol. 25, no. 9, 
pp. 1211–1213, May 2009. 
[257] D. Betel, M. Wilson, A. Gabow, D. S. Marks, and C. Sander, “The microRNA.org 
resource: targets and expression.,” Nucleic Acids Res., vol. 36, no. Database issue, pp. 
D149-53, Jan. 2008. 
[258] K. Luo, “Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways.,” 
Cold Spring Harb. Perspect. Biol., vol. 9, no. 1, Jan. 2017. 
[259] A. Krämer, J. Green, J. J. Pollard, and S. Tugendreich, “Causal analysis approaches in 
Ingenuity Pathway Analysis.,” Bioinformatics, vol. 30, no. 4, pp. 523–530, Feb. 2014. 
[260] O. Le Tonquèze, B. Gschloessl, V. Legagneux, L. Paillard, and Y. Audic, “Identification 
of CELF1 RNA targets by CLIP-seq in human HeLa cells,” Genomics Data, vol. 8, pp. 
97–103, 2016. 
[261] V. Agarwal, G. W. Bell, J.-W. Nam, and D. P. Bartel, “Predicting effective microRNA 
target sites in mammalian mRNAs,” Elife, vol. 4, Aug. 2015. 
[262] G. Blobel and B. Dobberstein, “Transfer of proteins across membranes. I. Presence of 
proteolytically processed and unprocessed nascent immunoglobulin light chains on 
membrane-bound ribosomes of murine myeloma.,” J. Cell Biol., vol. 67, no. 3, pp. 835–
51, Dec. 1975. 
[263] D. W. Reid and C. V Nicchitta, “Primary role for endoplasmic reticulum-bound ribosomes 
in cellular translation identified by ribosome profiling.,” J. Biol. Chem., vol. 287, no. 8, 
pp. 5518–27, Feb. 2012. 
[264] K. D. Mansfield and J. D. Keene, “The ribonome: a dominant force in co-ordinating gene 
expression.,” Biol. cell, vol. 101, no. 3, pp. 169–81, Mar. 2009. 
[265] F. Bergqvist et al., “Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and 
Lipidomic Profiles in A549 Lung Cancer Cells.,” Front. Pharmacol., vol. 10, p. 636, 2019. 
[266] M. J. Ochs, E. Ossipova, G. Oliynyk, D. Steinhilber, B. Suess, and P. J. Jakobsson, 
“Mass spectrometry-based proteomics identifies UPF1 as a critical gene expression 
regulator in MonoMac 6 cells,” J. Proteome Res., vol. 12, no. 6, pp. 2622–2629, 2013. 
[267] I. A. Vlasova and P. R. Bohjanen, “Posttranscriptional regulation of gene networks by 
GU-rich elements and CELF proteins.,” RNA Biol., vol. 5, no. 4, pp. 201–7. 
[268] H. Xia et al., “CELF1 preferentially binds to exon-intron boundary and regulates 
alternative splicing in HeLa cells,” Biochim. Biophys. Acta - Gene Regul. Mech., vol. 
1860, no. 9, pp. 911–921, 2017. 
[269] A. D. Siddam et al., “The RNA-binding protein Celf1 post-transcriptionally regulates 
p27Kip1 and Dnase2b to control fiber cell nuclear degradation in lens development.,” 
PLoS Genet., vol. 14, no. 3, p. e1007278, 2018. 
[270] N. A. Timchenko, A. L. Lu, X. Welm, and L. T. Timchenko, “CUG repeat binding protein 
(CUGBP1) interacts with the 5’ region of C/EBP mRNA and regulates translation of 
References 
__________________________________________________________________________ 
 
94 
 
C/EBP isoforms,” Nucleic Acids Res., vol. 27, no. 22, pp. 4517–4525, Nov. 1999. 
[271] V. Procaccio et al., “Mapping to 1q23 of the human gene (NDUFS2) encoding the 49-
kDa subunit of the mitochondrial respiratory Complex I and immunodetection of the 
mature protein in mitochondria.,” Mamm. Genome, vol. 9, no. 6, pp. 482–4, Jun. 1998. 
[272] I. M. Fearnley, M. Finel, J. M. Skehel, and J. E. Walker, “NADH:ubiquinone 
oxidoreductase from bovine heart mitochondria. cDNA sequences of the import 
precursors of the nuclear-encoded 39 kDa and 42 kDa subunits.,” Biochem. J., vol. 278 
( Pt 3, pp. 821–9, Sep. 1991. 
[273] O. Zurita Rendón, L. Silva Neiva, F. Sasarman, and E. A. Shoubridge, “The arginine 
methyltransferase NDUFAF7 is essential for complex I assembly and early vertebrate 
embryogenesis.,” Hum. Mol. Genet., vol. 23, no. 19, pp. 5159–70, Oct. 2014. 
[274] L. H. Ngu et al., “A catalytic defect in mitochondrial respiratory chain complex I due to a 
mutation in NDUFS2 in a patient with Leigh syndrome.,” Biochim. Biophys. Acta, vol. 
1822, no. 2, pp. 168–75, Feb. 2012. 
[275] S. E. Marin, R. Mesterman, B. Robinson, R. J. Rodenburg, J. Smeitink, and M. A. 
Tarnopolsky, “Leigh syndrome associated with mitochondrial complex I deficiency due 
to novel mutations In NDUFV1 and NDUFS2.,” Gene, vol. 516, no. 1, pp. 162–7, Mar. 
2013. 
[276] H. A. L. Tuppen et al., “The p.M292T NDUFS2 mutation causes complex I-deficient 
Leigh syndrome in multiple families.,” Brain, vol. 133, no. 10, pp. 2952–63, Oct. 2010. 
[277] R. H. Triepels, L. P. Van Den Heuvel, J. M. Trijbels, and J. A. Smeitink, “Respiratory 
chain complex I deficiency.,” Am. J. Med. Genet., vol. 106, no. 1, pp. 37–45, 2001. 
[278] B. H. Robinson, “Human complex I deficiency: clinical spectrum and involvement of 
oxygen free radicals in the pathogenicity of the defect.,” Biochim. Biophys. Acta, vol. 
1364, no. 2, pp. 271–86, May 1998. 
[279] J. Loeffen et al., “Mutations in the complex I NDUFS2 gene of patients with 
cardiomyopathy and encephalomyopathy.,” Ann. Neurol., vol. 49, no. 2, pp. 195–201, 
Feb. 2001. 
[280] J. W. Wu et al., “Crystal structure of a phosphorylated Smad2. Recognition of 
phosphoserine by the MH2 domain and insights on Smad function in TGF-beta 
signaling.,” Mol. Cell, vol. 8, no. 6, pp. 1277–89, Dec. 2001. 
[281] Y. Shi, A. Hata, R. S. Lo, J. Massagué, and N. P. Pavletich, “A structural basis for 
mutational inactivation of the tumour suppressor Smad4.,” Nature, vol. 388, no. 6637, 
pp. 87–93, Jul. 1997. 
[282] F. Itoh, H. Asao, K. Sugamura, C. H. Heldin, P. ten Dijke, and S. Itoh, “Promoting bone 
morphogenetic protein signaling through negative regulation of inhibitory Smads.,” 
EMBO J., vol. 20, no. 15, pp. 4132–42, Aug. 2001. 
[283] F. Liu, C. Pouponnot, and J. Massagué, “Dual role of the Smad4/DPC4 tumor 
suppressor in TGFbeta-inducible transcriptional complexes.,” Genes Dev., vol. 11, no. 
23, pp. 3157–67, Dec. 1997. 
[284] T. Gaarenstroom and C. S. Hill, “TGF-β signaling to chromatin: how Smads regulate 
transcription during self-renewal and differentiation.,” Semin. Cell Dev. Biol., vol. 32, pp. 
107–18, Aug. 2014. 
[285] A. Cano et al., “The transcription factor snail controls epithelial-mesenchymal transitions 
by repressing E-cadherin expression.,” Nat. Cell Biol., vol. 2, no. 2, pp. 76–83, Feb. 
References 
__________________________________________________________________________ 
 
95 
 
2000. 
[286] A. Eger et al., “DeltaEF1 is a transcriptional repressor of E-cadherin and regulates 
epithelial plasticity in breast cancer cells.,” Oncogene, vol. 24, no. 14, pp. 2375–85, Mar. 
2005. 
[287] J. Yang et al., “Twist, a master regulator of morphogenesis, plays an essential role in 
tumor metastasis.,” Cell, vol. 117, no. 7, pp. 927–39, Jun. 2004. 
[288] Y. Katsuno, S. Lamouille, and R. Derynck, “TGF-β signaling and epithelial-
mesenchymal transition in cancer progression.,” Curr. Opin. Oncol., vol. 25, no. 1, pp. 
76–84, Jan. 2013. 
[289] A. Wilczynska and M. Bushell, “The complexity of miRNA-mediated repression,” Cell 
Death Differ., vol. 22, no. 1, pp. 22–33, Jan. 2015. 
[290] M. Brower, D. N. Carney, H. K. Oie, A. F. Gazdar, and J. D. Minna, “Growth of cell lines 
and clinical specimens of human non-small cell lung cancer in a serum-free defined 
medium.,” Cancer Res., vol. 46, no. 2, pp. 798–806, Feb. 1986. 
[291] I. Baumann, “Dissertation: Post-Transcriptional Regulation of mPGES-1 by the Balance 
between CUGBP1 and miR-574-5p,” 2017. 
[292] D. Kamei et al., “Microsomal prostaglandin E synthase-1 in both cancer cells and hosts 
contributes to tumour growth, invasion and metastasis.,” Biochem. J., vol. 425, no. 2, 
pp. 361–71, Dec. 2009. 
[293] R. Takahashi et al., “Roles of microsomal prostaglandin E synthase-1 in lung metastasis 
formation in prostate cancer RM9 cells.,” Biomed. Pharmacother., vol. 68, no. 1, pp. 71–
7, Feb. 2014. 
[294] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer.,” Cell, vol. 100, no. 1, pp. 
57–70, Jan. 2000. 
[295] J. P. Thiery and J. P. Sleeman, “Complex networks orchestrate epithelial-mesenchymal 
transitions.,” Nat. Rev. Mol. Cell Biol., vol. 7, no. 2, pp. 131–42, Feb. 2006. 
[296] C. L. Chaffer and R. A. Weinberg, “A perspective on cancer cell metastasis.,” Science 
(80-. )., vol. 331, no. 6024, pp. 1559–64, Mar. 2011. 
[297] P. Cohen, “The TLR and IL-1 signalling network at a glance.,” J. Cell Sci., vol. 127, no. 
Pt 11, pp. 2383–90, Jun. 2014. 
[298] A. Freischmidt, K. Müller, A. C. Ludolph, and J. H. Weishaupt, “Systemic dysregulation 
of TDP-43 binding microRNAs in amyotrophic lateral sclerosis.,” Acta Neuropathol. 
Commun., vol. 1, p. 42, Jul. 2013. 
[299] Y. Kawahara and A. Mieda-Sato, “TDP-43 promotes microRNA biogenesis as a 
component of the Drosha and Dicer complexes.,” Proc. Natl. Acad. Sci. U. S. A., vol. 
109, no. 9, pp. 3347–52, Feb. 2012. 
[300] B. Beuth, M. F. García-Mayoral, I. A. Taylor, and A. Ramos, “Scaffold-independent 
analysis of RNA-protein interactions: the Nova-1 KH3-RNA complex.,” J. Am. Chem. 
Soc., vol. 129, no. 33, pp. 10205–10, Aug. 2007. 
[301] N. A. Faustino and T. A. Cooper, “Identification of putative new splicing targets for ETR-
3 using sequences identified by systematic evolution of ligands by exponential 
enrichment.,” Mol. Cell. Biol., vol. 25, no. 3, pp. 879–87, Feb. 2005. 
  
Appendix 
__________________________________________________________________________ 
 
96 
 
Appendix 
Abbreviations 
  
µL Microliter 
5’ m7G 5’ 7-methylguanylate cap 
AGO Argonaute protein 
An 3’ 3' Pol-A tails 
ARE AU-rich element 
AS Alternative splicing 
ATCC American Type Culture Collection 
BACE1 β-site of APP cleaving enzyme 
BCA Bicinchoninic acid assay 
BSA Bovine serum albumine 
C. elegans Caenorhabditis elegans 
CDCP1 CUB domain-containing protein 1 
CDH1 Cadherin-1 
CDS Coding sequence 
CEBPA CCAAT/enhancer-binding protein alpha  
CEP41 Centrosomal Protein 41 
CerS1 Ceramid synthase 1 
CHES1 Checkpoint suppressor 1 
CID ITMS Collision induced dissociation Ion Trap Mobility Spectroscopy  
cJUN Jun Proto-Oncogene, AP-1 Transcription Factor Subunit 
Clip seq  Cross-linking immunoprecipitation-high-throughput sequencing 
COX-2 Cyclooxygenase-2 
CPLX2 Complexin-2 
CRE Cis-regulatory element 
CSDC2  Cold Shock Domain Containing C2 
CST5 Cystatin D 
CUGBP1 CUG-RNA binding protein 1  
Da Dalton 
DAPI 4´,6-Diamidine-2´-phenylindole dihydrchloride 
DGCR8 DiGeorge Syndrome Critical Region 8  
DIG Digoxigenin 
DM1 Myotonic dystrophy 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EBF1 Early B Cell Factor 1 
EDTA Ethylenediaminetetraacetic acid 
eIF Eukaryotic Translation Initiation Factor 
EMT Epithelial-to-mesenchymal transition 
et al. And others 
FCS Fetal calf serum 
FDR False Discovery Rate  
FISH Fluorescence in situ hybridization 
FTMS Fourier transform mass analyzers 
GLOD4 Glyoxalase domain-containing protein 4 
GRE GU-rich elements 
GRIPAP1 GRIP1 Associated Protein 1 
GTF2E2 General transcription factor IIE subunit 2 
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GTP Guanosine-5'-triphosphate 
h Hour 
HMGA2 High-mobility group AT-hook 2 
HNF4A Hepatocyte Nuclear Factor 4 Alpha 
hnRNP E2 Heterogenous Nuclear Ribonucleoprotein E2 
IL-1β Interleukin 1 beta 
IP Immunoprecipitation 
IPA Ingenuity pathway analysis 
Δ Knockdown 
LC-MS Liquid chromatography–mass spectrometry 
LEO1 LEO1 Homolog, Paf1/RNA Polymerase II Complex Component 
lncRNA /lnc Long non-coding RNA 
MACC1 Metastasis-Associated In Colon Cancer Protein 1 
MAFK MAF BZIP Transcription Factor K 
MAPT Microtubule associated protein tau 
MFI2 Melanotransferrin 
min Minute 
miR Micro RNA 
mPGES-1 Microsomal prostaglandin E2 synthase 1 
mRNA Messenger RNA 
MS Mass spectrometry 
mTOR Mechanistic Target of Rapamycin 
MYCBP MYC Binding Protein 
MYCN  MYCN Proto-Oncogene 
MyD88 Myeloid differentiation primary response gene 88  
NDUFS2 NADH- Ubiquinone Oxidoreductase Core Subunit S2 
NMD Nonsense-mediated mRNA decay 
Nova-1 NOVA Alternative Splicing Regulator 1 
NSCLC Non-small cell lung cancer 
nt Nucleotides 
oe Overexpression 
p38 Mitogen-Activated Protein Kinase 14 
p70S6K Ribosomal protein S6 kinase beta-1 
PAGE Polyacrylamide gel electrophoresis 
PAIP2 Poly(A) Binding Protein Interacting Protein 2 
PARN Poly(A)-Specific Ribonuclease 
p-body Processing body 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PG Prostaglandin 
PGE2 Prostaglandin E2 
pre-miR Precursor microRNA 
pri-miR Primary microRNA 
PTCSC3  Papillary Thyroid Carcinoma Susceptibility Candidate 3 
PTPRU. Protein Tyrosine Phosphatase Receptor Type U 
Qki Quaking 
qRT-PCR Quantitative real time polymerase chain reaction 
RAN Ras-related nuclear protein 
RBD RNA-binding domain 
RBM23 RNA Binding Motif Protein 23 
RBP RNA-binding protein 
RICTOR Rapamycin-Insensitive Companion Of MTOR  
RIP RNA immunoprecipitation 
RISC RNA-induced silencing complex 
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RNA Ribonucleic acid 
RNP Ribonucleoprotein 
rpm Rounds per minute 
RRM RNA recognition motif 
s Second  
SCAI Suppressor Of Cancer Cell Invasion  
SDS Sodium dodecylsulfate 
SELEX Systematic Evolution of Ligands by EXponential Enrichment 
SEM Standard error of mean 
SETD7 SET Domain Containing 7, Histone Lysine Methyltransferase 
SLC39A6 Solute Carrier Family 39 Member 6 
SMAD Mothers against decapentaplegic homolog  
Snail1 Snail Family Transcriptional Repressor 1 
snRNP Small ribonucleoproteins 
SOD2 Superoxide dismutase 2, 
SRP Signal recognition particles 
t Time 
TDP-43 Transactive response DNA binding protein43 kDa 
TGF Transforming growth factor 
TMT Tandem mass tag 
TP53 Tumor protein 53 
TRIF Toll-interleukin receptor domain containing adaptor-inducing interferon-β 
Tris Tris(hydroxymethyl)-aminomethan 
TSS Transcription start site  
TWIST1 Twist Family BHLH Transcription Factor 1 
UBE2R2 Ubiquitin Conjugating Enzyme E2 R2 
UBXN2B UBX Domain Protein 2B 
UTR Untranslated region 
V Voltage 
Wnt Wingless-Type MMTV Integration Site Family, Member 1 
ZDHHC14 Zinc Finger DHHC-Type Containing 14 
ZEB1 Zinc Finger E-Box Binding Homeobox 1 
ZNF469-3   Zinc Finger Protein 469 
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Supplementary data 
Table 12. Top three upregulated proteins of the proteomics study. 
 
Accession 
number 
Description 
x-fold to 
control 
ΔCUGBP1 
soluble fraction 
P04264 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
20.43 
Q5XKE5 
Keratin, type II cytoskeletal 79 OS=Homo sapiens GN=KRT79 
PE=1 SV=2 - [K2C79_HUMAN] 
6.50 
P13645 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 - [K1C10_HUMAN] 
3.80 
ΔCUGBP1 
microsomal 
fraction 
F8WBR5 
Isoform 3 of ADP-ribosylation factor-binding protein GGA1 
OS=Homo sapiens GN=GGA1 - [GGA1_HUMAN] 
3.47 
P10606 
Ubiquitin carboxyl-terminal hydrolase OS=Homo sapiens 
GN=UCHL1 PE=1 SV=1 - [D6R974_HUMAN] 
3.15 
E5RFX4 
Isoform 2 of Glyoxalase domain-containing protein 4 OS=Homo 
sapiens GN=GLOD4 - [GLOD4_HUMAN] 
2.65 
ΔmiR-574-5p 
soluble fraction 
P04264 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
3.25 
A0A024QZ42 
HCG1985580, isoform CRA_c OS=Homo sapiens GN=PDCD6 
PE=1 SV=1 - [A0A024QZ42_HUMAN] 
1.90 
H0YD99 
Eukaryotic translation initiation factor 4 gamma 2 OS=Homo 
sapiens GN=EIF4G2 PE=1 SV=1 - [H0YD99_HUMAN] 
1.76 
ΔmiR-574-5p 
microsomal 
fraction 
P19971 
Pre-mRNA-splicing factor SYF1 OS=Homo sapiens GN=XAB2 
PE=1 SV=2 - [SYF1_HUMAN] 
3.56 
Q9NVX0-2 
Thymidine phosphorylase OS=Homo sapiens GN=TYMP PE=1 
SV=2 - [TYPH_HUMAN] 
3.36 
P00403 
Isoform 2 of HAUS augmin-like complex subunit 2 OS=Homo 
sapiens GN=HAUS2 - [HAUS2_HUMAN] 
2.91 
miR-574-5p oe 
soluble fraction 
Q5XKE5 
Keratin, type II cytoskeletal 79 OS=Homo sapiens GN=KRT79 
PE=1 SV=2 - [K2C79_HUMAN] 
5.46 
P04264 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
5.12 
H0YL43 
Reticulocalbin-2 (Fragment) OS=Homo sapiens GN=RCN2 PE=1 
SV=1 - [H0YL43_HUMAN] 
2.67 
miR-574-5p oe 
microsomal 
fraction 
Q32P28-4 
Copine-1 OS=Homo sapiens GN=CPNE1 PE=1 SV=1 - 
[A6PVH9_HUMAN] 
5.93 
Q92990-2 
Protein S100 (Fragment) OS=Homo sapiens GN=S100A6 PE=1 
SV=1 - [R4GN98_HUMAN] 
5,70 
F8VZJ2 
Tetratricopeptide repeat protein 6 OS=Homo sapiens GN=TTC6 
PE=4 SV=1 - [G3V435_HUMAN] 
4,54 
X-fold regulation compared to each control upon ΔCUGBP1, ΔmiR-574-5p and miR-574-5p oe in in 
soluble and microsomal fraction of IL-1β-stimulated A549 cells. 
 
 
Table 13. Top three downregulated proteins of the proteomics study. 
 
Accession 
number 
Description 
x-fold to 
control 
ΔCUGBP1 
soluble fraction 
P55060-3 
Isoform 3 of Exportin-2 OS=Homo sapiens GN=CSE1L - 
[XPO2_HUMAN] 
-5.99 
Q9BQL6-3 
Isoform 3 of Fermitin family homolog 1 OS=Homo sapiens 
GN=FERMT1 - [FERM1_HUMAN] 
-4.15 
Q15427 
Splicing factor 3B subunit 4 OS=Homo sapiens GN=SF3B4 PE=1 
SV=1 - [SF3B4_HUMAN] 
-3.80 
ΔCUGBP1 
microsomal 
fraction 
O00566 
Leucine-rich repeat-containing protein 41 (Fragment) OS=Homo 
sapiens GN=LRRC41 PE=1 SV=1 - [A0A087WTI9_HUMAN] 
-5.22 
A0A0C4DFS8 
Isoform 5 of CUGBP Elav-like family member 1 OS=Homo sapiens 
GN=CELF1 - [CELF1_HUMAN] 
-3.09 
F8VSL3 
Ankyrin repeat and IBR domain-containing protein 1 OS=Homo 
sapiens GN=ANKIB1 PE=1 SV=3 - [AKIB1_HUMAN] 
-3.07 
ΔmiR-574-5p 
soluble fraction 
Q9Y5J9 
Mitochondrial import inner membrane translocase subunit Tim8 B 
OS=Homo sapiens GN=TIMM8B PE=1 SV=1 - [TIM8B_HUMAN] 
-3.51 
P62913-2 
Isoform 2 of 60S ribosomal protein L11 OS=Homo sapiens 
GN=RPL11 - [RL11_HUMAN] 
-3.18 
O00425 
Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo 
sapiens GN=IGF2BP3 PE=1 SV=2 - [IF2B3_HUMAN] 
-2.95 
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ΔmiR-574-5p 
microsomal 
fraction 
J3KS17 
Isoform 2 of Nucleolar protein 9 OS=Homo sapiens GN=NOP9 - 
[NOP9_HUMAN] 
-4.10 
Q86U38-2 
Calmodulin OS=Homo sapiens GN=CALM2 PE=1 SV=1 - 
[F8WBR5_HUMAN] 
-3.00 
F8WBR5 
Isoform 3 of ADP-ribosylation factor-binding protein GGA1 
OS=Homo sapiens GN=GGA1 - [GGA1_HUMAN] 
-2.87 
miR-574-5p oe 
soluble fraction 
P60903 
Protein S100-A10 OS=Homo sapiens GN=S100A10 PE=1 SV=2 - 
[S10AA_HUMAN] 
-4.48 
P09525 
Annexin A4 OS=Homo sapiens GN=ANXA4 PE=1 SV=4 - 
[ANXA4_HUMAN] 
-3.86 
Q8IVL5-2 
Isoform 2 of Prolyl 3-hydroxylase 2 OS=Homo sapiens 
GN=LEPREL1 - [P3H2_HUMAN] 
-2.43 
miR-574-5p oe 
microsomal 
fraction 
P17302 
Ninjurin-1 OS=Homo sapiens GN=NINJ1 PE=1 SV=2 - 
[NINJ1_HUMAN] 
-7.23 
Q9Y6A9 
Transmembrane emp24 domain-containing protein 5 OS=Homo 
sapiens GN=TMED5 PE=1 SV=1 - [TMED5_HUMAN] 
-5.16 
O75127 
Signal peptidase complex catalytic subunit SEC11A OS=Homo 
sapiens GN=SEC11A PE=1 SV=1 - [H0YKT4_HUMAN] 
-4.96 
X-fold regulation compared to each control upon ΔCUGBP1, ΔmiR-574-5p and miR-574-5p oe in in 
soluble and microsomal fraction of IL-1β-stimulated A549 cells. 
 
Table 14. IPA prediction of top five canonical pathways. 
 Name p-value Overlap 
ΔCUGBP1 
soluble fraction 
EIF2 Signaling 1.86E-45 55.7 % 103/185 
Regulation of eIF4 and p70S6K Signaling 6.46E-31 50.6 % 78/154 
Protein Ubiquitination Pathway 2.94E-27 39.0 % 99/254 
tRNA Charging 2.38E-19 76.3 % 29/38 
mTOR Signaling 2.92E-19 37.4 % 73/195 
ΔCUGBP1 
microsomal 
fraction 
EIF2 Signaling 1.61E-48 69.7 % 129/185 
Protein Ubiquitination Pathway 3.78E-31 52.8 % 134/254 
Mitochondrial Dysfunction 5.21E-27 58.2 % 96/165 
Regulation of eIF4 and p70S6K Signaling 2.30E-26 5 59.1 % 91/154 
Oxidative Phosphorylation 8.96E-23 64.4 % 67/104 
ΔmiR-574-5p 
soluble fraction 
EIF2 Signaling 2.36E-45 55.7 % 103/185 
Regulation of eIF4 and p70S6K Signaling 1.02E-31 51.3 % 79/154 
Protein Ubiquitination Pathway 7.62E-28 39.4 % 100/254 
tRNA Charging 2.55E-19 76.3 % 29/38 
mTOR Signaling 3.37E-19 37.4 % 73/195 
ΔmiR-574-5p 
microsomal 
fraction 
EIF2 Signaling 1.47E-48 69.7 % 129/185 
Protein Ubiquitination Pathway 3.48E-31 52.8 % 134/254 
Mitochondrial Dysfunction 4.89E-27 58.2 % 96/165 
Regulation of eIF4 and p70S6K Signaling 2.17E-26 59.1 % 91/154 
Oxidative Phosphorylation 8.56E-23 64.4 % 67/104 
miR-574-5p oe 
soluble fraction 
EIF2 Signaling 2.45E-45 55.7 % 103/185 
Regulation of eIF4 and p70S6K Signaling 1.05E-31 51.3 % 79/154 
Protein Ubiquitination Pathway 7.88E-28 39.4 % 100/254 
tRNA Charging 2.58E-19 76.3 % 29/38 
mTOR Signaling 3.46E-19 37.4 % 73/195 
miR-574-5p oe 
microsomal 
fraction 
EIF2 Signaling 1.51E-48 69.7 % 129/185 
Protein Ubiquitination Pathway 3.58E-31 52.8 % 134/254 
Mitochondrial Dysfunction 5.00E-27 58.2 % 96/165 
Regulation of eIF4 and p70S6K Signaling 2.21E-26 59.1 % 91/154 
Oxidative Phosphorylation 8.69E-23 64.4 % 67/104 
 
Table 15. IPA prediction of top five upstream regulators. 
 Name p-value 
ΔCUGBP1 
soluble fraction 
MYC 8.25E-72 
HNF4A 2.34E-58 
TP53 1.54E-57 
MYCN 3.64E-50 
MAPT 3.90E-42 
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Table 16. Summary of all analyzed proteins. 
mPGES-1  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) n.d. n.d. n.d. 
Western blot n.d. n.d. n.d. 
Microsomal fraction 
TMT Proteomics 1.03 1.50 -1.07 
IPA (Z-score) n.d. n.d. n.d. 
Western blot 1.42 0.5 2 
Smad2  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics 1.1 -1.3 1.2 
IPA (Z-score) n.d. n.d. n.d. 
Western blot 0.5 1.6 1.2 
Microsomal fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) 1.9 -2.1 n.d. 
Western blot 4.0 1.4 0.6 
Smad3  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics -2.1 1.0 -1.1 
IPA (Z-score) n.d. n.d. n.d. 
Western blot 0.6 1.7 1.8 
Microsomal fraction 
TMT Proteomics 1.1 1.1 1.2 
IPA (Z-score) 2.3 n.d. n.d. 
Western blot 2.2 1.4 0.6 
NDUFS2  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics 1.3 -1.3 1.4 
IPA (Z-score) n.d. n.d. n.d. 
Western blot 2.2 0.8 1.6 
Microsomal fraction 
TMT Proteomics 1.1 1.1 1.2 
IPA (Z-score) n.d. n.d. n.d. 
Western blot 1.4 1.1 0.8 
 
 
 
 
 
 
 
 
 
ΔCUGBP1 
microsomal 
fraction 
HNF4A 2.34E-82 
CST5 6.86E-70 
RICTOR 1.16E-53 
MYC 8.00E-49 
TP53 5.89E-43 
ΔmiR-574-5p 
soluble fraction 
MYC 1.54E-71 
TP53 9.48E-58 
HNF4A 1.39E-57 
MYCN 4.80E-50 
MAPT 7.02E-43 
ΔmiR-574-5p 
microsomal 
fraction 
HNF4A 4.44E-82 
CST5 6.03E-70 
RICTOR 1.04E-53 
MYC 6.60E-49 
TP53 4.75E-43 
miR-574-5p oe 
soluble fraction 
MYC 1.71E-71 
HNF4A 2.18E-58 
TP53 2.18E-58 
MYCN 5.02E-50 
MAPT 7.31E-43 
miR-574-5p oe 
microsomal 
fraction 
HNF4A 1.83E-82 
CST5 6.29E-70 
RICTOR 1.08E-53 
MYC 7.04E-49 
TP53 5.10E-43 
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GLOD4 ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics -1.3 -1.0 -1.1 
IPA (Z-score) n.d. n.d. n.d. 
Western blot n.d. n.d. n.d. 
Microsomal fraction 
TMT Proteomics 2.6 -1.3 1.5 
IPA (Z-score) 2.7 n.d. n.d. 
Western blot n.d. n.d. n.d. 
UBE2R2  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.5 -1.5 1.8 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
CPLX2  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics 1.2 -1.1 1.1 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 2.0 -2.5 -1.7 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
CEP41  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics 1.1 1.1 -1.2 
IPA(Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.5 -1.9 1.8 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
MAFK  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) -1.3 -2.4 -0.7 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.7 -1.5 1.0 
IPA (Z-score) -0.7 0.4 2.2 
Western blot no information no information no information 
SETD7  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics -1.40 1.02 1.01 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.58 -1.46 3.25 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
GRIPAP1  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics 1.31 1.00 1.05 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.67 -1.52 2.53 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
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SLC39A6  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Microsomal fraction 
TMT Proteomics 1.65 -1.68 1.74 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
LEO1  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics n.d. n.d. n.d. 
IPA (Z-score) n.d. n.d. n.d. 
Western blot n.d. n.d. n.d. 
Microsomal fraction 
TMT Proteomics 1.53 -1.65 1.58 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
GTF2E2  ΔCUGBP1 ΔmiR-574-5p miR-574-5p oe 
Soluble fraction 
TMT Proteomics -1.42 1.14 -1.51 
IPA (Z-score) n.d. n.d. n.d. 
Western blot n.d. n.d. n.d. 
Microsomal fraction 
TMT Proteomics 1.51 -1.55 1.56 
IPA (Z-score) n.d. n.d. n.d. 
Western blot no information no information no information 
Regulation in TMT proteomics study, IPA (Z-score) prediction and Western blot analysis in soluble and 
microsomal fraction upon ΔCUGBP1, ΔmiR-574-5p and miR-574-5p oe in IL-1β-stimulated A549 cells. 
TMT Proteomics: TMT ratio compared to control sample; no information: not analyzed via Western blot 
analysis; n.d.: not determined. 
 
Table 17. Transcripts from bioinformatical 3’UTR analysis 
Gene 
name 
Ensemble transcript 
ID 
CUGBP1 
Binding motif 
potential 
intron (nt) 
Number of 
distinct 
binding sites 
Fraction in TMT 
proteomics study 
CEP41 ENST00000489512 TGTGTGTGT 199 2 microsomal 
CEP41 ENST00000616628 TGTGTGTGT 199 2 microsomal 
MAFK ENST00000343242 TGTGTGTG 384 2 microsomal 
MAFK ENST00000403150 TGTGTGTG 384 2 microsomal 
RBM23 ENST00000359890 TGTGTGTG 7513 2 microsomal 
SETD7 ENST00000274031 TGTGTGTG 409 2 microsomal 
UBE2R2 ENST00000263228 TGTGTGTG 592 2 microsomal 
UBXN2B ENST00000399598 TGTGTGTG 551 2 microsomal 
CPLX2 ENST00000359546 TGTGTGTG 1548 3 microsomal 
SOD2 ENST00000538183 TGTGTGTGTGT 7537 2 soluble 
CDCP1 ENST00000296129 TGTGTGTG 2382 2 soluble 
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